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5I Foreword
Each year, between 6 300 and 8 000 drug-induced deaths are reported in Europe. In the 
20 years since the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) 
started reporting on the drug situation, we have counted more than 140 000 drug 
overdose deaths. This is a conservative figure; the real number is likely to be much higher. 
Opioids, mainly heroin or its metabolites, are present in most overdose cases and we can 
say with confidence that these drugs account for the large majority of overdose deaths.
With appropriate intervention many opioid overdose deaths may be preventable. Naloxone 
is a life-saving overdose reversal drug that rapidly counteracts the effects of opioids. It has 
been used in emergency medicine in hospitals and by ambulance personnel since the 
1970s to reverse the respiratory depression caused by opioid overdose, and it is included 
in the World Health Organization’s list of essential medicines.
We know from research that many opioid overdoses occur when others are present. This 
means that an opportunity for potentially lifesaving action may exist, if bystanders can be 
empowered to act. Unfortunately, often this does not happen, either because there is a 
failure to recognise the seriousness of the situation or, for fear of police involvement, 
emergency services are called late — or not at all.
The rationale for making naloxone available at places where overdoses are likely to occur is 
that overdose is common among opioid users — over a third have experienced a (non-
fatal) overdose and two-thirds have witnessed one — and that there is willingness among 
bystanders to intervene. After calls for the introduction of emergency naloxone as a 
harm-reduction measure in the 1990s, community-based programmes started to 
distribute naloxone kits to partners, peers and families of drug users and train them in 
overdose response and naloxone use.
With evidence on its effectiveness growing, ‘take-home’ naloxone provision has gained 
more attention in recent years. In Europe, take-home naloxone initiatives operate at city 
level in Denmark, Estonia, Germany, Italy, Norway, and at regional level in Spain (Catalonia) 
and the United Kingdom (Scotland and Wales).
A number of other European countries are currently exploring the topic and considering 
adding take-home naloxone to an existing range of interventions to prevent drug-related 
deaths. It is timely and appropriate for the EMCDDA to share existing experiences in 
order to broaden the knowledge base for decision-making. Authored by a group of 
experts who are well known in this field, this book provides an overview of take-home 
naloxone provision, describing the diffusion, practice and effectiveness of the 
intervention.
One of the main challenges for take-home naloxone programmes is to achieve sufficient 
coverage of at-risk populations, so that substantial reductions in opioid overdose deaths 
can be attained. The wider use of naloxone is often restricted by legal and regulatory 
barriers. In most jurisdictions, naloxone is a prescription-only medicine and its use is 
restricted to medical personnel or to patients to whom it is prescribed. The introduction of 
provision in some countries would therefore require adjustments to be made to current 
regulations, as has occurred in the United Kingdom and in some US states. Allowing local 
services in contact with high-risk drug users to stock naloxone kits for emergency 
use — as in Scotland — or handling it legally in the same way as another potentially 
life-saving drug that can be injected by bystanders — adrenaline to treat anaphylactic 
shock, for example — also merits serious policy consideration as does the introduction of 
‘Good Samaritan’ legislation, which exempts drug users from prosecution when they call 
emergency services after witnessing an emergency.
Preventing opioid overdose deaths with take-home naloxone
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Currently, available naloxone formulations are licensed for intramuscular, intravenous or 
subcutaneous injection. Whereas the use of a syringe can be an obstacle for non-medical 
responders, administration via nasal spray will offer advantages for wider dissemination of 
the intervention. While this book was being prepared for press, the US Food and Drug 
Administration approved a nasal naloxone preparation. The drug will be available through 
pharmacies across the United States, and in 15 states it will be available without 
prescription. These developments raise the prospect that nasal naloxone will be available 
in Europe in the near future.
Each of the 19 lives lost every single day to overdose in Europe is worth all our efforts to 
improve overdose prevention and response. Empowering bystanders to deliver a 
potentially life-saving intervention is an important next step in a diversified and balanced 
European response to drugs.
Alexis Goosdeel
Director, EMCDDA
7I Executive summary
Individuals who overdose on heroin or other opioids classically receive treatment when the 
ambulance or emergency medical care arrives, at which point the opioid antagonist 
naloxone is typically given. Naloxone is a semi-synthetic competitive opioid antagonist, 
which reverses opioid overdose and has been used in clinical and hospital overdose 
management since the 1970s. However, over the past 20 years, the provision of naloxone 
kits to opioid users and others likely to witness opioid overdoses has emerged as a novel 
harm-reduction intervention to make the antidote available in situations of need. Several 
countries in Europe and elsewhere have introduced take-home naloxone programmes that 
combine provision of the antidote with training in overdose prevention and emergency 
management. In November 2014, the World Health Organization (WHO) released new 
guidelines, recommending that take-home naloxone should be made available to anyone 
likely to witness an overdose.
This Insights publication provides both practitioners and policymakers with an analysis of 
the current evidence base on take-home naloxone. Specifically, it includes a 
comprehensive review of take-home naloxone initiatives in Europe. It also guides the 
reader through key issues of implementation, including training and programme evaluation. 
Finally, it engages in current debates around naloxone availability, including the 
development of non-injectable formulations and facilitating laws.
Chapter 1 describes the pharmacological basis of opioids and opioid reversal. Opioids 
have unique pain-relieving, anti-anxiolytic and sedative effects, but in the event of 
overdose this group of drugs can suppress the rate of breathing to the point of loss of 
consciousness, organ failure and death. The potential dangers of opioid drugs are 
illustrated by the example of heroin and its effects on the respiratory system. The chapter 
also explores risk factors that influence the likelihood of overdose. The chapter then 
introduces the opioid antagonist naloxone and summarises its pharmacology, how it is 
metabolised and other factors that influence its mechanism of action, such as the half-life 
of opioid agonists. The high specificity of naloxone in blocking opioid action is described as 
its defining feature, explaining why, 50 years after its original manufacture, naloxone 
remains the antidote of choice for reversing opioid overdose.
Chapter 2 covers the use of emergency naloxone by healthcare professionals in the 
emergency department and ambulance settings. In addition to comparing the different 
licensed routes of administration, it addresses the side effects of naloxone, with particular 
focus on precipitated withdrawal in opioid-dependent individuals. Naloxone administration 
also bears the risk of post-recovery re-intoxication due to the short half-life of naloxone 
relative to some of the opioids: the naloxone-induced blockade of opioid receptors wears 
off with time, and naloxone doses may need to be repeated to ensure that the overdose 
victim does not drift back into overdose. A concluding section discusses dosage 
recommendations and dose titration.
Chapter 3 highlights the significant contribution of heroin and the opioids to the high level 
of premature and preventable drug-induced deaths in Europe. The chapter contains a 
comprehensive review of the risk factors for opioid overdose. Personal correlates and 
predictors of risk of overdose include age, gender, history of use and comorbid medical 
conditions. Behavioural risk determinants include route of administration, co-use of other 
substances, reduced tolerance and using alone. Overdose deaths are typically clustered 
around specific situations, most prominently the periods following release from prison and 
discharge from residential detoxification and recovery treatment. In consideration of the 
fact that most overdoses occur in the presence of others, take-home naloxone is presented 
as a harm-reduction intervention that offers lay bystanders direct access to a potentially 
life-saving medication.
Preventing opioid overdose deaths with take-home naloxone
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Chapter 4 describes the historical development of take-home naloxone provision, from its 
grassroots origins in Chicago to its current role in government-funded public health 
programmes in Europe and beyond. Take-home naloxone was first proposed in the 
mid-1990s as a previously overlooked opportunity to prevent deaths by providing naloxone 
to peers and family and consequently reducing the time between overdose onset and 
naloxone administration. The chapter reviews two decades of take-home naloxone 
research, covering its first mention in the peer-reviewed literature, through initial 
exploration of feasibility and attitudes among potential target populations, the assessment 
of safety and legal concerns, to reports and programme evaluations. The chapter includes 
a summary of current take-home naloxone programmes in Europe and beyond, which is 
enriched by outcome data, examples of good practice and lessons learnt. A timeline of the 
history of take-home naloxone development is also provided.
Chapter 5 explains how take-home naloxone programmes can be implemented in practice, 
identifying the main target populations as well as necessary resources. Training is 
described as an essential part of take-home naloxone distribution programmes that can 
effectively increase participants’ knowledge, confidence and skills in managing an opioid 
overdose. Training can be offered to opioid users (former or current), carers and staff in 
frequent contact with users. It should be tailored to each setting, taking into account 
participant needs and available resources. Three levels of training are described: brief, 
standard and advanced. The chapter also includes assessment tools that can be used to 
test overdose-related knowledge and competence before and after training. The chapter 
concludes with a summary of methods for monitoring post-training impact.
The final chapter addresses naloxone options for the future, covering new products in 
development, new research initiatives and new legislation. It briefly summarises available 
systematic reviews on the effectiveness of naloxone programmes and gives an overview of 
recent WHO guidelines on community management of opioid overdose, which recommend 
widespread take-home naloxone provision. Barriers to naloxone access in the European 
Union are identified from policy, provider and research perspectives. The final sections of 
the chapter address the latest developments in the area of non-injectable naloxone 
products as well as initiatives to improve legal frameworks and raise awareness among 
healthcare service providers. These are identified as crucial facilitators for the wider 
availability of a life-saving intervention.
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I Introduction
Drug use is one of the major causes of avoidable mortality among young people in Europe, 
and a large proportion of the yearly 6 000–8 000 drug-induced deaths in Europe are 
caused by opioids, which are potent respiratory depressants. Overall, opioid users are at 
least 10 times as likely to die in any one year than their peers of the same age and gender 
(EMCDDA, 2015a). However, many of these deaths are preventable.
An effective medication that reverses the central nervous system-depressant effects 
caused by opioid overdose is naloxone, an opioid-receptor antagonist. Naloxone is used in 
hospital emergency departments and by ambulance staff, is highly effective and is 
inexpensive. Traditionally it is given by intravenous, intramuscular and subcutaneous 
routes, but paramedics also administer the drug intranasally to treat suspected opioid 
overdose. Although naloxone is a prescription medicine in most countries, it is not a 
controlled substance and has no abuse potential.
Based on the rationale that more opioid-overdose deaths could be prevented if people who 
witness overdoses recognised the danger in which the victims are and were able to 
administer the overdose-reversal drug, ‘take-home’ naloxone programmes have been 
developed to increase the availability of the antidote in places where overdoses are 
especially likely to occur. Under these programmes, an emergency supply of naloxone is 
given out, together with instructions about its administration, to drug users and their close 
friends, partners and families, as well as other individuals likely to witness overdoses, so 
that, in the event of an opioid overdose, naloxone is readily available and can be 
administered to the overdose victim before the arrival of an ambulance.
The first programmes in the United States and Europe began distributing naloxone in 1996 
and a report on outcomes in two European sites — Berlin, Germany, and Jersey, Channel 
Islands — was published in 2001 (Dettmer et al., 2001). Besides nationwide programmes 
in the community and before release from prison in Scotland and Wales, further naloxone 
initiatives in Europe have been implemented in Catalonia, Denmark, Estonia, Italy and 
Norway.
Evidence about naloxone programmes has grown. Since 2005, several studies have been 
published addressing different aspects of these programmes. The European Monitoring 
Centre for Drugs and Drug Addiction (EMCDDA) recently reviewed the effectiveness of 
education and training interventions complemented by take-home naloxone, including 21 
studies, and found evidence that these programmes decrease overdose-related mortality 
(EMCDDA, 2015b).
As interest in ‘take-home’ naloxone is greater than ever before among policymakers, 
agency staff and drug-user interest groups across Europe, it is the aim of this publication 
to bring together available background information, evidence and best-practice examples 
of take-home naloxone programmes.
Chapter 1 addresses the pharmacology and physiological mechanisms of opioid overdose 
and response by describing the specific dangers of heroin and other opioid drugs, 
explaining the impact of opioids on the breathing mechanism and the risks inherent in 
different routes of administration, and naloxone’s effects on the human body.
Chapter 2 addresses the use of emergency naloxone in clinical practice by medical 
professionals in the emergency department or in a pre-hospital setting by ambulance 
staff. In addition to comparing the different licensed routes of administration, it 
addresses the side effects of naloxone and discusses dosage recommendations and 
dose titration.
Preventing opioid overdose deaths with take-home naloxone
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Chapter 3 highlights the role of opioids in drug-induced deaths in Europe and reviews 
personal correlates and predictors of risk of overdose, including behavioural risk 
determinants as well as situational aspects of overdose risk.
Chapter 4 gives an overview of the history of take-home naloxone projects in Europe and 
beyond, reviewing project reports and programme evaluations, and research about 
feasibility and attitudes among potential target populations, assessing safety and legal 
concerns. Good practice and lessons learnt in current take-home naloxone programmes in 
Europe are described.
Chapter 5 presents how take-home naloxone programmes can be set up and run. It 
provides an overview of the main target populations for and the importance and 
effectiveness of training, as well as of the resources necessary to implement a 
comprehensive take-home naloxone programme, including training curriculum, materials 
and personnel.
The final chapter briefly summarises available evidence on the effectiveness of naloxone 
programmes and gives an overview of recent World Health Organization (WHO) guidelines 
on community management of opioid overdose, which recommend naloxone provision. It 
addresses barriers to the wider availability of take-home naloxone programmes, and future 
challenges, presenting an overview of the latest developments regarding products and 
initiatives to improve legal frameworks and to raise awareness among healthcare service 
providers.
I References
I  Dettmer, K., Saunders, B. and Strang, J. (2001), ‘Take home naloxone and the prevention of deaths 
from opiate overdose: two pilot schemes’, BMJ 322(7291), pp. 895–896.
I  EMCDDA (2015a), European drug report: Trends and developments 2015, Publications Office of the 
European Union, Luxembourg.
I  EMCDDA (2015b), Preventing fatal overdoses: A systematic review of the effectiveness of take-home 
naloxone, EMCDDA Papers, Publications Office of the European Union, Luxembourg.
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The first part of this chapter describes the 
pharmacological basis of opioids, with a particular focus 
on the potential dangers of heroin and its effects on the 
respiratory system. The second part introduces and 
describes the drug naloxone, and summarises its 
pharmacology, how it is metabolised and other factors 
that influence its function. It shows the accuracy and 
specificity of naloxone’s action as an opioid antagonist, 
how we understand its functions and why, 
50 years after its original manufacture, naloxone 
remains the opioid antagonist of choice for reversal 
of overdose.
I  Heroin and other opioids: understanding their particular dangerousness
I What are opioids?
Although the terms ‘opiate’ and ‘opioid’ are sometimes 
used interchangeably (see Table 1.1 for definitions), in 
medicine ‘opiate’ describes any of the opioid analgesic 
chemicals found as natural products in the opium poppy 
plant (Papaver somniferum) (Shook et al., 1990). Both 
opiates and opioids have been used medicinally, 
predominantly for pain relief but also for their strong 
sedative (sleep disorders), anxiolytic (reducing anxiety), 
anti-tussive (cough suppressant) and anti-diarrhoeal 
properties. Since the nineteenth century, it has been 
possible to obtain opiate products through the chemical 
isolation and extraction of the active ingredient from the 
opium poppy plant (Berridge, 1999). Major opium 
alkaloids are morphine, codeine and thebaine, of which 
morphine and codeine have analgesic properties and 
depressant effects, while thebaine has no direct 
therapeutic effect.
TABLE 1.1
Definitions
Opiate
One of a group of alkaloids derived as natural 
products from the opium poppy (Papaver 
somniferum), with the ability to relieve pain, induce 
euphoria and induce sleep, and, at higher doses, to 
induce respiratory depression and coma. Examples 
are morphine and codeine. The term excludes 
synthetic opioids.
Opioid
A generic term applied to natural opium alkaloids, 
their synthetic and semi-synthetic analogues (which 
in some cases may have a very different chemical 
structure from natural opium alkaloids) and 
molecules (e.g. β-endorphin, enkephalins, dynorphin) 
synthesised in the body which interact with opioid 
receptors in the brain and have the ability to induce 
analgesia, euphoria (a sense of well-being) and, at 
higher doses, respiratory depression and coma.
‘Opioid’ is a wider term that includes the semi-synthetic 
analogues such as methadone and buprenorphine, and 
also heroin. Heroin, which has the chemical name 
diacetylmorphine (also called diamorphine) is produced 
by a simple chemical reaction from morphine, a natural 
extract of the opium poppy, and was first marketed in 
1898 by the chemical company Bayer in Germany under 
the trade name ‘Heroin’. The chemical processes of 
converting opium into diacetylmorphine (i.e. 
diamorphine or heroin) involve first processing opium 
into morphine before acetylation to produce heroin. The 
term ‘opioid’ also encompasses the naturally occurring 
opiate and opiate-like drugs, including molecules that 
are very different from natural opiates but nevertheless 
activate the opioid receptors in the human body, 
producing similar effects to natural opioids (e.g. 
endorphins).
Some people experience a euphoric reaction to opioid 
medications, as opioids also affect the areas of the brain 
involved in reward (NIDA, 2014). Their strong medicinal 
effects and their euphoric properties may explain why 
the opioids are among the most commonly used groups 
CHAPTER 1
Pharmacology and physiological 
mechanisms of opioid overdose 
and reversal
Basak Tas and Ed Day
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An opioid antagonist is a substance that blocks opioid 
receptors. Opioid antagonists differ in their 
pharmaceutical uses: some have a quick, strong and 
short action and can be used for immediate reversal of 
opioid-induced respiratory depression (as with the 
emergency medicine naloxone, which is effective only 
with opioids) whereas others bind to the receptors for 
longer and can be used to block the potential longer-
term effects of heroin as part of a treatment 
programme for heroin dependence 
(as with naltrexone).
Opioid receptors
Opioid receptors are located in various locations of the 
brain that are implicated in the control of breathing and 
respiration, euphoria and pain control. They are also 
located in peripheral regions such as the intestinal tract, 
and in areas relating to respiratory feedback drive, for 
example in the carotid bodies and the vagi (Pattinson, 
2008) (see section ‘Impact of opioids on breathing 
mechanisms’ for a more detailed description).
There are three main groups of opioid receptors: mu 
(μ), delta (δ) and kappa (κ). All three produce analgesia 
when activated, but differ in other effects. The μ-opioid 
receptor is the most widespread opioid receptor in the 
body and the primary target for a great variety of 
therapeutic drugs. However, μ-opioid receptors can 
also produce undesirable effects such as respiratory 
depression and constipation (Pasternak, 2006). The 
group of μ-opioid receptor agonists includes heroin, 
morphine, oxymorphone, methadone and fentanyl. The 
effect of other opioid receptors on respiration is less 
well understood. Δ-opioid receptors appear to have 
some inhibitory action on respiration and κ-opioid 
receptors have little or no effect on respiration (Shook 
et al., 1990).
Heroin pharmacology
Heroin is regarded as a powerful opioid. In its 
pharmacologically purest form it is more powerful than 
morphine, weight for weight. If consumed orally it 
enters the digestive system and then undergoes 
metabolism in the liver, with a considerable proportion 
becoming deactivated. However, if injected 
intramuscularly or intravenously it enters straight into 
the bloodstream and crosses the blood–brain barrier, a 
cellular system that exists to protect the brain from 
potentially toxic molecules. The effect of heroin peaks 
within 20 seconds of intravenous injection, and slightly 
later following intramuscular administration (eMC, 
of drugs for recreational and self-medication purposes. 
The distinct properties of opioids that will be explored in 
this publication can lead to physical and psychological 
dependence, and carry a high risk of overdose. 
Most of the heroin found in the illicit market in Europe at 
present is in the form of a brown powder (base) which 
originates from south-west Asia. The base is not water-
soluble but is suitable for vaporisation with heat 
(‘chasing’, sometimes also called ‘smoking’, although no 
combustion of heroin takes place). It requires an acidifier 
(e.g. vitamin C) and heat to dissolve it in water and allow 
it to be injected. The white powder (salt) form of heroin, 
traditionally originating from south-east Asia, is soluble 
in water and can more easily be injected (although it 
often still requires heat).
I How do heroin and other opioids work?
Heroin and the opioids affect a number of different areas 
in the human body. The primary areas of action are the 
brain, spinal cord and gastrointestinal tract, where the 
opioids bind to receptors in the nervous system and 
produce their actions through processes of activation or 
inhibition. Receptors act as a ‘key’ in controlling 
physiological and psychological responses such as 
analgesia (pain reduction), sedation, euphoria, reduced 
breathing (respiratory depression), drowsiness, 
constricted pupils and nausea. The physiological and 
psychological effects differ depending on the particular 
opioid and the type of receptor that is activated or 
inhibited.
Agonist and antagonist
An agonist is a substance that elicits a response when it 
interacts with a receptor, whereas an antagonist 
prevents the effect of an agonist. If they both have an 
affinity for the same type of receptor (i.e. ability to bind 
to it), an antagonist acts by competing with the agonist 
to bind to the receptor, thus preventing the agonist from 
being able to promote its action and thereby eliminating 
the agonist’s effects. This is called ‘competitive 
antagonism’. The extent to which an agonist effect still 
occurs in the presence of an antagonist depends on the 
power balance between the agonist and the antagonist, 
namely their binding affinity to the receptor and the 
intrinsic activity of each. Full agonists bind to the 
receptor and produce a full effect on it, whereas partial 
agonists bind in the same way but exert only part of the 
effect on the receptor. Examples of full opioid agonists 
include morphine, heroin, methadone and fentanyl. 
Partial agonists include buprenorphine.
CHAPTER 1 I Pharmacology and physiological mechanisms of opioid overdose and reversal
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TABLE 1.2
Opioids along with their respective half-life 
approximations (Pasternak, 2006)
Drugs Approximate half-life
Heroin (diamorphine) 6 minutes
Morphine 120 minutes
Hydromorphone 150 minutes
Oxymorphone 150 minutes
Codeine 180 minutes
Fentanyl 220 minutes
Tramadol (immediate release) 6 hours
Methadone 24 hours
Buprenorphine 37 hours
Heroin/opioid metabolism
There are two ways in which opioids are broken down in 
the liver (metabolised): by the enzymes known as the 
cytochrome P450 system (2); and by other types of 
reactions, most commonly by a reaction known as 
glucuronidation (3). Some opioids (e.g. methadone, 
tramadol and fentanyl) undergo only the former process 
and some undergo only the latter process (e.g. heroin 
and morphine). If taken orally, heroin undergoes 
extensive metabolism as it enters the liver and 
consequently does not reach the systemic circulation. In 
this instance, heroin is largely converted to morphine 
before it reaches the general circulation (and hence 
before it reaches the brain). Heroin absorbed by the 
gastrointestinal tract travels directly to the liver, where 
this conversion occurs (known as hepatic first-pass 
metabolism). Consumption through the intranasal, 
inhalatory, intramuscular and intravenous routes 
bypasses this initial stage in the liver, and therefore 
produces more prominent brain effects than the oral 
route (Brunton et al., 2008; Smith, 2009).
I  Definition of overdose and pharmacological overdose risk factors
The EMCDDA (2015) defines drug-related death as a 
death ‘directly due to use of illegal substances, although 
these often occur in combination with other substances, 
such as alcohol or psychoactive medicines. These 
deaths occur generally shortly after the consumption of 
the substance’ and are therefore considered ‘directly 
caused by drugs’. They are also known as ‘drug-induced 
(2)  This is one of two systems of enzymes (the other, less significant, 
group is known as UDP-glucuronosyltransferases) involved in the 
breakdown of opioids and has gained great attention since we have 
developed a stronger understanding of the genetic influences on the 
effectiveness of the breakdown pathway (Holmquist, 2009).
(3)  Glucuronidation is a general process that occurs in the breakdown of 
chemicals, mainly in the liver.
2013; Klous et al., 2005). Heroin rapidly crosses the 
blood–brain barrier but is also rapidly broken down into 
the active metabolites morphine, morphine glucuronide 
and 6-acetylmorphine (Inturrisi et al., 1983). Heroin 
could therefore be considered not only as a drug in its 
own right but also as a pro-drug (1) for morphine 
(Sawynok, 1986). A key feature of heroin is that its 
chemical structure allows it to cross the blood–brain 
barrier more easily than most other opioids. As a result, 
heroin has a very fast onset of action for brain effects 
and associated euphoric effects, which contributes 
to its high potential for addiction relative to other 
opioids.
Heroin is a strong agonist for opioid receptors, with 
particular affinity for the μ-opioid receptor: the heroin 
metabolite occupies the receptor until it loses its ability 
to bind. Figure 1.1 demonstrates the binding fit of a 
heroin metabolite (or any other opioid agonist) onto an 
opioid receptor.
Other opioids
Opioids differ greatly in their duration of action, and this 
is influenced by their elimination half-life, that is, the 
amount of time it takes for half of the drug to be 
eliminated from the body. The half-life of a drug does not 
necessarily equate to its peak effects or its 
concentration at the relevant receptors, and in fact all 
drugs will continue to produce some effects after the 
stated half-life duration. Table 1.2 summarises some of 
the more commonly used opioids and their approximate 
half-lives.
(1)  ‘A pro-drug is a pharmacologically inactive substance that is the 
modified form of a pharmacologically active drug to which it is 
converted by a metabolic conversion process in the body’ 
(Merriam–Webster dictionary, 2014).
FIGURE 1.1
Illustration of a heroin metabolite (blue) attaching 
to an opioid receptor (grey triangle)
Heroin metabolite
Opioid receptor
NB: This simplified illustration represents the metabolites of heroin, 
3-monoacetylmorphine, 6-monoacetylmorphine and morphine.
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In Table 1.3, routes of administration are listed in order 
of increasing risk of overdose, assuming that dose and 
purity are constant.
Unknown purity
‘Street’ heroin is subject to unpredictable variations in 
drug purity and may contain a variety of adulterants or 
contaminants mixed in, making it difficult for the user to 
determine the amount of active substance to use. 
However, the picture is far from clear, as large numbers 
of fatal overdose sufferers have low concentrations of 
morphine in the blood, often below, or similar to, those of 
living intoxicated heroin users or of heroin users who 
died from other causes (Darke et al., 2010; Darke and 
Farrell, 2014; Davidson et al., 2003). Additional important 
factors may be the individual’s tolerance level, 
consumption of other depressants or organ (lung, liver) 
failure. Furthermore, harmful contaminants that may 
have contributed to the fatal outcome of the overdose 
may often not be detected in toxicological analyses of 
blood, drugs and used syringes.
Concurrent use of other drugs
There is an increased risk of overdose from heroin or 
other opioids if alcohol and other sedative drugs (e.g. 
deaths’ (a term used in the United States and 
increasingly in the European Union), as ‘poisonings’ 
(which corresponds to the terminology used in the 
International Classification of Diseases) or in more 
common language as ‘overdoses’.
There are many factors that contribute to the risk of 
overdose in general and to fatal overdose in particular. 
Non-fatal overdoses are more common than fatal ones 
but the risk factors for both are the same. According to 
Frisher et al. (2012), the more risk factors are present, 
the more likely it is that the overdose will be fatal. 
Behavioural and situational risk factors are examined in 
detail in Chapter 4. The focus below is on the 
pharmacological aspects of overdose.
Route of administration and relevant risk  
of overdose
A high bioavailability (the proportion of the actual drug 
that reaches the systemic bloodstream) usually equates 
to a high rate of absorption and increased risk of 
overdose. Bioavailability is considerably affected by the 
route of administration, which determines what type of 
metabolism (breakdown) the drug undergoes, but also 
by the dose taken and the purity of the drug. The 
combination of the last two factors will determine the 
total amount of active substance consumed.
TABLE 1.3
Risk of overdose by route of administration (descending order)
Route Characteristics
Intravenous (injecting 
into vein)
Powder or crushed tablets are prepared for injection, usually using water and an acidifier (e.g. heroin or 
crushed pharmaceutical opioid drugs); this is typically self-administered (or given by fellow drug user) as a 
bolus, thus delivering sudden full onset of drug effect when the bolus of drug reaches and crosses the 
blood–brain barrier. Because delivery following the pushing of the syringe plunger is instant, there is no scope 
to reduce the dose if the effect of the heroin is greater than expected. Heroin through this route has 100 % 
bioavailability.
Intramuscular 
(injecting into muscle)
Similarly, this is typically self-administered quickly but, by virtue of being injected into muscle (instead of into a 
vein), it is absorbed more slowly, so, even if eventually fully absorbed, it does not produce the same front-end 
bolus effect as intravenous use. As with intravenous use, there is no scope to reduce the dose if the effect of 
the heroin is greater than expected. Bioavailability is slightly lower than that of intravenous (Girardin, 2003).
Inhalation (smoking, 
‘chasing’)
Vaporising heated heroin base (brown powder), usually on foil, is known as ‘chasing the dragon’. By utilising 
the vast surface area of the lungs (as with cigarette smoking), ‘chasing’ produces rapid absorption and 
hence rapid brain effect. However, the technique involves running the melted heroin up and down the 
heated foil and inhaling the sublimate in the vapours. This technique is not instant in the same way as 
pushing a syringe plunger and, consequently, does not produce the rapid bolus effect. Hence, inhalation 
results in a slightly slower onset, which thereby gives the opportunity to reduce the dose if the effect is 
larger than expected.
Intranasal (snorting) Although not common, the white powder (salt) form of heroin occurs in some countries and communities. 
Snorting results in a mix of effects, some of fairly rapid-onset and other of more extended duration. Heroin 
bioavailability intranasally is approximately half that of the intramuscular route (Cone et al., 1993).
Oral Ingesting any drug orally as a tablet/capsule/liquid (e.g. methadone, morphine sulphate or dihydrocodeine) is 
likely to produce a slow-onset effect as it is gradually absorbed from the stomach or further down the 
alimentary tract. The extent to which it then produces effects on the brain varies greatly among the different 
opioid drugs, and is markedly affected not only by how comprehensively it is absorbed but also, crucially, by 
the extent of first-pass metabolism (see section ‘Heroin pharmacology’). Thus there is no opportunity to 
reduce the dose if the effect is larger than expected, but there is also no sudden-onset bolus effect. Heroin 
has < 35 % bioavailability when taken orally (Rook et al., 2006).
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substances in the body) and is typically accompanied by 
a decrease in blood oxygen (hypoxaemia) and finally 
hypoxia (a condition in which the tissue in a region of the 
body or the whole body is deprived of oxygen). If this 
state of low oxygen and high carbon dioxide in the blood 
is prolonged, it is usually fatal (Levitzky, 2013).
Why do these drugs cause respiratory depression?
Morphine, heroin and other opioids with agonist activity 
at the μ-opioid receptor in the respiratory centre produce 
depressant effects soon after binding. The activity in 
brain areas associated with inspiration (taking air in) is 
reduced by opioids, but the areas associated with 
expiration (breathing air out) are unaffected, so the 
breathing rhythm becomes slow and irregular (Leino et 
al., 1999). This causes hypercapnia (elevated CO
2
 levels 
in the blood) and hypoxaemia (low levels of blood 
oxygen). The effect on oxygen levels is demonstrated by 
Figure 1.2, which shows a considerable drop in oxygen 
just after intravenous heroin injection.
In the absence of opioids, any dampening of the 
ventilatory system leads the peripheral sensors to relay 
information to the respiratory centres of the brain to 
command the lungs to increase the rate of ventilation in 
order to counter hypercapnia and hypoxaemia (see 
feedback loop mechanism in Figure 1.3). However, in the 
presence of opioids, this protective regulatory 
mechanism is stunted (Pattinson, 2008). If the 
ventilatory drive is reduced for an extended time, the 
individual will eventually stop breathing (respiratory 
benzodiazepines) are also consumed. This ‘cocktail’ of 
drugs and alcohol contributes to a great number of 
overdose deaths. In the presence of other drugs that 
depress the central nervous system , a dose of heroin 
that is usually well-tolerated can prove fatal.
I Impact of opioids on breathing mechanisms
To understand why heroin and other opioids are 
particularly dangerous, it is important to consider the 
fundamentals of breathing and lung physiology.
Introduction to respiration
The lungs function to exchange oxygen and carbon 
dioxide continually with the external environment in order 
to maintain low concentrations of carbon dioxide and high 
concentrations of oxygen in the tissues of the body 
(Levitzky, 2013). Normal resting breathing is driven by the 
respiratory centres of the brain, located in the medulla 
and pons regions of the brainstem. Blood oxygen is 
monitored by sensors (also known as chemoreceptors) 
located in the body (peripheral sensors, e.g. the carotid 
body, see Table 1.4), and in the brain. Together these 
support a precise self-regulating system by constantly 
monitoring blood oxygen to detect any drops in levels. 
These chemoreceptors are also sensitive to increasing 
levels of carbon dioxide, as a failsafe second-level 
detection system. The respiratory centres monitor the 
feedback from the peripheral sensors and send the 
appropriate stimuli to initiate breathing.
A build-up of carbon dioxide in the blood is poisonous. If 
not adequately expelled via the lungs, an accumulation 
of carbon dioxide can lead to the condition known as 
hypercapnia. This in turn causes a decrease in blood pH 
(known as acidosis, the accumulation of acid 
TABLE 1.4
Glossary
Alkaloid
A naturally occurring chemical, mainly found 
in plants
Carotid body A group of receptors of the carotid artery 
(supplying blood to the head and neck) that 
detect small changes in oxygen and carbon 
dioxide
Medullary and 
pontine nuclei
Areas of the brainstem involved in respiration
Partial 
pressure (P
a
)
An estimate of the pressure of a gas (e.g. 
oxygen and carbon dioxide) if it were alone in 
the volume of blood. It is a hypothetical figure 
but is the standard measurement to provide
Ventilation 
rate
The volume of air that the lungs exchange per 
minute; basic indicator of pulmonary 
physiology
FIGURE 1.2
Oxygen saturation levels after intravenous opioid injection
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control respiration and breathing, such as the medullary 
and pontine nuclei of the brainstem (see Table 1.4), but 
which are also found in the carotid body.
Heroin and other opioids bind to these receptors, reduce 
their responsivity and thereby cause a ‘dampening’ 
effect on the respiratory system of the body, which 
causes breathing to slow down to potentially dangerous 
rates. When breathing slows down significantly, the level 
of carbon dioxide in the blood rises and the level of 
oxygen falls to dangerously low levels. However, because 
the respiratory centres of the brain are dampened by 
opioids, the feedback loop between the central 
respiratory centres and the lungs is interrupted. In 
normal circumstances (without any opioid agonistic 
effect), the breathing rate increases to counter the 
changes in blood gases. However, when respiratory 
centres are dampened, the lungs are not signalled to 
increase the breathing rate. This exacerbates the 
abnormal levels of oxygen and carbon dioxide in the 
blood, and, as the combined losses of hypercapnic and 
hypoxic drives deprive the victim of the stimulus to 
breathe (Doyon et al., 2014), results in respiratory 
acidosis, respiratory arrest and possibly death.
I  Naloxone: pharmacology and mechanisms of action
I What is naloxone?
Naloxone is a medication that counters the effects of 
heroin and other opioids by reversing respiratory 
depression caused by these drugs. It was first 
synthesised in the early 1960s: the Japanese company 
Sankyo submitted the first patent application, and a 
second application by Fishman and Lewenstein of Endo 
Laboratories (New York) followed in March 1961 
(Yardley, 2013). Naloxone was conceived of as a safer 
and more powerful opioid antagonist with fewer side 
effects than its predecessors. In 1971, naloxone 
received regulatory approval from the US Food and Drug 
Administration (US FDA) for intravenous, intramuscular, 
and subcutaneous administration.
Naloxone is made from a component of the opium poppy 
plant called thebaine. Thebaine is a minor component of 
the poppy, contributing to between 0.1 % and 2 % of all 
the extracts from the plant (UNODC, 1953). As 
described earlier, these extracts of the poppy plant, 
including morphine and thebaine, are collectively known 
as alkaloids and all have different uses and properties. 
The commonly found opium poppy alkaloids are 
arrest) and/or there will be excessive build-up of carbon 
dioxide in the blood (hypercapnia), leading to respiratory 
acidosis. Vital organs and tissues no longer receive 
sufficient oxygen (hypoxia), ultimately leading to risk of 
organ failure, coma or death. The severity of this 
respiratory depressant effect varies between opioids, 
but there is no opioid that does not have this effect.
It should be noted that respiratory depression caused by 
opioids, particularly μ-opioid receptor agonists, is more 
likely in people who have underlying pulmonary disease 
(e.g. emphysema or chronic bronchitis). It is thus much 
more common in cigarette smokers. However, the risk of 
overdose is still significant in heroin users without 
pre-existing lung pathology.
Polydrug use
In some cases, combined use of other depressant drugs 
(e.g. benzodiazepines) with opioids (see section 
‘Concurrent use of other drugs’) also leads to respiratory 
difficulties. Emergency overdose cases that involve other 
drugs are often not affected by the use of naloxone, and 
require use of other forms of resuscitation. For example, 
flumazenil is used to reverse benzodiazepine overdoses.
Summary of physiology
Opioids act on specific receptors, which are 
predominantly located in the regions of the brain that 
FIGURE 1.3
Respiratory feedback loop
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FIGURE 1.4
Illustration of naloxone competing with heroin 
metabolites for µ-opioid receptors
Heroin metabolites
Naloxone
Opioid 
receptor
in brain
Pharmacodynamics: how does naloxone  
affect the body?
Naloxone produces effects only if opioids are present in 
the body. If opioids have been taken and are producing 
an effect (e.g. pain relief, euphoria, sedation, respiratory 
depression), then a dose of naloxone will compete with 
the opioid at the receptor and will partially or completely 
reverse the opioid effect. The extent of this reversal will 
depend on the dose of naloxone, the dose of opioids that 
had previously been taken and their relative affinities for 
the opioid receptor. In persons with physical 
dependence on opioids, small subcutaneous doses of 
0.5 mg of naloxone can produce moderate to severe 
withdrawal symptoms, which appear within minutes of 
administration and subside after around 2 hours 
(McEvoy, 2012). The duration and severity of withdrawal 
symptoms will depend on the dose of naloxone, the 
route of naloxone administration, and the degree and 
type of opioid dependence.
Where opioids are administered during surgery, 
naloxone can be used for partial reversal of opioid 
depression in a post-operative setting (McEvoy, 2012). 
The dose of naloxone is usually titrated to effect, as this 
is less likely to cause undesirable cardiovascular side 
effects. Small doses (0.1–0.2 mg) of naloxone are used 
for the reversal of respiratory depression, and the 
patient’s response is observed. Sometimes repeat 
doses are required and are given at 2- to 3-minute 
intervals.
In an emergency, non-clinical overdose setting, titration 
is often not possible, as the person administering 
naloxone may see the urgent reversal of the heroin effect 
as the priority. Injection (0.4–0.8 mg) of naloxone can 
morphine, thebaine, narcotine, papaverine and codeine. 
To create the final naloxone molecule, thebaine 
undergoes many reactions after extraction, which is why 
naloxone is commonly referred to as a semi-synthetic 
antagonist. Extracted thebaine is also used in the 
production of semi-synthetic medicinal drugs such as 
hydrocodone, oxycodone and buprenorphine (Machara 
et al., 2012; Rinner and Hudlicky, 2012). Thebaine has no 
direct therapeutic uses itself. The WHO has included 
naloxone as a specific antidote in its Model List of 
Essential Medicines (WHO, 2013), a listing of the most 
efficacious, safe and cost-effective medicines for priority 
conditions.
Administration of naloxone
Naloxone is produced for injection, and is commercially 
available in formulations ranging from 0.4 mg/ml to a 
more concentrated 1-mg/ml solution. In paediatric 
formulations, this dose is diluted to 0.02 mg/ml (NIH, 
2007a; Joint Formulary Committee, 2014). It is licensed 
for administration into a vein (intravenous), into a muscle 
(intramuscular), or under the skin (subcutaneous) (NIH, 
2007a). Work is under way to develop an adequately 
formulated naloxone nasal spray for pre-hospital use; in 
the interim, some clinical services have improvised a 
nasal spray by combining a naloxone syringe with a 
spray adapter (see Chapter 6). A pilot project about the 
nasal use of naloxone is currently under way in Norway. 
The possibility of a buccal tablet (in the mouth, against 
the cheek) is also being explored (EudraCT: 2014-
001802-16).
I How does naloxone work?
General mechanism of action
Naloxone is a μ-opioid competitive antagonist (see 
section ‘How do heroin and other opioids work?’ for 
further information on agonists and antagonists). It has 
an affinity for the μ-opioid receptor and works by 
competing with other relevant drugs for a space on the 
receptor. Thanks to its ability to compete and control the 
specific opioid receptors, naloxone can reverse the 
effects (e.g. respiratory depression) that were caused by 
heroin (or another opioid) by preventing heroin 
metabolites from exercising influence on the receptor’s 
normal functioning (see Figure 1.4). Reversal is a fairly 
rapid event at the μ-opioid receptor, and partly at the 
δ-opioid receptor, the main instigators of respiratory 
depression in heroin/opioid consumption (Pazos and 
Florez, 1984; Shook et al., 1990) (see section ‘Impact of 
opioids on breathing mechanisms’).
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Metabolism of naloxone
As described in the section ‘Heroin/opioid metabolism’, 
opioids are mainly broken down (metabolised) by the 
cytochrome P450 enzyme system in the liver, or by the 
process known as glucuronidation. Naloxone, like heroin 
and morphine, is metabolised predominantly by the latter 
process and is broken down to naloxone-3-glucuronide. 
This is an inactive metabolite, but can be used as a marker 
when measuring the levels of naloxone in the body (Smith 
et al., 2008). Naloxone is completely metabolised in one 
pass through the liver, and when taken orally only a small 
proportion reaches the systemic circulation. 
Consequently it has to be given by a route that bypasses 
this initial stage in the liver (i.e. by injection) for maximum 
effectiveness (Brunton et al., 2008).
After a parenteral dose of naloxone, 25–40 % of the drug 
will have been excreted in urine within 6 hours, 50 % 
within 24 hours and 60–70 % within 72 hours.
Paediatric use of naloxone
In a post-operative setting, naloxone has been shown to 
reverse respiratory depression caused by opioids in 
children and new-borns, and appears to be safe and 
effective in reversing respiratory depression (Fischer and 
Cook, 1974; McEvoy, 2012; Segal et al., 1980). It is not 
known whether or not naloxone is excreted into human 
milk, but it crosses the placenta readily, and its effect on 
the foetus is not well understood.
I Naloxone’s actions with other opioids
Chemical differences
The effects of naloxone differ slightly according to the 
opioid that it is countering. Naloxone competes for the 
opioid receptors, μ, κ and σ, with the greatest affinity 
(attraction) for the μ receptor. Similarly, morphine and 
heroin also act on the μ and κ receptors, with greatest 
affinity for the μ receptor (Table 1.5). This similarity 
explains why naloxone is particularly effective at 
reversing the respiratory depressant actions of heroin 
and morphine.
Furthermore, the chemical structures of the opioids and 
naloxone are generally very similar. Naloxone is 
particularly similar to both heroin and morphine in its 
structure but with four slight variations to its functional 
groups (Figure 1.5). These slight tweaks to the bonds 
and atoms of the molecule create the difference 
between a pure agonist and a pure antagonist.
produce a prompt reversal of the effects produced by 
heroin/opioids. Where respiratory depression is present, 
naloxone typically causes increased respiratory rate 
within 1–2 minutes of intravenous administration 
(Nguyen et al., 2012; NIH, 2007a) and within 
3–4 minutes of intramuscular or subcutaneous (McEvoy, 
2004; MHRA, 2011) administration. Generally speaking, 
1 mg of naloxone administered intravenously will 
completely block the effects of a standard dose (around 
25 mg) of heroin.
Pharmacokinetics: how does the body handle 
naloxone?
Once absorbed, naloxone is distributed around the body 
very rapidly (NIH, 2007a). When administered 
intravenously its onset of action (i.e. the time required 
after administration of a drug for a response to be 
observed) is rapid, i.e. within 1 to 2 minutes. It is slightly 
slower in onset when administered subcutaneously or 
intramuscularly, after which onset of action is typically 
reached within 3 to 7 minutes (McEvoy, 2004; UNODC 
and WHO, 2013). The duration of action depends on the 
dose and route of administration (intramuscular 
administration leads to a longer duration of action than 
intramuscular administration), but the effect of naloxone 
generally lasts for up to 2 hours. The half-life of naloxone 
in serum (the period of time required for the amount of 
drug in the body to be reduced by one-half) is variable 
(e.g. from 30 to 80 minutes), with an average time of 
about an hour (NIH, 2007a).
The pharmacokinetics of intranasal naloxone have been 
published in only one study (Dowling et al., 2008) to 
date. The study tested intranasal naloxone doses of 
0.8 mg/2 ml and 2 mg/5 ml and found intranasal 
absorption to be rapid, but only low amounts of naloxone 
were absorbed into the bloodstream. The bioavailability 
of intranasal naloxone was only 4 % of that of 
intravenous administration. The authors pointed out that 
subjects might have swallowed some of the naloxone 
solution (Dowling et al., 2008). Future studies will 
therefore need to study more concentrated nasal 
naloxone formulations.
It is important to note that the duration of action of 
naloxone is shorter than that of some opioids. Heroin is 
one of the shorter-acting opioids, so its effects have 
usually dissipated by the time naloxone wears off. 
However, with longer-acting opioids, the effects of the 
opioid may return once the effects of naloxone start to 
disappear (see section ‘The heroin substitutes’ and 
Chapter 2), leading to a requirement for repeat doses of 
naloxone.
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dose or more frequent doses of naloxone. However, 
individual variability plays a crucial role here. Therefore, it 
is difficult to specify a dose of naloxone to counter 
respiratory depression caused by buprenorphine.
Methadone, a synthetic opioid agonist, is administered 
either in oral form, as a liquid or tablet, or in injectable 
form. It binds to the μ-opioid receptor strongly and has a 
long duration of action (NIH, 2007b; AHFS, 2014). 
Methadone can be used as a maintenance medication in 
the treatment of opioid dependence, as it has minimal 
euphoric effects and can relieve craving (Joseph et al., 
2000). It can also be used in the treatment of chronic pain.
Once the peak effects of naloxone disappear, 
respiratory-depressant effects in longer-acting opioids 
are more likely to reappear; this is known as recurrence 
of toxicity. The long-acting nature of methadone means 
that recurrence of toxicity is more likely than with heroin, 
and naloxone may be required in repeated doses 
(Waldron et al., 1973; Wanger et al., 1998). In a study 
looking at naloxone responses to opioid overdose in an 
emergency department, 30 % of those patients who 
responded to naloxone showed recurrence of toxicity, 
which was significantly correlated to long-acting opioids 
(Watson et al., 1998) (see Chapter 2 for further details 
on recurrence of toxicity).
Other opioids
Tramadol, a synthetic opioid analgesic that can cause 
significant respiratory depressant effects, also 
contributes to opioid-related overdoses (in the United 
Kingdom, 100 tramadol-related deaths were recorded in 
2013; ONS, 2014). It has a fairly long half-life of around 
6 hours (Dayer et al., 1994) and thus, as with 
methadone, there is a chance of recurrence of toxicity. In 
the few reported cases of naloxone reversal of tramadol, 
naloxone appears to be effective at reversing respiratory 
depression at standard doses (Stamer et al., 2008; 
Sachdeva and Jolley, 1997).
FIGURE 1.5
Chemical structures of heroin, naloxone, morphine and 
buprenorphine
Heroin Naloxone
Morphine Buprenorphine
The heroin substitutes
Heroin substitutes such as methadone and 
buprenorphine display similar respiratory depressant 
effects to heroin or morphine (Mégarbane et al., 2010), 
but these effects are not as effectively reversed by 
naloxone, particularly those of buprenorphine (Yassen et 
al., 2007).
Although rare, buprenorphine overdoses can occur, often 
due to the co-ingestion of benzodiazepines (e.g. 
Hakkinen, 2015). Buprenorphine is referred to as a 
partial agonist (Table 1.5) and sometimes as a mixed 
agonist/antagonist, with the agonist or antagonist effect 
varying by dose, by receptor and between individuals 
(Jacob et al., 1979). Therefore, the mechanism of 
naloxone’s reversal of buprenorphine effects differs from 
the mechanism of its reversal of heroin effects. 
Furthermore, buprenorphine has a very high affinity for 
the μ-opioid receptor and attaches to the receptor with 
greater affinity and for much longer than naloxone; in 
some circumstances, this means that naloxone cannot 
compete for a space on the receptor for a long enough 
time (Yassen et al., 2007).
Because buprenorphine’s effects on opioid receptors 
vary, the effect of naloxone administration is a little more 
complicated. If high-dose buprenorphine has been 
consumed, it may be necessary to administer a higher 
TABLE 1.5
Opioids and their relative opioid receptor affinities 
(Brunton et al., 2008)
Drug
Opioid receptor
µ δ κ
Naloxone – – – – – –
Morphine +++ No effect +
Methadone +++ No effect No effect
Buprenorphine P No effect – –
Fentanyl +++ + +
–, antagonist action; +, agonist action; strength of action is indicated by 
number of signs; P, partial agonist action.
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naloxone (24–30 mg) have been found to cause only 
slight drowsiness (McEvoy, 2012; Palermo, 1999). In 
other studies, extremely high-dose intravenous naloxone 
(up to 5.4-mg/kg boluses and 4 mg/kg/h) has been 
administered without adverse effects (Bracken et al., 
1990; Groeger and Inturrisi, 1987), although mild 
elevations in blood pressure and decreased 
performance in memory tests were seen with doses 
exceeding 20 mg (Terman, 2012). However, with the high 
risk of mortality in opioid overdose, the risk–benefit ratio 
of naloxone administration is clearly acceptable (Kim et 
al., 2009).
I Summary
Opioids are a particularly interesting group of drugs that 
have been used for centuries (in particular, opium, 
before morphine was originally isolated) for their 
pain-relieving, sedative, anti-anxiolytic and cough-
suppressant effects. However, they also possess a 
negative side effect that has been the crux of 
pharmaceutical development over many decades: 
respiratory depression, a dangerous reduction in 
breathing. Opioids act on a wide range of areas of the 
brain and body through molecules that elicit or inhibit 
effects (known as receptors).
In an opioid overdose, the impact of opioids on breathing 
centres of the brain can cause respiratory depression, 
which leads to low levels of oxygen in the blood and, if 
prolonged, can cause loss of consciousness, organ 
failure and death. There are numerous risk factors 
influencing the likelihood of an overdose, including, but 
not limited to, the type of opioid, its strength and the 
amount that is absorbed into the blood. Individual 
factors, such as tolerance, current health status, 
duration of use and genetic influences, among others, 
add to the intricacy and complexity surrounding opioid 
overdose.
Naloxone is a safe and effective antidote to the 
respiratory-depressant effects of heroin and other 
opioids. It works best in reversing the effects of a heroin 
or morphine overdose, but, depending on dose and route 
of administration, it also works to reverse respiratory 
depression caused by other opioids, including 
methadone. The short duration of action of naloxone 
means that repeated doses may be required for full 
effectiveness at reversing respiratory depression.
Naloxone has a strong affinity for the opioid receptors, 
particularly μ receptors, and it works by competing with 
the opioid and taking its space on the receptor, thereby 
Slow-release morphine (or extended-release morphine 
sulphate) is a long-acting opioid agonist used for its 
analgesic properties as well as in the treatment of opioid 
dependence as an opioid maintenance medication (Jegu 
et al., 2011). Naloxone is considered effective at 
increasing the respiratory rate in morphine-related 
overdose cases (McEvoy, 2012); however, because of 
the long-acting effects of slow-release morphine, toxicity 
is likely to occur. Similarly to the previously listed 
long-acting opioids, repeated doses are often required 
for slow-release morphine, although very few clinical 
cases have been reported.
Fentanyl is a strong opioid receptor agonist with 
analgesic properties and is commonly used to relieve 
cancer-related pain or breakthrough pain (pain that 
appears suddenly and is not relieved by standard pain 
medication). The duration of action of fentanyl ranges 
from 6 minutes (intranasal) to 27 hours (transdermal 
patch) (Foster et al., 2008; NIH, 2014). Again, the 
standard resuscitation procedure is to administer repeat 
doses of naloxone, but the clinical outcome may vary 
from case to case.
I Adverse effects
Naloxone has not been found to produce any 
independent psychoactive or physiological effects of 
note. However, if opioids are already present in the 
system, naloxone competitively displaces them from 
opioid receptors in both the brain and the periphery. This 
may trigger a secondary loss of opioid pain relief, the 
emergence of a time-limited acute withdrawal syndrome, 
or both (see also Chapter 2, section on ‘Side effects of 
emergency naloxone’, such as precipitated withdrawal 
and renarcotisation). Patient-specific effects of naloxone, 
including pulmonary oedema, have been reported, 
although these may be related to the individual’s 
underlying health conditions and independent of the 
actions of naloxone. Adverse effects usually occur when 
naloxone is provided during or after an operation, after 
administration of morphine as an analgesic. In non-
opioid-dependent patients, the most commonly reported 
side effect of using naloxone is the reversal of the 
analgesia (Pasternak, 2006).
Naloxone may sometimes be administered in cases 
where respiratory depression is not due to opioid 
overdose. If naloxone is administered in the absence of 
opioid drugs (or of physiological dependence and an 
ongoing abstinence syndrome), it is unlikely to produce 
any pharmacological activity at all. Studies of 
subcutaneous naloxone administration have not found 
any subjective effects, and even very high doses of 
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deactivating the receptor and reversing overdose. 
Naloxone itself has very few independent effects but 
does precipitate an acute withdrawal syndrome if given 
to a person who is dependent on opioids. The following 
chapters will explore the evidence surrounding the use 
of naloxone in preventing overdose deaths, with a 
particular focus on the provision of emergency naloxone 
to those who are likely to be present at an overdose.
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I  Naloxone availability, pricing and formulations
Naloxone is a prescription-only medication in most 
countries. Globally, access to naloxone is generally 
limited to health professionals, and in many countries 
there is limited availability of naloxone even in medical 
settings, including ambulances (WHO, 2014).
There is variation across Europe in the authorisation and 
availability of naloxone in emergency settings, and the 
administration of naloxone may be restricted to 
medically trained staff (see Chapter 4). In some 
jurisdictions the notification of overdose events can 
trigger a report to the police, which may discourage 
overdose witnesses from contacting emergency medical 
services (WHO, 2014).
Naloxone is formulated as naloxone hydrochloride and 
available in vials of 0.02 mg, 0.4 mg and 1 mg per 1 ml, 
2-mg/1 ml, 2-mg/2 ml and 2-mg/5 ml pre-filled syringes 
and a 4-mg/10 ml multi-dose vial. It is currently not 
under patent and is available through generic 
manufacturers (WHO, 2014).
According to a survey among selected European 
countries conducted as follow-up to a 2014 EMCDDA 
expert meeting on take-home naloxone (4), naloxone is 
most frequently supplied in a concentration of 0.4 mg/
ml. There is considerable variation in the price of 
naloxone between countries; for example, 1-ml glass 
ampoules cost the equivalent of EUR 8.20 in the United 
Kingdom versus EUR 1.38 in Poland, a unit cost five 
times greater. National economics do not fully account 
for the variation in cost; to illustrate, the United Kingdom 
ranks tenth in the European Union in terms of per capita 
gross domestic product according to Eurostat, but in 
(4)  For more information see www.emcdda.europa.eu/events/2014/
meetings/naloxone
Austria, which has the fourth highest per capita gross 
domestic product level in the European Union, a 1-ml 
glass ampoule of the same formulation costs just 
EUR 4.14, half the UK price.
This variation in cost between products can partly be 
explained by factors such as manufacturing and 
licensing costs (not explored further here). Pre-filled 
syringes are also typically more expensive than 
ampoules. In countries where naloxone products are 
disproportionately expensive, it is likely that cost has a 
substantial impact on clinical practice, especially when it 
concerns the introduction of a new expenditure for 
which no financial allowance had previously been made.
I Side effects of emergency naloxone
I  Precipitating the acute opioid withdrawal syndrome
Naloxone is a potentially life-saving medication, and 
failing to use it at the earliest opportunity in cases of 
opioid overdose may result in the death of the overdose 
victim. It is essential to know how to use naloxone safely, 
what potential side effects can occur and how these can 
be managed (see Chapter 1). A rapid reversal of opioid 
effects by naloxone may precipitate an acute withdrawal 
syndrome in physiologically dependent individuals. The 
side effects, or unwanted effects, of naloxone can 
therefore include symptoms of the opioid withdrawal 
syndrome. Opioid withdrawal symptoms may include 
nausea, stomach cramps, muscular tension, muscle 
spasms/twitching, aches and pains, insomnia, vomiting, 
sweating, tachycardia, hyperventilation, increased blood 
pressure, trembling and violent behaviour, and the 
objective signs listed in Table 2.1 (Taylor et al., 2012). 
Most commonly, the side effects will be a component of 
the opioid withdrawal syndrome in varying proportions 
and to varying degrees.
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‘clinicians are clearly walking a tightrope between 
precipitating acute withdrawal symptoms and avoiding 
recurrence of toxicity’. Therefore, naloxone doses may 
need to be repeated. Furthermore, the length of time for 
which further monitoring is needed depends on the type 
of opioid used (if known to the medical professionals 
assessing the case); for example, if heroin has been 
used in combination with methadone, the latter having a 
longer half-life, a more protracted monitoring period may 
be needed.
One-quarter (12 of 47; Boyd et al., 2006) to almost 
one-third (26 of 84; Watson et al., 1998) of presumed 
heroin overdose patients need repeat doses of naloxone 
to avoid recurrent opioid toxicity.
In a Finnish study of the incidence of recurrent opioid 
toxicity and how long after pre-hospital treatment it 
occurs in presumed heroin-overdose patients, of the 47 
patients taken to the emergency department for further 
monitoring who had been given naloxone and 
responded to it, 25 % (12 people) needed further 
naloxone to be administered in the emergency 
department because of signs of recurrent opioid toxicity, 
including respiratory depression in all 12 cases, or other 
adverse events within 1 hour after administration of 
naloxone before entry to hospital (Boyd et al., 2006). In 
the same study, however, 71 patients who had naloxone 
administered to them did not come to the emergency 
department after receiving pre-hospital naloxone, and 
during a 12-hour follow-up period no life-threatening 
events were recorded. However, the authors noted that 
in some cases, in this retrospective study, false 
identification details, such as names, dates of birth and 
identity numbers, may have been given, so that 
following up and correctly matching the data may not 
always have been possible. Moreover, in terms of 
comparing these data with results from other countries, 
Acute withdrawal syndrome affects all systems of the 
body. It is an extremely unpleasant experience for the 
patient and difficult to medicate fully while maintaining 
reversal of toxicity. The syndrome is effectively 
characterised by the same aversive symptoms that 
would cause an opioid-dependent individual to seek 
opioids in the natural environment because of craving. If 
some of these symptoms occur following naloxone 
administration, support and encouragement are 
essential, and symptomatic medication for withdrawal 
may be required.
The alpha-2 adrenergic agonist lofexidine is licensed for 
the treatment of opioid withdrawals in the United 
Kingdom. It inhibits the release of noradrenaline in the 
central and peripheral nervous system and thereby 
reduces those opioid withdrawal symptoms that are due 
to adrenergic hyperactivity. Lofexidine is prescribed 
initially as 800 μg daily in divided doses, and can be 
increased as necessary in steps of 400–800 μg daily up 
to a maximum of 2.4 mg daily in divided doses, the 
maximum single dose being 800 μg (Joint Formulary 
Committee, 2015). The recommended duration of 
treatment is 7–10 days (without opioid use) but longer 
treatment may be required (Joint Formulary Committee, 
2015). Further symptomatic management may also be 
needed.
I Recurrence of toxicity
On the other side of the pharmacotherapeutic see-saw, 
it is possible that a patient can re-enter respiratory 
depression; as naloxone has a shorter half-life than some 
opioids that may cause overdose, the naloxone-induced 
blockade of opioid receptors can wear off (leading to 
relief from withdrawal symptoms) and respiratory 
depression may return. To quote Clarke et al. (2005), 
TABLE 2.1
Objective opioid withdrawal signs, based on the Objective Opioid Withdrawal Scales 
Symptom No withdrawal Mild to moderate withdrawal Severe withdrawal
Lactorrhoea Absent Eyes watery Eyes streaming/wiping eyes
Rhinorrhoea Absent Sniffing Profuse secretion (wiping nose)
Agitation Absent Fidgeting Cannot remain seated
Perspiration Absent Clammy skin Beads of sweat
Piloerection Absent Hairs barely palpably standing up Readily palpable, visible
Pulse rate (BPM) < 80 80–100 > 100
Vomiting Absent Absent Present
Shivering Absent Absent Present
Yawns/10 minutes < 3 3–5 ≥ 6
Dilated pupils Normal < 4 mm Dilated 4–6 mm Widely dilated > 6 mm
Source: Taylor et al. (2012).
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Other authors have reported higher frequencies of 
repeat naloxone dosing. In one study, over 70 % of 
patients received two naloxone doses following 
continued medical assessment in the field before being 
signed off (Vilke et al., 2003).
Paramedics in San Diego County have a protocol that 
allows patients who have received naloxone to be signed 
off ‘against medical advice’ (AMA) without being 
admitted to hospital if they are oriented in time and 
place, not impaired by drugs or alcohol, are competent to 
refuse care, have discussed the risks and consequences 
and have been advised that medics will return if called 
back. In a retrospective study that covered a 5-year 
period during which a total of 998 patients were given 
naloxone after heroin overdoses in the field and then 
allowed to sign out AMA if this stringent list of safety 
criteria was checked first, the authors found no 
identifiable opioid overdose deaths (Vilke et al., 2003). It 
should be noted that over 70 % of the patients received 
two naloxone doses following continued medical 
assessment in the field before being signed off AMA; in 
other words, they did receive some continued 
assessment before the AMA status was reached. 
Moreover, of those receiving two doses, more than three 
in four patients (77 %) received intravenous followed by 
intramuscular naloxone. Intramuscular administration 
has slower onset than intravenous but the naloxone 
effect acts for longer (Vilke et al., 2003). This dosing 
regimen also has the potential to be explored further in 
future study protocols.
The risk of recurrence of toxicity and the potential need 
for re-administration of naloxone emphasise the 
importance of transferring patients to the emergency 
department whenever possible. Expert assessment is 
needed to ascertain who is at greatest risk and requires 
ongoing monitoring.
I Other adverse reactions to naloxone
Besides the risks of precipitated withdrawals and 
re-intoxication, other side effects may more rarely occur. 
The other potential adverse effects are influenced by 
underlying conditions present at the time of naloxone 
administration (MHRA, 2011):
n  cardiac disorders — tachycardia, pulmonary oedema, 
cardiac arrest/failure and ventricular fibrillation;
n  gastrointestinal disorders — nausea and vomiting;
n  nervous system disorders — convulsions, 
paraesthesia and grand mal convulsion;
it should be noted that, in the majority (87 %) of cases in 
this study, an emergency physician was on scene to 
evaluate the condition of the patient, and, even when 
patients were treated solely by paramedics, the 
paramedics consulted an emergency physician before 
leaving a patient at the scene or in police custody. All 
patients had therefore been carefully assessed, 
including those allowed not to come to the emergency 
department, and the more unwell or those deemed most 
likely to have a recurrent respiratory depression were 
taken to hospital (Boyd et al., 2006). This would explain 
the high incidence of repeat naloxone administered to 
those taken to the emergency department. It also 
suggests that the findings regarding the low incidence 
of complications after leaving patients at the 
assessment scene should be treated with caution when 
making comparisons with other parts of Europe if other 
healthcare systems do not always provide the same 
level of expert on-scene assessment; without such 
expert assessment, a higher degree of caution would 
need to be applied regarding those who refuse to attend 
the emergency department. Expert assessment is 
needed to ascertain who is at greatest risk and requires 
ongoing monitoring. Under these circumstances of 
careful assessment, the authors concluded that 
allowing presumed heroin-overdose patients to sign out 
after pre-hospital care with naloxone is safe and that, if 
patients had been transported to an emergency 
department, a 1-hour observation period after naloxone 
administration seemed to be adequate for recurrent 
heroin toxicity (Boyd et al., 2006).
In a study addressing the frequency of opioid toxicity 
recurrence after a response to naloxone in adult 
emergency department patients, Watson et al. (1998) 
carried out a retrospective case–control study of 
naloxone-treated patients with opioid toxicity over an 
8-year period, and found that, in approximately one-third 
of cases, opioid toxicity recurred after a response to 
naloxone. Over the study period, 221 people were given 
a diagnosis of opioid toxicity, of whom 90 were treated 
with naloxone and 84 were included in their analysis. 
There was a response to naloxone in 50 % of the 84 
cases and, in approximately one-third of adult 
emergency department opioid overdose cases treated 
with naloxone over the 8-year period, opioid toxicity 
recurred after a response to naloxone (Watson et al., 
1998). This is a higher figure than found in the later 
Finnish study (Boyd et al., 2006), where the authors had 
noted that only the more serious cases or those more 
likely to have a recurring respiratory depression attended 
the emergency department. Recurrence of toxicity was 
more common in patients who had used long-acting 
opioids, and was not associated with the route of opioid 
exposure (Watson et al., 1998).
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particular interest in the intramuscular route because of 
the greater ease with which a member of the public 
without medical training may administer the dose, 
especially given that long-term drug injecting often 
makes it relatively difficult to find access to a vein.
Emergency medical systems vary across Europe. This 
may affect how and where naloxone is given, and what 
assessments and follow-up care take place. In 2006, for 
example, Boyd et al. described the emergency medical 
system in Helsinki as three tiered. The first tier consists 
of firefighters, trained as emergency medical technicians 
(EMTs), staffing the ambulances. The second tier 
consists of three advanced life-support units staffed by 
paramedics and one paramedic supervisor unit. The 
paramedics are licensed to administer drugs 
intravenously, such as naloxone, after physician 
consultation or by following written standing orders. The 
third tier is made up of a mobile intensive-care unit 
staffed by two EMT-firefighters and one emergency 
physician (Boyd et al., 2006).
Internationally, in paramedical settings, there is a drift 
away from the original reliance on intravenous naloxone, 
with increasing numbers of ambulance crews preferring 
the alternative intramuscular route (Horowitz, 1998; 
Wanger et al., 1998), and some studies finding the 
intramuscular route to be as effective as the intravenous 
route (Sporer et al., 1996). Although other variables are 
introduced by intramuscular administration, such as 
depth of injection and muscle blood flow (Clarke et al., 
2005), the greater ease of intramuscular or 
subcutaneous administration is also important, 
especially when many patients have challenging venous 
access (Horowitz, 1998; Wanger et al., 1998). Some 
studies have found the slower rate of absorption via the 
subcutaneous route to be offset by the greater ease of 
use of this route over intravenous administration, for 
example if there is a delay in establishing an intravenous 
route (Wanger et al., 1998). Also important is the likely 
greater ease of use by the passer-by Samaritan (Wanger 
et al., 1998).
The existing opioid overdose management, provision 
and use of naloxone within drug, ambulance and police 
services was surveyed throughout England in 2005 to 
determine the feasibility of extended naloxone access 
to reduce fatalities from opioid overdose. The largest 
group of drug services reported that they would 
administer naloxone intramuscularly (49 %, 36 of 73), 
16 % intravenously and only 1 % subcutaneously, 
and 19 services reported that they used 
a combination of routes, predominantly intravenously 
and intramuscularly (23 %, 17 of 73) 
(Strang et al., 2007).
n  psychiatric disorders — agitation, hallucinations and 
tremulousness;
n  respiratory and thoracic disorders — dyspnoea, 
respiratory depression and hypoxia;
n  skin and subcutaneous tissue disorders — non-
specific injection-site reaction and sweating;
n  vascular disorders — hypertension, hypotension and 
hot flushes.
Evaluations of the safety and efficacy of hospital-based 
naloxone administration suggest that naloxone is 
associated with a moderately low rate (< 1.5 %) of serious 
adverse events (e.g. convulsions, cardiovascular problems, 
pulmonary oedema) and hypotension (Osterwalder, 1995, 
1996; Taylor et al., 2012). Based on case studies, 
surveillance for at least 8 hours has been advocated in 
some cases after successful treatment, to exclude 
delayed pulmonary oedema in patients intoxicated with 
heroin or heroin mixtures (Osterwalder, 1995).
In the United Kingdom in 2014, following three patient 
safety incidents, including two that resulted in death, 
NHS England released advice stating that ‘naloxone 
must be given with great caution to patients who have 
received longer-term opioid treatment for pain control or 
who are physically dependent on opioids’ and pointing 
out that according to the British National Formulary, a 
reference book with prescribing recommendations, the 
doses used in acute opioid overdose may not be 
appropriate for palliative patients and other chronic 
opioid users (NHS England, 2014). The advice noted that 
use of naloxone in larger doses than recommended can 
cause a rapid reversal of the physiological effects for 
pain control, leading to intense pain and distress, and an 
increase in sympathetic nervous stimulation and 
cytokine release, precipitating an acute withdrawal 
syndrome.
Clarification regarding naloxone dosing in palliative care 
and for chronic pain patients receiving long-term opioids 
is required internationally; after naloxone administration 
there is still a need for careful monitoring and for 
maintaining or restoring pain relief (NHS England, 2014).
I  Route of administration of naloxone in the pre-hospital clinical setting
Naloxone is approved for administration intravenously, 
intramuscularly or subcutaneously. There has been 
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I Naloxone doses
Naloxone is a registered medication in all western 
European countries, but advice about use and its 
availability vary between and within countries.
Clinically, the scenarios to consider are whether to start 
at a lower or higher dose within the accepted dose 
range (0.4–2 mg); how many repeated doses may be 
needed; which route would be best (intravenous, 
intramuscular or subcutaneous, with intranasal 
potentially being a future additional option; see 
Chapter 6); and whether or not the patient is using 
opioids in the long term for palliative care, which creates 
a different scenario from those using opioids for other 
reasons or overdoses in naive users.
The doses used in acute opioid overdose may not be 
appropriate for the management of opioid-induced 
respiratory depression and sedation in those receiving 
long-term opioids for palliative care and other chronic 
opioid use. The recommended dose for adults in post-
operative respiratory depression and for palliative care 
and chronic opioid use by intravenous injection is 
100–200 μg (1.5–3 μg/kg). If the response is inadequate, 
a subsequent dose of 100 μg should be given every 
2 minutes (Joint Formulary Committee, 2014; NHS 
England, 2014).
Following reports of fatalities (see section ‘Other 
adverse reactions to naloxone’; NHS England, 2014), 
NHS England has noted a need for further clarification 
on the recommended dosing regimens to be used for a 
patient following a suspected acute opioid overdose (as 
distinct from the advice for management of reduced 
consciousness and/or respiratory depression in chronic 
opioid users including some palliative care patients, 
which had prompted the initial report), given this lack of 
clarity around dosing. Within single countries there may 
be conflicting dosing advice from different sources 
(such as that provided in the British National Formulary, 
in the manufacturers’ individual product characteristics 
documents, in ToxBase and in the Palliative Care 
Formulary) (NHS England, 2015). NHS England 
therefore emphasised that low starting doses are 
recommended in all of these clinical scenarios (NHS 
England, 2015). Arguably, however, more cautious 
starting doses may heighten the need for monitoring for 
recurrent respiratory depression (see section 
‘Recurrence of toxicity’), but this has yet to be explored 
prospectively.
UK Medicines Information has agreed to undertake the 
production of a document addressing the naloxone 
doses to be used in adults, which will consider the 
Horowitz (1998) notes that either an subcutaneous or an 
intramuscular injection of naloxone may awaken the 
patient more gradually than one administered 
intravenously and reduce the risk to the paramedic of 
needle-induced blood exposure. She also suggests that 
repeat doses and/or intravenous naloxone 
administration may be needed in patients who do not 
respond to the initial intramuscular or subcutaneous 
dose. An important factor to consider when comparing 
routes is that any future approved intranasal naloxone 
product — not currently licensed, and explored further in 
Chapter 6 — would presumably be easier to administer, 
primarily because it does not involve a needle. Venous 
access can be difficult to achieve in individuals with a 
history of intravenous drug use; and even intramuscular 
administration runs the risk of a needle-stick injury, 
which is hazardous in a population with a relatively high 
prevalence of blood-borne viruses.
Figure 2.1 illustrates the relative positions of where a 
naloxone dose can be administered, showing where the 
vein runs, set in the muscle, with the subcutaneous 
(‘under the skin’) layer above this. Above the 
subcutaneous layer are the three skin (cutaneous) 
layers, subdermal, dermal and subepidermal, illustrated 
here as the dermis and epidermis. The naloxone dose 
may be administered into a vein, muscle or the 
subcutaneous layer.
FIGURE 2.1
Anatomy of soft tissue layers
Muscle 
Subcutaneous 
tissue 
Dermis 
1
2
3
NB: The naloxone dose may be administered into muscle (needle 1), a 
vein (needle 2), or the subcutaneous layer (needle 3).
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relevant literature base and consult with experts in the 
field (NHS England, 2015). Dosing coherence across 
Europe would have the potential to further enhance 
patient safety.
With regard to naloxone dosing, the WHO guidelines on 
the management of opioid overdose (2014) note that 
‘the choice of initial dose will depend on the formulation 
of naloxone to be used and the context’. The guidelines 
note that dose titration is usually standard practice in 
the medical setting, and advise that, although the initial 
dose should be 0.4–2 mg, in most cases a dose of 
between 0.4 mg and 0.8 mg will be effective at targeting 
recovery of breathing. The guidelines also highlight the 
importance of achieving a balance between treating the 
overdose and avoiding marked opioid withdrawal 
symptoms, with initial doses above 0.8 mg administered 
intramuscularly, intravenously or subcutaneously 
increasing the risk of precipitating significant withdrawal 
symptoms.
Most European injectable naloxone formulations are 
dosed as 0.4 mg. In adults suffering from opioid 
overdose, a single dose of 0.4 mg should be 
administered immediately. The dose of 0.4 mg can be 
repeated every 2–3 minutes in subsequent resuscitation 
cycles until the contents of a syringe are used up (Joint 
Formulary Committee, 2014); or an initial adult dose of 
400 μg to 2 mg of naloxone may be administered 
intravenously. If the desired degree of counteraction and 
improvement in respiratory function is not obtained, 
doses may be repeated at 2- to 3-minute intervals. 
Further doses may be needed if respiratory function 
deteriorates.
A dose range (rather than a specific dose) is provided in 
part because the amount needed to provide the 
necessary antagonistic effect depends upon the number 
of opioid receptors that have been occupied (Clarke et 
al., 2005), which cannot be known in advance, so, 
effectively, the response must be a titrated one or a 
higher one-dose-fits-all style solution. However, the 
latter risks causing a more aversive withdrawal reaction 
in the individual, which in the longer term could reduce 
the likelihood of the opioid user community engaging 
with naloxone.
The debate lies in the question of whether or not 
emergency naloxone treatment should be more explicitly 
based on giving an initial dose judged to be probably 
adequate, with the option of further doses if the 
overdose is not promptly reversed (i.e. titrating dose 
against effect).
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I  Overdose deaths in the European Union: trends over time
The EMCDDA epidemiological key-indicator ‘drug-related 
deaths and mortality’ has two components: deaths 
directly caused by illegal drugs (drug-induced deaths, 
commonly referred to as poisonings or drug overdoses) 
and deaths among problem drug users as a 
consequence of drug-related diseases, violence or 
accidents. In line with the EMCDDA definition (EMCDDA, 
2010), in this publication, the term ‘overdose’ is used to 
describe a drug-induced death that occurs generally 
shortly after the consumption of the substance.
Since the EMCDDA assumed its role of monitoring the 
European drug situation in 1995, more than 140 000 
drug-related deaths have been reported in Europe. This 
is an underestimate of the real number, as data gaps 
exist and under-reporting or under-ascertainment (5) of 
drug-induced deaths occur in some countries.
Overall, across the 30 countries reporting to the 
EMCDDA (the 28 EU Member States, Norway and 
Turkey), between 6 000 and 8 000 drug-induced deaths 
(overdoses) a year are reported, and the majority of them 
are associated with heroin and other opioids (EMCDDA, 
2015). Most countries reported an increasing trend in 
overdose deaths from 2003 until around 2008/9, when 
overall levels first stabilised and then began to decline, 
but this stalled and, in recent years, deaths have 
remained at high levels with no clear trend. For 2013, the 
average mortality rate due to overdoses in Europe was 
estimated at 16 deaths per million inhabitants in the age 
range of 15–64 years, with some countries, including 
Estonia, Norway and Sweden, reporting multiples of that 
rate (between 70 and 127 deaths per million population). 
Direct comparison of countries is, however, difficult, as 
(5)  Under-ascertainment refers to false negatives, i.e. cases that fulfil the 
criteria of a drug-induced death but are not identified as such.
national differences exist in coding and reporting 
practices, and systematic under-reporting in some 
countries may also happen (EMCDDA, 2015, pp. 56–57).
Opioid-related deaths are of particular importance for 
policy and public health action, since many of them are 
potentially preventable by a number of different 
interventions, including the timely emergency 
administration of the opioid antagonist naloxone. 
Besides heroin, other opioids including methadone, 
buprenorphine, fentanyls and tramadol are regularly 
mentioned in toxicological reports, and these 
substances are now associated with a substantial share 
of overdose deaths in some countries (EMCDDA, 2015, 
p. 57). Other central nervous system depressants 
including alcohol and medicines, in particular 
benzodiazepines, may also be causally implicated.
I Personal predictors of risk
Compared with the beginning of the heroin epidemics in 
Europe in the 1980s, there is now more knowledge 
about which individuals are at greatest risk of overdose 
death, as well as a more precise understanding of when 
they are at particularly increased risk (see Frisher et al., 
2012).
Variation in overdose mortality by age and gender
Examination of overall patterns reveals some important 
characteristics, which have a direct bearing on personal 
predictors of risk. Patterns of deaths and their 
distribution by age and gender are of obvious 
importance.
Europe’s opioid-using population is ageing, and risk of 
overdose death increases with age. The ageing trend 
among the user population is reflected in mortality data: 
between 2006 and 2013, overdose deaths decreased 
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Chronic users are at greater risk than naive users; 
nevertheless, recreational users can also become fatal 
cases (Zador et al., 1996). Other common 
characteristics of overdose victims have been identified 
as being single, being in deprived circumstances, having 
severe depressive symptoms and not being in treatment 
(Cornish et al., 2010; Warner-Smith et al., 2001).
Poor health
Overdose can also be associated with poor health. 
Opioid users have poorer health status than the general 
population, and some factors such as impaired liver 
function resulting from chronic viral infections could put 
them at greater risk of overdosing. Hepatitis B and C are 
highly prevalent among drug users and also among fatal 
cases. An association between heroin overdose 
mortality and liver disease (hepatitis B and C) has been 
suggested (Sheedy et al., 2003). It is likely that reduced 
metabolism of opioids in a damaged liver may prolong 
the depth and duration of intoxication, increasing the risk 
and dangers of overdose (Warner-Smith et al., 2001). 
Finally, it is also important to consider the effect that 
changes in body function related to normal ageing might 
have in increasing overdose risk. This is particularly 
relevant because the heroin-using population in Europe 
is ageing.
I A typology of drug overdose
Drug overdoses can usually be considered as being 
either accidental or with clear suicidal intent. Although 
suicidal ideation contributes to at least some drug 
overdoses, it is clearly a minor contribution. In general, 
the vast majority of overdoses in this population are in 
the category of accidental drug overdose (Farrell et al., 
1996). It is worth noting that toxicological tests can be 
inconsistent and opioid overdose nomenclature can vary, 
so some deaths might be misidentified. Some opioid-
related deaths will also fall into an overlap zone where, 
despite the absence of overt suicidal intent, there was 
nevertheless a lack of regard to safety as a result of 
personal mood state and circumstances (Vingoe et al., 
1999). Regarding the potential contribution of wider use 
of naloxone, it is likely that we will observe the biggest 
benefit from take-home naloxone in accidental drug 
overdoses that occur in the presence of peers or in a 
family home.
From a pharmacological and physiological perspective, 
overdoses can be further distinguished into sudden- and 
slow-onset cases. In sudden-onset (also called 
catastrophic) overdoses, the victim may lose 
among younger users, but increases were found among 
older users (EMCDDA, 2015, p. 56).
Of all recorded drug-induced deaths in Europe, 43 % 
occur in individuals aged 40 and older, with a further 47 % 
in the 25–39 age bracket and only 10 % among those 
aged under 25 years (EMCDDA, 2014; see Figure 3.1).
A gender imbalance is evident in data, with 77 % of all 
reported drug-induced deaths being of males. This 
reflects the predominance of males in the current opioid 
user population. For example, 80 % of all clients who 
entered drug treatment with heroin as their primary drug 
in 2013 were men (EMCDDA, 2015). This suggests that 
drug-induced deaths are only half as likely to happen to 
women as to their male drug-using counterparts. This 
greater mortality risk due to drug overdose among men 
using opioids remains striking even after controlling for 
other variables (Bird, 2010; Bird et al., 2003; Merrall et 
al., 2012; Pierce et al., 2015). The gender difference 
could perhaps be related to female opioid users being 
less likely to inject, using smaller amounts and using in 
the company of others (Powis et al., 1996). Female users 
might also be better at perceiving risk than males, while 
males tend to take greater risks (Sheedy et al., 2003; 
Spigner et al., 1993). However, study of these data has 
thus far not adequately explained either the age 
difference or the gender difference.
Heroin use career
Length of exposure to injection drug use has also been 
identified as an important risk factor for overdose death. 
FIGURE 3.1
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to include the irreversibility of pressing the syringe-
plunger compared with the slower process of ‘chasing 
the dragon’, which, by occurring over several minutes, 
allows for the possibility of titrating the drug dose 
against effect (and perhaps stopping any further heroin 
use if the heroin is found to be exerting an unexpectedly 
powerful effect, for example).
Of the possible injection routes (intravenous, 
intramuscular, subcutaneous), it is intravenous drug use, 
which is most likely to cause sudden-onset overdose, 
presumably because of the rapid induction of respiratory 
depression by the bolus of heroin as it reaches the 
respiratory drive centres in the brain.
Although injecting heroin presents a greater risk of 
mortality, it needs to be remembered that routes with a 
slower onset of action may contribute to slow-onset 
overdose. Non-injecting routes may be a greater risk 
when other substances are ingested simultaneously 
(Darke and Ross, 2000). Another particular risk moment 
in the heroin user’s career is when a heroin smoker 
chooses to inject for the first time. It is a common 
scenario for drug addicts to initiate their heroin use by 
snorting or ‘chasing the dragon’ and then change their 
habit to injecting as their tolerance increases 
(Donoghoe, 1999). This change in the route of 
administration increases their chances of overdose and 
also puts them at greater risk for contracting a blood-
borne virus.
It is possible to rank routes of administration (assuming 
dose and purity are not influences in this consideration) 
by descending risk of overdose: intravenous, 
intramuscular, inhalation, intranasal, and oral (see 
Table 1.3 for detailed description).
The influence of concurrent use of other substances
There is an increased risk of overdose from heroin or 
other opioids if alcohol and other sedative drugs (e.g. 
benzodiazepines) are also consumed (Pierce et al., 
2015). The use of a ‘cocktail’ of drugs (or of drugs and 
alcohol) contributes to a great number of the deaths 
caused by a drug-induced overdose. In the presence of 
other depressant drugs, a dose of heroin that is usually 
well tolerated can prove fatal.
Experimental research in a clinical laboratory setting has 
tested the extent to which benzodiazepines aggravate 
the degree of respiratory depression resulting from 
opioids (Lintzeris et al., 2006, 2007). The co-
administration of benzodiazepines makes respiratory 
depression more severe, thus giving laboratory 
consciousness with the needle still in situ, whereas in 
slow-onset (also called insidious) overdose cases the 
victim may be thought to be sleeping soundly when in 
reality they are drifting into coma; death may occur not 
as a result of lack of emergency medication but simply 
because friends or family fail to realise the danger. The 
sudden-onset, catastrophic overdose occurs classically 
after intravenous administration of heroin, whereas 
overdose with oral methadone or oral pharmaceutical 
opioids would typically be a slow-onset, insidious 
overdose.
I Identification of further drug-use risk factors
The risk of overdose from heroin (and other opioids) is 
increased by a range of individual and behavioural 
factors (pharmacological aspects of opioid overdose are 
explored in Chapter 1). Firstly, blood morphine 
concentrations detected in instances of apparently clear 
heroin overdose death are often not significantly 
different from the blood levels detected in individuals 
taking heroin without detectable overdose (Darke and 
Zador, 1996; Zador et al., 1996). Secondly, even in the 
context of supervised heroin maintenance treatment, 
sudden-onset heroin overdose still occasionally occurs, 
even though the individual patient has had their dose 
personally titrated and is being supervised (Oviedo-
Joekes et al., 2009; Strang et al., 2010). We need to 
realise that factors that we do not easily recognise 
nevertheless contribute to unexpected overdose events 
in ways that neither we nor heroin users themselves 
adequately understand.
However, some factors are within our understanding 
(some increasing the risk of overdose and of fatal 
outcome, and others decreasing it). Below, we will look at 
these, first those that are related to behaviour and then 
the factors related to situation.
Behavioural risk factors
Injection use
Heroin overdose is particularly associated with the use 
of the drug by injection. The stark difference in risk of 
overdose was evident in the London-based study 
comparing heroin users who were taking their heroin by 
injection with those who were ‘chasing the dragon’ (see 
Table 1.3 in Chapter 1) (Griffiths et al., 1994; Strang et 
al., 1999a). Only 2 % of the heroin chasers had 
overdosed, compared with 31 % of the heroin injectors 
(Gossop et al., 1996). Whatever various factors may 
influence this difference in overdose risk, they are likely 
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confirmed that people who died of heroin overdose had 
lower concentrations of morphine in their hair compared 
with current living heroin users.
Situational risk factors
Release from prison
Prisons are important for at least two different reasons. 
First, society produces (for other reasons, admittedly) 
an extraordinary concentration of drug misusers in its 
prison population (Fazel and Baillargean, 2011). 
Regarding the potential of naloxone to prevent 
overdose deaths, we are particularly interested in 
opioid users. The prevalence rates in prison compared 
with those in the community are startling: the 
population lifetime prevalence in most European 
countries is less than 1 % among the general public, but 
this contrasts sharply with prevalence rates in the 
region of 30 % in the prison population, both in 
sentenced populations (Bird et al., 1992, 1995; Fazel et 
al., 2006; Maden et al., 1992; Rounds-Bryant and Baker, 
2007) and also in remand populations (Brooke et al., 
1998; Mason et al., 1997). This disproportion is 
confirmed in recent European data, with the highest 
prevalence of heroin use reported among prisoners in 
Italy, Portugal, Spain and the United Kingdom, 
(Montanari et al., 2014). It is particularly high among 
(the smaller number of) female prisoners (Maden et al., 
1990). Prisons can also be places where heroin use is 
initiated (Boys et al., 2002; Gore at al., 1995).
The second reason why we need to pay particular 
attention to the prison setting is that there is an 
extraordinarily high rate of drug overdose deaths (mostly 
involving heroin or other opioids) in the weeks 
immediately following release from prison (Binswanger 
et al., 2007; Bird and Hutchinson, 2003; Farrell and 
Marsden, 2008; Merrall et al., 2010; Seaman et al., 
1998) — so much so that a commentary described this 
post-release period as a ‘period of extremely high risk’ 
during which we observe ‘carnage among recently 
released prisoners’ (Darke, 2008). This post-release 
clustering of overdose deaths has now been 
demonstrated in many different countries, with risk of 
overdose death increased more than sevenfold in the 
first fortnight after release (and remaining significantly 
elevated in the second fortnight) before gradually 
subsiding back to heroin users’ baseline (but still high) 
mortality rate. Of prisoners with a previous history of 
heroin injecting who are released from prison, one in 
every 200 will die of a heroin overdose within the first 4 
weeks following release from prison (Bird and 
Hutchinson, 2003).
confirmation of the effects observed clinically, 
epidemiologically and in forensic analyses.
There is now good awareness that the risk overdose 
from heroin or other opioids is increased if alcohol or 
other sedative drugs such as benzodiazepines have 
also been taken, and it is probable that such combined 
overdoses contribute prominently to drug overdose 
deaths (Bird and Robertson, 2011). However, general 
management remains similar, and the life-saving 
potential of emergency naloxone remains valid, 
even though the resuscitated overdose victim may 
still be under the influence of the sedative drug 
or alcohol.
Using alone
By its very nature, risk of overdose death is greatest 
when the overdose occurs in the absence of any 
witnesses. As with many other medical emergencies 
(epilepsy, diabetes, anaphylaxis), it often falls to others 
present to implement the essential initial resuscitation 
procedures. Additional risk factors include other 
situations of social isolation and marginalisation, at 
least partly through an increase in solitary drug use. 
Fear of calling official services or agency personnel 
(e.g. hostel staff) can further increase risk of overdose, 
and increase the dangerousness of overdose when it 
occurs.
Emergency resuscitation is obviously more likely to be 
effective if the person present is familiar with 
resuscitation techniques. Training programmes have 
now been established, and training both for drug users 
themselves (Strang et al., 2008b) and for families 
(Strang et al., 2008a; Williams et al., 2014) has been 
shown to improve knowledge and confidence regarding 
overdose emergency management (see Chapter 5).
Loss of tolerance
Reduced tolerance has been found to be an important 
risk factor for opioid-overdose deaths. Many studies 
have reported low blood-morphine concentrations found 
in autopsies of people who died of overdoses (Darke et 
al., 2002; Tagliaro et al. 1998). Darke and Zador (1996) 
reported a considerable overlap between the blood-
morphine levels of people who died of overdoses and the 
blood-morphine levels of living heroin users. Supporting 
this evidence, hair analysis of a sample in Verona in Italy 
found that heroin-overdose fatalities occurred mainly 
after a period of abstinence (Tagliaro et al. 1998). Darke 
et al. (2002) replicated the Italian study in Australia and 
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certainly true that there are variations in drug purity and 
a variety of adulterants or other psychoactive drugs are 
often also part of illicit heroin samples (for an analysis of 
the significance of different added components of illicit 
heroin, see Strang et al., 1997). The picture is far more 
complicated than the simple descriptions from coroner’s 
courts, from newspaper reports or from expert opinions. 
Indeed, for many fatal overdose cases, post-mortem 
analyses find only relatively low blood morphine 
concentrations, often below or similar to those of living 
intoxicated heroin users, or of heroin users who died 
from other causes (Darke and Zador, 1996; Zador et al., 
1996). Furthermore, although illicit heroin may contain a 
wide variety of other psychoactive or inert substances, it 
is rare for harmful contaminants to be detected (or 
tested for) in toxicological analyses of blood, drugs and 
used syringes.
A related protective effect is apparent from reduction in 
the purity (and increase in price) of street heroin, as was 
observed in the prolonged ‘heroin drought’ in Australia in 
the early 2000s, over which period there was a marked 
reduction in heroin overdose deaths (Degenhardt et al., 
2005, 2006).
Speed of response of emergency services
The longer the delay between recognition of the 
overdose and the arrival of emergency medical services, 
the greater will be the risk that severe damage or 
overdose death may occur. This will be a greater problem 
in rural areas, and in communities that have poor access 
and poor emergency medical services. The actions of 
family or peers as ‘first responders’, including the use of 
naloxone, can make the difference between life and 
death.
I Individuals likely to witness an overdose
Over recent years, we have learnt much about drug 
overdose deaths by interviewing individuals about their 
overdose experiences, using study methods such as 
privileged access interviewing (Griffiths et al., 1993). Such 
interviews typically address overdoses the individual has 
taken (sometimes followed by detailed debriefing on the 
last such event) as well as overdoses the individual has 
witnessed (with debriefing about the circumstances and 
the actions then taken). More than half of all fatal 
overdoses occur in the victim’s home and more than half 
occur with another person present (Zador et al., 1996). 
Even greater proportions are identified when the 
examination is of the contexts and circumstances of all 
drug overdose events (Strang et al., 1999b).
Discharge from residential rehab/detox
A similar phenomenon appears to exist in the period 
following discharge from inpatient detoxification or 
following return to the general community after 
residential rehabilitation, although this has not been 
studied so intensively and rigorously. At an earlier point, 
Strang et al. (2003) found that opioid-dependent 
patients who had successfully completed detoxification 
treatment were more likely to die of overdose than those 
who had failed to complete the programme. Subsequent 
investigations with stronger designs have confirmed this 
observation (Bauer et al., 2008; Cornish et al., 2010; 
Davoli et al., 2007; Merrall et al., 2012; Pierce et al., 2015; 
Ravndal and Amundsen, 2010). These periods of 
abstinence may leave opioid users vulnerable to 
overdose when a relapse occurs. If this is correct, then it 
points to another instance of localisation in time and 
context, which can guide future initiatives to prevent 
opioid overdose deaths.
Start of opioid agonist treatment
Treatment is generally protective against risk of overdose 
death, not only in those receiving treatments involving 
total abstinence (such as drug-free residential 
rehabilitation, and naltrexone antagonist treatments) but 
also in ambulatory opioid-substitution treatment (most 
commonly methadone or buprenorphine maintenance). 
There is robust international research evidence that 
opioid substitution treatment with either methadone or 
buprenorphine reduces mortality from all causes, 
including reducing risk of drug overdose deaths (Mattick 
et al., 2009, 2014). However, there are complexities to 
the relationship between the treatment and the 
reduction of risk of overdose death. Several independent 
research studies in different countries have identified an 
increased risk of death for a short period of time during 
the first few weeks of treatment (Caplehorn and 
Drummer, 1999; Cornish et al., 2010) before it reaches 
the reduced mortality rate generally associated with this 
treatment (Faggiano et al., 2003). In a pattern similar to 
the increased mortality after release from prison, there 
is also a transient increased mortality rate in the weeks 
immediately after treatment ends.
Unexpected change of purity
It is unclear to what extent unexpected changes in purity 
contribute to drug overdose deaths. Even though this 
factor is often presented by the media, and sometimes 
by drug experts, as the explanation for heroin overdose 
deaths, it is unlikely to be a sufficient explanation. It is 
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they hold). A sense of responsibility and ‘duty of care’ for 
each other is clearly expressed by fellow users (Wright 
et al., 2006). Best and colleagues (2000b) highlight the 
fact that most witnesses try to assist the victims in many 
ways, but some actions that are not taken are among the 
most important ones, such as calling for an ambulance. 
Hickman et al. (2007) estimated that one in four 
fatalities could have been prevented if the witness had 
acted differently. Beliefs that putting the person in a cold 
bath, injecting salt solution or giving stimulants would 
help have been reported among drug users (Beswick et 
al., 2002; Davidson et al., 2002). All those beliefs are 
incorrect and can be potentially dangerous, delaying 
appropriate assistance being given to the victim.
Drug users need to be made aware of the particular 
danger of intravenous use, of injecting alone, and of 
mixing heroin with sedative drugs, including alcohol. 
Harm-reduction measures targeted at preventing 
overdose need to increase awareness, with the explicit 
objective of promoting behaviour change away from 
injecting, and, if not, then away from mixing drugs and 
from solitary injecting.
Case 1: peer-user setting, London
I was using with someone else. Their lips went blue and 
they stopped breathing — I knew they had gone over. 
Didn’t have a problem putting it [naloxone] 
together — they came round in about 3 minutes … I saw 
him walking on the street yesterday.
Clinical case studies, Davis and Finch, 2008, 
unpublished
Case 2: peer user/passer-by setting, Berlin
Three days ago, I was walking along the canal with a 
friend of mine. We saw a guy lying on the ground … The 
guy was blue in the face and hardly breathing any more … 
I gave him one ampoule of naloxone … We tried to give 
him CPR and we called 911. Then the guy started to wake 
up and he started to breathe and shake a little bit. He was 
so thankful … When the medics came I told them I had 
given him the naloxone. The medics said “Wow! So you 
guys have even got naloxone now?” But he thought it was 
great. He said we had probably just saved the guy’s life.
Dettmer et al., 2001
Family members and carers
Family members of heroin users can get closely involved 
with their relatives’ drug use. It is likely that family 
members may witness an overdose event, particularly 
when part of the same household.
Drug users and peers
The circumstances in which overdoses happen indicate 
that a fatal outcome can often be prevented. First, 
overdoses seldom take place in isolation. Most 
overdoses occur at private homes (McGregor et al. 
1998) and, most importantly, between 70 % and 80 % of 
them occur in the presence of someone else: peers, 
family members or partners (Best et al., 2002; Darke et 
al., 1996; Lagu et al., 2006; McGregor et al., 1998; Powis 
et al., 1999; Strang et al., 2000; Tobin et al., 2005).
Another crucial characteristic of opioid overdoses is that, 
in the majority of cases, death will not occur 
instantaneously. Many deaths happen 2 or 3 hours after 
injection (Sporer, 1999; Zador et al., 1996). Only 
one-quarter of deaths happen immediately after drug 
administration (Darke and Zador, 1996). This time frame 
provides a window of opportunity for interventions to 
take place.
The majority of witnesses have made active 
interventions to address the emergency situation (Best 
et al., 2002; Beswick et al., 2002), even though many of 
the actions taken may have been incorrect. In many 
cases, witnesses fail to recognise the early signs of 
these symptoms or to distinguish them from a state of 
intoxication. In a London audit of overdose fatalities, 
Hickman et al. (2007) found that, in most of the 148 
cases, the overdose symptoms were not noticed until it 
was too late to intervene. This may be a result of lack of 
knowledge and lack of training, so it should be easily 
remediable through the prior provision of training.
In many situations of overdose, medical help is not 
sought or is sought too late. One of the reasons for not 
calling an ambulance is fear of police involvement 
(Sporer, 1999). However, other reasons for not 
summoning emergency services have been identified, 
among them related costs, possible eviction from hostel 
accommodation or loss of tenancy, previous negative 
experience with hospital staff and that the victim had 
regained consciousness (Davidson et al., 2002; Wright 
et al., 2006). An ambulance is most frequently called in 
the fatal cases (Davidson et al., 2002), probably after 
failure of attempts to resuscitate the victim.
There is a mistaken belief that drug users do not help 
each other in overdose situations. In a naloxone 
feasibility survey among opioid users, 89 % of those who 
had witnessed an overdose death said they would have 
administered naloxone to the victim if they had had 
access to the antidote (Strang et al., 1999b). Drug users 
are thus willing to help, but in many cases they do not 
know which actions to take (or are mistaken in the beliefs 
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Overdose prevention is a pivotal topic for those involved 
with opioid users, who are already recognised as a group 
that has an excessive risk of mortality which is largely 
caused by overdoses. Proposals for the provision of 
take-home naloxone have been well accepted by many 
clinicians but translation into clinical practice has been 
slow. Moreover, take-home naloxone could be offered on 
its own or as part of a harm-reduction package which 
would also include training on preventing blood-borne 
virus transmission (hepatitis C and human 
immunodeficiency virus) and safer injecting. Please see 
further information in Chapter 5.
I Conclusion
Training of family and friends is increasingly being 
recognised as an essential component of urgent interim 
management and maintenance of breathing and airway 
while awaiting arrival of emergency medical care.
Willingness to take part in training is greatest when 
people realise a family member or friend is potentially 
at risk of overdosing (Seal et al., 2003; Worthington et 
al., 2006; Wright et al., 2006). On the other hand, the 
fact that naloxone administration involves the use of a 
syringe and a needle can act as a major psychological 
barrier for many non-medical professionals 
who could otherwise give a life-saving dose 
of naloxone.
Training of family and peers and provision of take-home 
naloxone are important strategies that can prevent or 
minimise the excessive mortality among opioid users.
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I  Background: discovery of naloxone and usage in emergency room and pre-hospital emergency care
Naloxone, an opioid-receptor blocker that antagonises 
the effect of opioid drugs, was discovered at the 
beginning of the 1960s and approved for intravenous, 
intramuscular and subcutaneous administration in 1971 
(see Chapter 1). The antidote was initially marketed 
under the trade name Narcan, and now also exists as a 
generic prescription medicine. For the quickest 
absorption into the bloodstream and onset of action, 
naloxone was recommended for intravenous 
administration, which became standard clinical practice 
for nearly two decades.
Hospital emergency departments routinely used 
naloxone intravenously for the antidote’s three 
indications: to reverse respiratory and central nervous 
system depression in opioid overdose, to reverse the 
therapeutic effects of opioids in medical use (e.g. after 
general anaesthesia) and as a diagnostic tool (opioid 
challenge test; i.e. naloxone can be used to diagnose 
illicit opioid use, as it precipitates withdrawal symptoms). 
In the 1990s, in a move towards improving the 
prevention of overdose deaths in the community, 
ambulance services in the United States started to train 
their staff in the management of suspected opioid 
overdose, including intramuscular naloxone 
administration in conjunction with bag–valve–mask 
ventilation, and positive outcomes were reported (Sporer 
et al., 1996).
Spurred by the AIDS epidemic, clinicians became 
increasingly wary of the risk of needle-stick injury. As a 
result, there was pronounced interest in non-injecting 
routes of naloxone administration as a safer alternative 
for use in the high-risk opioid user population. Loimer et 
al. (1994) explored the intranasal administration of 
naloxone, which is still under investigation today (see 
Chapter 6). Alongside this line of work, a Vancouver-
based ambulance study by Wanger et al. (1998) 
compared time to recovery (interval from crew arrival to 
reversal of respiratory depression) between intravenous 
and subcutaneous administration. The study found that 
the slower absorption rate from subcutaneous 
administration was offset by the delay in establishing 
intravenous access in overdose victims, thus resulting 
in equal clinical efficacy for both routes. Similarly, for 
the intramuscular route, it has been established that 
adequate breathing in opioid overdose victims will 
resume on average 5 minutes after naloxone delivery 
(UNODC and WHO, 2013). In addition, Horowitz (1998) 
noted that subcutaneous (or intramuscular) 
administration led to a more gradual patient recovery 
from overdose, compared to intravenous 
administration.
This shift from intravenous towards subcutaneous and 
intramuscular administration of naloxone in clinical 
practice, and the growing awareness that most 
overdoses are witnessed by others, set the scene for the 
development of take-home naloxone provision, which 
enables bystanders without formal medical training to 
administer an emergency dose of naloxone in order to 
save the life of an opioid overdose victim.
I  Take-home naloxone: original proposal and first implementation
Compared with over 40 years of naloxone use in medical 
care, the notion of providing the antidote directly to 
opioid users and family members (‘take-home 
emergency naloxone’) is relatively new.
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described in more detail later in this chapter in the 
section ‘Take-home naloxone in Europe’ (see also 
Table 4.1).
I Testing the notion
I Is take-home naloxone necessary?
When the take-home naloxone proposal was published 
(Strang et al., 1996), the rate of heroin overdose deaths 
in Europe was on the rise (Davoli et al., 1993). Despite 
fluctuations in the total number of opioid-induced deaths 
in subsequent years and differences in trends between 
countries, heroin and other opioids continue to be the 
main contributors to drug-related deaths today, as opioid 
users in Europe and beyond experience markedly 
elevated excess mortality rates compared with not only 
the general population but also users of other illicit drugs 
(e.g. cocaine) (Degenhardt et al., 2011; EMCDDA, 2015b) 
(see Chapter 3).
I Who should be trained in take-home naloxone?
Based on the probability of witnessing an overdose, 
three target populations for take-home naloxone 
programmes were identified: users, carers (close 
contacts of users including peers and family members) 
and agency staff likely to interact with users.
People who use drugs: Opioid users and in particular 
those who inject are the primary target group for 
take-home naloxone because of their double function of 
potentially having an overdose in the future (50–70 % 
lifetime risk) as well as constituting willing 
interventionists highly likely to become bystanders of an 
overdose (Strang et al., 1999; Warner-Smith et al., 2001). 
Research identified the following groups of users as 
prone to overdose: current injecting opioid users 
(Gossop et al., 1996), heroin injectors upon release from 
prison (Bird and Hutchinson, 2003; Seaman et al., 1998), 
former opioid users upon release from in-patient 
detoxification/rehabilitation (Davoli et al., 2007; Strang 
et al., 2003) and individuals starting methadone 
maintenance treatment (Caplehorn and Drummer, 1999; 
Degenhardt et al., 2009) (see Chapter 3). More recently, 
Merrall et al. (2013) have shown a high rate of drug-
related death among persons registered for drug misuse 
treatment in the first 4 weeks after hospital discharge, 
irrespective of the reason for hospitalisation. Among 
high-risk users, those who are currently in treatment or 
re-entering the community after a stay in an institution 
(e.g. prison or hospital) can be accessed reasonably 
The possibility was originally mooted at the Third 
International Harm Reduction Conference in March 1992 
(Strang, 1992) as a throwaway example of harm 
reduction alternatives that were being overlooked. The 
first serious consideration of take-home emergency 
naloxone followed in a 1996 BMJ editorial (Strang et al., 
1996), which explored the possibility of take-home 
naloxone distribution more thoroughly. Analogous to 
other harm reduction measures, take-home naloxone 
was presented as a strategy to give users direct access 
to the best available treatment.
Firstly, the editorial explored several different potential 
applications, such as the provision of a take-home dose 
to individuals believed to be at high risk of overdose, 
including patients leaving residential treatment after 
detoxification and former users on release from prison.
Secondly, it identified the need to consider wider 
populations beyond those in treatment for their 
addiction, including active users with lower levels of 
engagement with treatment (such as attendees of 
needle and syringe exchange schemes) and users not in 
contact with treatment services.
Thirdly, the poor suitability of existing naloxone products 
was identified, as was the medico-legal challenge of the 
probable need to instruct third parties, such as friends or 
family members, in how to administer naloxone in an 
emergency.
I First implementation
The first instance of actual provision of take-home 
naloxone occurred in Chicago (Cook County), where the 
Chicago Recovery Alliance began dispensing naloxone 
as early as autumn 1996. The Chicago Recovery Alliance 
had been conducting harm-reduction outreach since 
1992. Following the death of one of its founding 
members in May 1996, the Chicago Recovery Alliance 
started training users in overdose prevention and 
equipped them with take-home naloxone kits. The 
distribution volume grew between 1997 and 1999, and, 
because of high user demand for the antidote, naloxone 
distribution was continued and converted into a formal 
programme with a standardised training curriculum in 
2001 (Bigg, 2002; Maxwell et al., 2006). The programme 
was initiated after a fourfold increase in drug-induced 
deaths reported by the Medical Examiner Officer from 
1996 to 2000.
In the late 1990s, take-home naloxone was also 
introduced in Germany (Berlin), the Channel Islands 
(Jersey) and Italy (Turin, Bologna and Padua), as 
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al., 1998) and in the presence of others: peers, family 
members or partners (Best et al., 2002; McGregor et al., 
1998; Powis et al., 1999). Consequently, close contacts 
of opioid users were identified as the second target 
group. A postal survey of carers in England (Strang et al., 
2008) underlined close contacts’ willingness to 
intervene in an overdose emergency and administer 
naloxone, with nearly 90 % of carers wanting training in 
overdose management and the same proportion wanting 
training in naloxone administration. In practice, peers or 
family members may accompany users to overdose-
education training and can also be accessed through 
support groups and advertising at health facilities and 
social service agencies.
easily. Harder to reach are the estimated 50 % of opioid 
users in the European Union who are thought not to be 
engaged with formal addiction treatment services 
(EMCDDA, 2015b).
A separate target group that may also benefit from 
take-home naloxone is prescription opioid users, such as 
chronic pain patients. This group will need different 
recruitment approaches and language in information 
material from ‘street opioid users’.
Carers (family members and other close contacts of drug 
users): Research in the late 1990s revealed that most 
opioid overdoses occur in private homes (McGregor et 
TABLE 4.1
Implementation timeline of take-home naloxone (THN)
Year Event
1961 First patent is filed for naloxone 
1971 United States: FDA licenses naloxone as prescription-only medication; naloxone enters clinical practice in Europe in 
subsequent years
1992 Notion of THN is mooted at International Harm Reduction Conference (Strang, 1992)
1994 First reported use of intranasal naloxone for overdose reversal (Loimer et al., 1994)
1996 BMJ editorial states ‘Home based supplies of naloxone would save lives’ (Strang et al., 1996)
United States: Chicago Recovery Alliance distributes first THN kits
Italy: Reports of THN distribution in Padua
1998 Channel Islands: Island of Jersey starts THN distribution
1999 Germany: Fixpunkt Berlin starts THN distribution
2001 Spain: Reports of underground THN distribution in Barcelona
United States: New Mexico and San Francisco launch THN programmes
First published report of THN distribution (Dettmer et al., 2001)
United Kingdom: Introduction of first mainland THN scheme (south London)
2002 Chicago programme reports first lives saved in BMJ (Bigg, 2002)
2005 United States: Intranasal naloxone is distributed as part of THN kits in Massachusetts
United Kingdom: Legal status of naloxone changed to permit emergency administration of naloxone by any member of the 
general public (Schedule 7 of the Medicines Act)
2006 United Kingdom: National Treatment Agency for Substance Misuse (NTA) funds THN training initiative for users and carers in 16 
pilot sites
2007 United Kingdom: Scotland and Wales establish THN pilots
2008 United Kingdom: Medical Research Council funds N-ALIVE trial
Spain: Formal THN programme launched in Barcelona
2011 United Kingdom: Scottish Lord Advocate issues new guidelines
United Kingdom: Scotland and Wales launch national THN programmes
Australia: First THN programme is introduced in Canberra
2012 Wales: first evaluation of national naloxone programme (Bennett and Holloway)
UNODC Resolution 55/7 states ‘Opioid overdose treatment, including the provision of opioid receptor antagonists such as 
naloxone, is part of a comprehensive approach to services for drug users’
2013 Denmark: THN programme starts (intranasal)
Estonia: THN distribution launched in Harju and East-Viru counties
2014 Norway: THN programme starts (intranasal)
WHO releases new guidelines, stating ‘People likely to witness an opioid overdose should have access to naloxone and be 
instructed in its administration’ (WHO, 2014)
EMCDDA hosts meeting ‘Take home naloxone to reduce fatalities: scaling up a participatory intervention across Europe’
2015 EMCDDA publishes systematic review, stating ‘There is evidence that educational and training interventions with provision of 
THN decrease overdose-related mortality’ (EMCDDA, 2015a)
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naloxone, such as the fear of experiencing withdrawal 
symptoms after naloxone administration, the potential that 
they might increase their drug use, and having to contend 
with management difficulties in those revived such as 
hostility or the urge to re-administer heroin to counteract 
possible withdrawal symptoms (Kerr et al., 2008; Seal et 
al., 2003; Strang et al., 1999; Worthington et al., 2006). 
Moreover, several drug users were doubtful of bystanders’ 
competency in using the medication (Worthington et al., 
2006), and the majority of the Melbourne-based sample of 
drug users (75 %) pointed out that that they preferred 
intranasal administration to injectable naloxone to reduce 
the risk of infection with blood-borne viruses (Kerr et al., 
2008). With an eye to possible legal repercussions, drug 
users expressed reservations about contacting ambulance 
services and voiced concern over naloxone being 
confiscated by the police (Richert, 2015; Seal et al., 2003).
Carers: Family members too have been found to be 
supportive of the proposal. In an England-based postal 
survey of 147 carers attending support groups (Strang et 
al., 2008), the majority were caring for a heroin user, and 
half of those cared for had already overdosed. The study 
found that only a third of carers had relevant knowledge 
or awareness of overdose management. It also 
highlighted carers’ strong interest in both training and 
emergency use of naloxone. A randomised controlled 
trial showed that training family members in emergency 
recovery procedures and naloxone administration led to 
greater overdose-related knowledge than controls (who 
had received only basic information) and that these 
training gains were maintained over a 3-month follow-up 
period (Williams et al., 2014).
Agency staff: ‘Technology transfer’ of naloxone supply 
from standard medical settings (i.e. ambulance and 
emergency rooms) to layperson use constitutes the 
foundation of take-home naloxone distribution. Several 
studies have explored whether or not healthcare providers 
would be supportive of the practice, yielding mixed 
results. A New York-based postal survey (Coffin et al., 
2003) of professionals with prescribing authority (i.e. 
physicians, physician assistants and nurse practitioners) 
showed that a third were willing to prescribe naloxone, 
whereas two-thirds of respondents were unsure or 
unwilling to do so. A survey (Tobin et al., 2005) of 
emergency service providers in Baltimore (Maryland) 
revealed overall negative attitudes towards take-home 
naloxone programmes, and 56 % felt that training would 
not have an impact on drug-related deaths. Willingness to 
prescribe was correlated with positive attitudes towards 
drug users, and vice versa (Beletsky et al., 2007). Some of 
the areas of potential concern raised by clinicians mirror 
those highlighted by drug users, such as competency in 
administering naloxone (Byrne, 2006; Tobin et al., 2009), 
Agency staff (those who work with people who use drugs): 
Thirdly, there are trained health professionals at drug 
treatment agencies as well as other professionals who 
work with at-risk individuals (e.g. at hostels or shelters for 
the homeless, needle and syringe programmes and 
outreach programmes) and first responders, such as 
ambulance, fire, police and other staff of law enforcement 
and criminal justice services. For all of the above, 
‘targeting’ refers to the need to engage employees, 
educate them on the need for overdose intervention and 
train them in the provision of take-home naloxone 
treatment (see Chapter 5). It has been documented that 
in the United States, jurisdictions in 24 states have 
passed legal provisions to authorise law enforcement 
officers and firefighters to administer naloxone and that 
over 220 law enforcement agencies currently carry the 
antidote, which represents a significant shift from the 
traditional role of police officers (Davis et al., 2015). 
Evaluations of the public health benefit and cost-
effectiveness of these programmes are forthcoming.
I  Is take-home naloxone acceptable to those involved?
Following the 1996 take-home naloxone proposal, 
research efforts focused on testing the feasibility of the 
proposed intervention and assessing the attitudes of 
users, carers and providers.
People who use drugs: Surveys investigating the practical 
feasibility of take-home naloxone found substantial 
support for the proposal among drug users. Attitudes of 
drug users towards take-home naloxone were first 
explored in London in the late 1990s. In a cohort of 454 
drug users from a deprived area (Strang et al., 1999), 70 % 
agreed with the proposal that naloxone should be provided 
for emergency management of future possible overdose, 
with nearly 90 % of those who had witnessed an overdose 
stating they would have used the medication if it had been 
available. Subsequent UK-based surveys found that heroin 
users were willing to take part in training to manage 
overdoses and administer naloxone (Bennett and Higgins, 
1999), store naloxone at home and intervene in an 
overdose situation (Best et al., 2002; Strang et al., 2000). 
These findings have since been replicated internationally. 
For instance, in a cohort of 82 street users in the San 
Francisco Bay Area (Seal et al., 2003), 84 % expressed the 
wish to carry naloxone and train peers. Similar results were 
obtained in a New York-based focus group study with 13 
representatives from a naloxone distribution programme 
(Worthington et al., 2006) as well as among a sample of 
99 needle and syringe programme participants in 
Melbourne (Kerr et al., 2008). However, drug users also 
expressed some concerns surrounding take-home 
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Similarly, in a more recent Danish study of 3 245 cases 
of naloxone administration, death from rebound toxicity 
occurred in only three cases (0.09 %) while all remaining 
3 242 overdose victims survived (Rudolph et al., 2011).
To conclude, empirical findings on the safety of take-
home naloxone programmes are favourable, and there 
have been very few reports of adverse effects beyond 
the expected onset of withdrawal symptoms and 
agitation in the revived overdose victim.
I Is take-home naloxone legal?
Parallel to the first take-home naloxone pilots, 
explorations of regulatory obstacles were undertaken 
(Burris et al., 2001). Two central legal challenges were 
identified. Firstly, could naloxone be lawfully 
administered to the overdose victim by a bystander, who 
would not be the person to whom naloxone was 
prescribed? Secondly, would it be lawful for a take-home 
naloxone recipient to use the naloxone that was 
prescribed to him-/herself to rescue an overdose victim, 
even though that particular naloxone kit was never 
prescribed to the overdose victim? The first scenario is 
similar to the provision of other emergency medications 
to patients and family; for example, family members of 
patients known to suffer from severe allergies can be 
trained to administer adrenaline in case of an acute 
allergic anaphylactic reaction. The second scenario is 
more challenging, as it involves doctors issuing a 
prescription-only medication to a patient, without 
knowledge about the eventual recipient of the antidote. 
Medical providers as well as service users raised 
concerns about civil or criminal liability. Service users in 
the United States also expressed concerns over the risk 
of naloxone confiscation by the police.
Certain jurisdictions have passed Good Samaritan laws 
to free lay responders from liability and facilitate the 
availability of take-home naloxone. The legal situation 
and availability of take-home naloxone in Europe is 
explored in the following sections of this chapter.
I Take-home naloxone in Europe
I  Naloxone: the legal situation in the European Union
According to Article 71 of the EU Medicinal Products 
Directive (2001/83), ‘Medicinal products shall be 
subject to medical prescription where they […] are 
normally prescribed by a doctor to be administered 
parenterally.’ Since naloxone is currently licensed only 
the possibility of implicitly promoting drug use (Tobin et 
al., 2005) and the risk of unsafe disposal of needles 
(Tobin et al., 2005). Potential use as street currency was 
also mentioned (Byrne, 2006). Most importantly, perhaps, 
providers voiced strong concerns over the uncertain 
medico-legal status of take-home naloxone and potential 
liability issues (Burris et al., 2001).
I Is take-home naloxone safe?
Providers and also some users raised concerns over the 
safety of the technology transfer of naloxone into the public 
sphere. In particular, it was unclear whether or not the 
availability of take-home naloxone might encourage heroin 
use, and if the duration of action of naloxone (half-life: 
1–1.5 h) would be sufficient to prevent overdose victims 
from re-entering overdose (so-called rebound toxicity). 
Similarly, there was concern that an overdose victim, once 
revived with naloxone, might inject another dose of heroin 
to overcome withdrawal symptoms, provoking an even 
more serious overdose by the time the naloxone wore off.
Surveys of drug users conducted at the end of the 1990s 
concluded that take-home naloxone was unlikely to lead 
to more risky heroin consumption (Strang et al., 1999), 
and there were no reports of revived overdose victims 
injecting heroin after overdose reversal (Vilke et al., 1999).
Early implementation pilots provided the first data on the 
safety of take-home naloxone provision. In the first 
published Europe-based take-home naloxone pilot, 
conducted in Berlin (Germany) and in Jersey (Channel 
Islands), the researchers reported 34 peer rescues from 
overdose in Berlin and found naloxone administration to 
be inappropriate in only one case (a cocaine overdose). 
All overdose victims were successfully revived. No 
increased use of heroin or occurrence of adverse effects 
(other than withdrawal symptoms) was observed. Among 
the five overdose reversals reported in Jersey, none 
involved adverse events (Dettmer et al., 2001).
The first US-based take-home naloxone programme in 
Chicago reported 319 overdose reversals between 2001 
and 2006 (Maxwell et al., 2006). Adverse events 
included one death and two cases of severe adverse 
reactions; however, the latter were likely to have been 
associated with polydrug use.
A recent evaluation of the Massachusetts-based 
take-home naloxone programme reported that average 
heroin use in the previous 30 days among a subsample 
of programme participants (n = 325) who participated in 
a pre–post survey was not affected by naloxone 
availability (Doe-Simkins et al., 2014).
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n  In Germany, first responders are protected by the civil 
law, with its basic principle of duty to rescue those in 
need to avoid greater harm. If a person is in danger, a 
bystander is obliged to provide aid. In fact, failure to 
provide aid may constitute a violation of Section 323c 
of the German criminal code (Strafgesetzbuch): ‘Who 
fails to provide help in cases of disaster or imminent 
danger or distress, although this [help] is necessary 
and reasonable under the circumstances, [and is] 
especially without considerable danger for his own 
and without violation of other important duties 
possible, will be penalised with imprisonment up to 
one year or fined’.
n  In the Netherlands, the law makes ‘no objection’ to 
the administration of prescription medicines by third 
parties in emergencies, if the medication (naloxone) 
is needed (Hughes, 2014).
n  In Luxembourg, a duty-to-rescue law has been 
embedded in the national penal code since 1985 
(Article 410-1 Code Pénal 1879). In addition, the 
national drug legislation (first introduced in 1973) 
was amended in 2001 to promote harm-reduction 
measures. With regard to overdoses, Articles 7 and 
8c of the law state that a drug user who witnesses an 
emergency and immediately seeks qualified 
assistance for the drug user in need (i.e. overdose 
victim) cannot be prosecuted for drug possession. 
Further, if the assisting overdose witness has 
committed a drug-related offence, a reduction of 
penalties may be granted (EMCDDA, 2012).
n  In the United Kingdom, parenteral (injectable) 
medicines can be administered only by the patient 
him-/herself, or by ‘an appropriate practitioner or a 
person acting in accordance with the directions of an 
appropriate practitioner’ (s.58(2)(b) Medicines Act 
1968, UK Government, 1968). However, in 2005, 
naloxone was added to Schedule 7 of the Medicines 
Act, which allows any member of the general public 
to administer naloxone in the event of an emergency, 
with the aim of saving a life, placing naloxone 
alongside adrenaline and other rescue medications. 
Although naloxone is a prescription-only medication, 
the Scottish Lord Advocate passed guidelines in 
2011 to allow local services in contact with high-risk 
drug users to stock naloxone kits for emergency use.
I  Take-home naloxone programmes in European countries
Currently, take-home naloxone programmes exist in 
seven European countries: Denmark, Estonia, Germany, 
for injection, it follows that naloxone should normally be 
available only by prescription. Prescription-only status 
implies that, self-administration being unlikely during 
overdose, naloxone can be administered to the patient to 
whom the prescription was issued by only a medical 
practitioner (e.g. doctor or nurse) or those acting under 
the medical practitioner’s instructions (e.g. family 
members).
In 2014, the EMCDDA consulted networks of experts 
from the 28 EU Member States to assess naloxone 
availability in the European Union (Hughes, 2014). 
National drug policy experts from 24 Member States 
completed one survey; no response was obtained from 
Finland, Ireland, Italy or Slovakia. These results were 
combined with data from a separate survey of experts 
via the national focal points. The results should be 
regarded with some caution, as inconsistencies were 
found in the data, possibly due to differing interpretation 
of some questions. Nevertheless, some numbers serve 
to illustrate the general picture of naloxone provision in 
Europe.
It was reported that naloxone is available by general 
medical prescription in 13 countries, but limited to 
prescription by clinicians in certain settings (e.g. 
hospitals) in 11 countries. None of the 24 countries 
participating in the survey reported that naloxone is 
available as over-the-counter medicine. One country 
reported that naloxone is not officially authorised as a 
medication and that any needs must be addressed 
through emergency imports of naloxone.
The respondents indicated that naloxone is permitted for 
hospital use or emergency response in 15 countries, and 
can be prescribed by any medical doctor in 17 countries. 
Naloxone is part of standard ambulance equipment in 16 
countries, and 14 countries confirmed that all 
ambulance personnel are trained to administer naloxone.
Asked about potential obstacles to wider naloxone 
availability (i.e. take-home naloxone), two respondents 
said that the prevalence rate of opioid overdoses in their 
country was too low to encourage naloxone provision. 
Most respondents mentioned potential legal concerns; 
for example, the possession or use of naloxone without 
authorisation could be considered an offence in seven 
countries. In at least five countries, first responders 
could theoretically be held liable for injury or death of an 
overdose victim, while one respondent considered that 
doctors could be held liable for prescribing naloxone.
However, in several European countries, examples were 
given of the legal code protecting first responders, as 
follows:
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design is not controlled, it is unclear whether or not a 
parallel downward trend in drug-related deaths in 
Denmark, which has occurred since, but had already 
begun before the project started, reflects the 
effectiveness of take-home naloxone.
The project coordinators point out that there is a heavy 
administrative burden associated with take-home 
naloxone distribution due to the antidote’s prescription-
only medication status, but are hopeful that intranasal 
naloxone may become available in Denmark as an 
over-the-counter medication after the end of the project 
(Saelan, 2014).
Estonia
Estonia has the highest drug-related mortality rate 
among adults (aged 15–64 years) in the European 
Union, with 111 deaths per million inhabitants in 2013, 
and most drug overdose fatalities are associated with 
the use of fentanyl, a highly potent synthetic opioid 
(EMCDDA, 2015d).
In September 2013, the National Institute for Health 
Development (NIHD) launched the Estonian take-home 
naloxone programme. The programme operates in Harju 
and East-Viru counties, which have the country’s highest 
prevalence of injection drug use. Persons at risk of opioid 
overdose (including patients enrolled in opioid 
substitution treatment as well as their family members 
are eligible to partake in the programme. Moreover, 
opioid substitution treatment providers and harm-
reduction outreach workers are eligible to take part. All 
programme participants must be at least 16 years of 
age, which has to be proven by the production of an 
identity document.
Programme participants receive training in overdose 
management, naloxone administration and infectious 
disease prevention, and receive a take-home naloxone 
kit if they pass an overdose prevention knowledge test. 
Like the Scottish take-home naloxone programme (see 
box below), patient lists are generated (instead of issuing 
individual prescriptions) and the distribution of naloxone 
kits is logged to comply with national legislation. 
Take-home naloxone kits contain the Prenoxad injection 
and an information leaflet. Since pre-filled syringes are 
not licensed in Estonia, Prenoxad kits are imported from 
the United Kingdom using a special authorisation from 
the Estonian State Agency of Medicines. The Estonian 
take-home naloxone is fully government funded, and 
provision of the service is carried out in cooperation with 
local healthcare providers and harm-reduction services. 
As of October 2014, 552 naloxone kits had been 
Italy, Norway, Spain and the United Kingdom (EMCDDA, 
2015c). The programmes vary largely in their format: 
some are small and time-limited pilots, whereas 
Scotland and Wales have recently launched nationwide 
programmes.
Denmark
According to 2006 capture–recapture estimates, there 
are around 13 000 injection drug users in Denmark 
(EMCDDA, 2015d). During the 1990s and 2000s, 
Denmark has seen 250–275 direct drug-induced deaths 
(overdoses) registered per year, the majority of which are 
related to methadone and heroin.
As a result of the high number of opioid-related 
overdoses, the Danish Ministry of Health decided in 
2012 to introduce a take-home naloxone programme, 
based on the positive outcomes of a pilot project in the 
capital city, and starting in March 2013 (Saelan, 2014).
Opioid users and potential bystanders, such as family 
members, friends and social service agency staff, are 
eligible to participate in the Danish take-home naloxone 
programme, which forms part of a wider agenda of 
harm-reduction measures. The government-funded 
project was initially rolled out in four Danish 
municipalities (Copenhagen, Aarhus, Odense and 
Glostrup) known to have a street scene of opioid use, 
but there are plans to expand the programme to other 
municipalities, provided the results of the ongoing 
evaluation — expected for mid-2015 — are positive. 
Training, data collection and project coordination 
are centrally managed by the municipality of 
Copenhagen.
After attending a training on overdose prevention and 
management, participants receive the naloxone kit, 
which contains a 2-mg/2 ml pre-filled naloxone syringe 
with nasal atomiser as well as three pieces of paper: a 
training certificate, an action card with overdose 
management instructions, and a data card (to complete 
and return to the Copenhagen team after an overdose 
event). Trainees are instructed to regard the 2-mg/2 ml 
formulation as five doses of 0.4 mg each: the first three 
doses are for intranasal administration and, in case of 
non-response, the fourth and fifth doses should be used 
for intramuscular administration.
As of October 2014, 100 people had been trained as 
trainers, and 121 drug users had received overdose 
prevention training and take-home naloxone kits. There 
have been seven instances of reported naloxone use for 
overdose reversal. However, because the evaluation 
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understanding of opioid overdose signs and risk 
factors, naloxone administration and overdose 
emergency management (calling an ambulance, 
recovery position and basic life support), they are 
issued a take-home naloxone kit by prescription. The 
project was launched in May 2015 (Department of 
Health, 2015). No data have been published to date, but 
a project website has been established (www.drugs.ie/
resources/naloxone).
Italy
The latest estimate of the number of high-risk opioid 
users in Italy suggests that there were about 168 000 
problem opioid users in Italy in 2013 (EMCDDA, 
2015b). For the same year, Italy reported a total number 
of 344 directly drug-induced deaths — the lowest 
number since 1999. A total of 196 drug-induced deaths 
had toxicology-testing results available, which 
indicated opioids as the most prevalent substance 
causing death in 146 cases. However, the prevalence of 
opioid use (including heroin) varies widely by region 
(EMCDDA, 2015d). Italy is the only country where 
naloxone is available without a prescription (so-called 
SOP status, Senza Obbligo di Prescrizione (WHO, 
2014)). Italian pharmacists can issue naloxone without 
a medical prescription, but naloxone cannot be publicly 
displayed on shelves to which customers have direct 
access, and customers need to request naloxone 
directly from the pharmacist. Take-home naloxone 
distribution was introduced in the cities of Bologna, 
Padua and Turin as early as 1996 (Schifano, 2001; 
Simini, 1998). In Padua, about 150 naloxone vials were 
given out to carers of methadone patients over the 
course of 18 months. However, there was no formal 
assessment and, although overdose deaths went down 
citywide, the trial was abandoned (Schifano, 2001). The 
current availability of community-based naloxone varies 
regionally.
Norway
Norway is among the countries with the highest 
drug-induced mortality rates in Europe, with 70 
overdose deaths per million adult inhabitants in 2013 
(EMCDDA, 2015d). There are an estimated 8 400 
people who inject drugs in Norway and the number of 
high-risk opioid users in the country is estimated to be 
7 700 (EMCDDA, 2015d). In 2012, a total of 246 
drug-induced deaths were recorded, and toxicological 
confirmations, available for nearly all drug-induced 
deaths, confirmed that 192 involved opioids with or 
without additional drugs.
distributed, which led to 72 repeat prescriptions and 71 
overdose reversals.
Future goals for programme development include (1) to 
increase the number of distributed naloxone kits to at 
least 1 000 and (2) to scale the programme up in other 
regions with high overdose prevalence. Moreover, NIHD 
plans to actively involve Estonian police in the 
programme (Abel-Ollo, 2014; Andrey Rylkov Foundation 
for Health and Social Justice, 2013).
Germany
Together with Jersey (see below), a Berlin-based pilot 
constitutes the first published report on take-home 
naloxone provision to heroin users for community-based 
overdose management (Dettmer et al., 2001). In January 
1999, take-home naloxone was introduced for clients 
attending a mobile needle and syringe exchange scheme 
and community programme (Fixpunkt). Within 16 months, 
124 take-home naloxone kits were issued, and 22 users 
reported having administered the naloxone in a total of 29 
overdose sufferers, all of whom recovered. The project 
continued until December 2002 and was well received 
among Fixpunkt clients, but could not secure funding 
beyond the pilot’s duration (Dettmer, 2014; Deutsche 
AIDS-Hilfe, 2013). Nonetheless, Fixpunkt continued to 
distribute take-home naloxone at a low volume. 
Furthermore, a counselling and treatment centre in 
Frankfurt (Integrative Drogenhilfe e.V.) runs a small-scale 
naloxone action research project in close partnership with 
the University of Applied Sciences Frankfurt/Main, with a 
special focus on identifying obstacles to establishing 
naloxone programmes as part of standard service 
provision. A first visible result of this cooperation was a 
guideline about how to set up and run programmes 
adapted to the German context (Stöver, 2015).
Ireland
The number of drug-related deaths in Ireland increased 
from 105 in 2003 to 181 in 2012. The majority of 
overdose fatalities registered in 2012 were opioid-
related, and toxicology results revealed that methadone 
was present in more cases than heroin (EMCDDA, 
2015d). In October 2014, the Irish Health Service 
Executive announced that it would fund a take-home 
naloxone demonstration project with an initial target 
sample size of 600 opioid users (Sheehan, 2014). 
Opioid users willing to participate in the project are 
required to attend a video-based training session and 
complete a post-training knowledge questionnaire. If 
project participants can demonstrate sufficient 
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In 2008, the Public Health Agency of Barcelona and the 
Public Health Agency of Catalonia launched a formal 
take-home naloxone programme. The Catalonian 
take-home naloxone programme was integrated into the 
Catalan Drug Abuse Care Centres Network (XADC), 
which covers 64 drug-treatment centres, 17 therapeutic 
communities, 10 detox units and 13 drug-consumption 
rooms, among other facilities. At participating sites, most 
staff members received training (on site or online) in 
overdose prevention and response, and at each site a 
project champion for implementation of the take-home 
naloxone programme from January 2009 onwards was 
identified. People who injected drugs received a financial 
incentive to attend training that covered overdose risk 
factors and overdose emergency management 
(including naloxone administration). As of December 
2013, 1 007 professionals and 4 738 injecting drug 
users had been trained and 5 830 naloxone kits had 
been distributed since start of the programme in 2008. 
Among those who received naloxone and witnessed an 
overdose, 40 % reported using the naloxone kit. In a 
cross-sectional study of 306 opioid users in Catalonia, 
44 % reported having participated in an overdose 
prevention programme (Arribas-Ibar et al., 2014), 
suggesting substantial coverage of the target population.
However, overdose deaths in Catalonia had been 
decreasing since well before the start of the take-home 
naloxone project, and it remains unclear whether or not 
the continuous decline in overdose deaths is the result 
of the take-home naloxone project. Major obstacles to 
the project are that (1) abstinence-oriented services 
have been reluctant to distribute naloxone and (2) some 
users are unwilling to carry naloxone. Both points need 
to be explored in more detail. Future aims of the 
Catalonian programme include offering shorter, more 
flexible training sessions, involving peers in the training 
and expanding take-home naloxone provision to prisons. 
Moreover, the project coordinators recommend that all 
drug care centres should systematically assess clients’ 
overdose risk, and that such programmes should also be 
deployed in prisons, since drug users have a higher risk 
of death from overdose in the weeks following their 
release from prison.
United Kingdom and Crown dependencies
Take-home naloxone distribution was first piloted 
through a community-based drug clinic on the island of 
Jersey (Dettmer et al., 2001), a Crown dependency, 
before it was introduced in the United Kingdom. 
Between October 1998 and January 2000, 101 drug 
users were trained in overdose management and 
received take-home naloxone kits. During this period, 
In April 2014, the Norwegian Minister for Health 
launched the national overdose-prevention campaign. 
The campaign covers a 5-year overdose-prevention 
strategy, including take-home naloxone distribution.
The Norwegian naloxone pilot, which officially started in 
late June 2014, involves take-home naloxone 
implementation in the country’s two largest cities 
(Bergen and Oslo) over a 2-year period. The initiative is 
mainly run out of 10 sites: primarily low-threshold health 
and care facilities, but also housing facilities, drop-in day 
centres and services ‘on wheels’. The project targets 
drug users (in and out of treatment), users’ families and 
peers, police officers and treatment facility staff 
members. At the end of a training session, which takes 
approximately 10 minutes, participants receive a 
2-mg/2 ml pre-filled syringe equipped with a nasal 
adapter (MAD300). Unlike the Danish pilot, the 
Norwegian naloxone kit does not contain a needle for 
naloxone injection, and only intranasal administration is 
possible. Since no needles are provided, no individual 
prescription is needed either. To distribute this off-label 
naloxone nasal spray formulation, the Norwegian pilot 
had to obtain special approval from the Norwegian drugs 
regulatory authority before the pilot started.
As of October 2014, 456 naloxone kits had been 
distributed, including 12 to police officers and 11 to 
family members. Seventy-six individuals returned for 
naloxone refills. As part of evaluation efforts, the project 
aims to link naloxone and questionnaire data with 
registry data on emergency medical service usage and 
mortality records.
Future aims include the expansion of the pilot to 
prisoners on release, detoxification units and 
maintenance treatment facilities. One setback for the 
pilot has been that the manufacturer of the nasal spray 
increased the product price by 50 % as soon as the 
project had received regulatory approval.
Spain (Catalonia)
In Barcelona, 64 overdose deaths were reported in 2012 
(Rodríguez-Sanz et al., 2014). A recent study estimates 
that Barcelona has the highest mortality rate in Spain 
(Espelt et al., 2015).
Early reports point to ‘underground’ distribution of 
take-home naloxone in Barcelona as early as 2001, 
which allegedly led to 60 successful overdose reversals 
(Trujols, 2001). However, medico-legal concerns 
prevented the authorisation of a take-home naloxone 
pilot study at the time.
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prescription only medicine requirements when it is 
supplied by a drug service commissioned by a local 
authority or NHS’ (DrugScope, 2015).
I  Take-home naloxone projects under consideration in Europe
France
Data from 2011 suggest that there are approximately 
210 000 opioid users in France, and opioids (mostly 
heroin) account for about a third of the country’s new 
entries into treatment. At seven deaths per million of the 
population aged 15–64 in 2012, the French drug-
induced mortality rate among adults is less than half the 
European average. Toxicological data reveal that opioids 
are involved in more than three-quarters of all drug-
related deaths in France (EMCDDA, 2015d).
To reduce opioid-related overdose mortality, the 
introduction of take-home naloxone programmes in 
France was recommended by the Addiction Committee 
in 2008 (Direction Générale de la Santé, 2008) and by 
the National Narcotics and Psychotropic Substances 
Commission in 2009 (Agence Française de Sécurité 
Sanitaire et des Produits de Santé, 2009). Emergency 
overdose management by a layperson without medical 
training was already legal, as French law places the onus 
five successful overdose reversals were reported, none 
of which involved adverse events. Together with a 
Berlin-based pilot, the Jersey initiative was documented 
in the first published report on take-home naloxone 
provision by Dettmer et al. (2001).
In the United Kingdom, naloxone distribution was first 
introduced in 2001, when south London-based 
addiction treatment services began prescribing 
take-home naloxone to methadone and detox patients 
at treatment initiation and discharge (Strang, 2001), 
which was later extended to diamorphine patients. In 
2005, the legal status of naloxone was changed to 
open the doors to naloxone administration by lay first 
responders (including peers, family members, hostel 
workers): naloxone was added to Schedule 7 of the 
Medicines Act, which allows any member of the general 
public to administer the drug in an emergency with the 
aim of saving a life, placing naloxone alongside 
adrenaline and other rescue medications. By 2011, at 
least 16 sites had implemented pilots in England 
(NTA, 2011).
The prescription-only status of naloxone has been under 
review by the Medicines and Healthcare Products 
Regulatory Agency (MHRA) since 2013, and new 
regulations are expected to come into effect in October 
2015. Public Health England (PHE) expects that, under 
the new regulations, naloxone will be ‘made exempt from 
In Scotland, three local take-home pilots (in Glasgow, 
Lanark and Inverness) were launched in or after 2007 
(McAuley et al., 2012). In 2011, the Lord Advocate 
passed guidelines that allowed naloxone to be 
provided to services without prescription for use in an 
emergency (ACMD, 2012). Moreover, the guidelines 
allowed the storage of naloxone in non-medical 
facilities. The guidelines facilitated the introduction of 
the Scottish National Naloxone Programme (SNNP) in 
2011. The programme involves take-home naloxone 
distribution in the community as well as in prisons 
(upon release). Community-based services can issue 
take-home naloxone to the person at risk of opioid 
overdose, to family members and peers (with 
documented consent of the person at risk) and to 
agency staff. The Scottish government funds the 
programme centrally, and all service providers are 
reimbursed for the number of naloxone kits issued.
During a 12-month period in 2013/14 alone, the SNNP 
issued a total of 6 472 naloxone kits, of which 5 395 
(83 %) were in the community and 1 077 (17 %) to 
prisoners on release. Among Scottish prisoners 
supplied with take-home naloxone, mortality within 4 
weeks after release had decreased to 4.7 % by 2013, 
compared with the pooled 2006–10 baseline of 9.8 % 
(Information Services Division, 2014). Similar 
reductions of overdose deaths were observed after 
hospital discharge. In fact, since the programme’s 
start in 2011, the number of heroin-related deaths 
within 4 weeks of prison release has decreased 
gradually every year, coinciding with a steady increase 
in the number of take-home naloxone kits provided. 
The significance of this reduction has been examined 
(Bird et al., 2015a), with study rationale as described 
by Bird et al. (2015b).
Example of good practice: Scotland
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Médicament et des produits de santé, 2015). The 
take-home naloxone programme will prioritize newly 
released inmates and patients after opioid withdrawal as 
target populations. 
Germany
A counselling and treatment provider in Cologne (Vision 
e.V.; www.vision-ev.de/) is planning to start a naloxone 
programme using a peer-based approach, and a regional 
drug user advocacy group in North Rhine-Westphalia 
(www.jesnrw.de/) is developing a concept for low-
threshold training and distribution of naloxone to drug 
users and their peers in a street setting, starting in 2016 
(JES e.V. NRW, personal communication).
on a bystander to assist in the event of an emergency: 
‘The French Law intends to punish — both in criminal 
and civil law — the bystander who, directly witnessing a 
dangerous incident, does not intervene even though to 
do so would pose no risk to him or a third party’ (DAN 
Legal Network, 2014). However, in the absence of 
political support, the implementation of a take-home 
naloxone programme did not appear on the 
government’s agenda. In February 2015, the National 
Narcotics and Psychotropic Substances Commission 
voted in favour of a take-home naloxone programme for 
drug users and third parties, which would use a naloxone 
nasal spray in the long term, depending on its market 
launch. As an interim solution, the commission also 
issued a favourable opinion for distribution of injectable 
naloxone, so that naloxone could be made available 
more rapidly (Agence Nationale de Sécurité du 
In 2008, the UK Medical Research Council awarded 
funding for the N-ALIVE pilot trial. The trial constitutes 
the first randomised controlled trial that assesses the 
impact of take-home naloxone provision on overdose 
mortality following discharge from prison (Strang et 
al., 2013). Specifically, the trial compares the rate of 
overdose deaths in the first 12 weeks of prison release 
between (former) heroin injectors who received a 
supply of take-home naloxone at release and those 
who did not.
Any prison inmate of at least 18 years of age, with a 
minimum duration of imprisonment of 7 days and a 
history of injection heroin use, was eligible for 
participation in the trial, which started in May 2012. 
Participants from 16 prisons in England were 
randomised to participate in the N-ALIVE trial. Upon 
release from prison, those randomised to the take-
home naloxone arm would receive an N-ALIVE wallet 
containing a pre-filled naloxone syringe and an 
instruction leaflet, as well as a DVD containing video 
instructions on overdose management and naloxone 
administration. Study subjects in the control group 
learnt, at the point of their release, that the N-ALIVE 
wallet given to them contained no naloxone.
Following the release of the 2013/14 data report from 
the Scottish National Naloxone Programme, and with 
the N-ALIVE finding from interim analysis that twice as 
many naloxone kits were used to resuscitate another 
person (whereas the trial was measuring only death or 
survival of the actual prison releasees), recruitment into 
N-ALIVE was terminated for ethical reasons: with this 
new information, the committee that oversaw the 
N-ALIVE pilot trial deemed it unnecessary to continue 
the trial, especially as most overdose victims who were 
benefiting from the N-ALIVE naloxone were not those 
who were being followed up in the trial (or, even worse 
from the point of view of the trial, might even be 
subjects allocated to the control condition). 
Randomisation to the N-ALIVE trial ended on 8 
December 2014. The committee recommended that, 
following the end of randomisation, take-home 
naloxone provision on release should be continued for 
all prisoners with a history of opioid use. In total, 1 685 
subjects were recruited into the N-ALIVE trial. The 
results of the trial will be released in 2015 (MRC, 2014).
Following N-ALIVE, non-randomised prison-based 
naloxone provision has been introduced in the United 
States, in San Francisco and Rhode Island (Clear, 
2015). In Russia, the AIDS Foundation East–West 
(AFEW) has recently funded a take-home naloxone 
programme that targets prisoners in the Tomsk prison 
system in Siberia (Open Society Foundations, 2013): 
upon release, (ex-)prisoners can choose to attend 
community-based overdose prevention training, 
where they are supplied with take-home naloxone.
Example of good practice: N-ALIVE and prison-based overdose prevention
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Take-home naloxone programmes have since been 
established in at least 15 US states and the District of 
Columbia. The rapid dissemination of take-home 
naloxone was made possible by the introduction of Good 
Samaritan laws (granting legal immunity to bystanders) 
and the amendment of medical liability laws (relieving 
naloxone prescribers of liability) (NPHL, 2014).
A recent US survey among 136 organisations (84 
community-based organisations, 28 healthcare facilities, 
18 public health departments and six pharmacies) 
reported providing overdose training and take-home 
naloxone kits to 152 283 individuals between 1996 and 
mid-2014, and documented 26 463 overdose reversals 
(Wheeler et al., 2015). Many of these programmes were 
introduced in response to rising mortality from 
prescription opioid overdose.
I Canada
In Canada, take-home naloxone initiatives of varying 
sizes exist in several regions. The only published 
Canadian study (Leece et al., 2013) reports on a 
I  Naloxone initiatives outside the European Union
There is an increasingly well-connected network of 
practitioners and policymakers interested in take-home 
naloxone, as well as interest and activism from injecting 
drug users and harm-reduction organisations. 
Consequently, it is important to track developments from 
outside Europe, to understand the potential for wider 
implementation and more effective prevention of opioid 
overdose deaths across Europe and beyond.
I United States
Following the pioneering Chicago Recovery Alliance 
take-home naloxone pilot, early adopters in the United 
States included New Mexico (Baca, 2001; Baca and 
Grant, 2005) and the San Francisco DOPE (Drug 
Overdose Prevention and Education) project 
(Seal et al., 2005), which both introduced naloxone 
distribution in 2001.
In the United States, the most comprehensive 
programme evaluation to date has been conducted by 
the Massachusetts Department of Public Health.
In the early 2000s, amidst rising overdose rates, 
Boston-based harm reduction activists began 
distributing take-home naloxone without formal 
approvals, through underground needle-exchange 
schemes. However, the activists maintained a log of 
the number of naloxone vials distributed and the 
number of overdose events reversed, and 
documented these numbers in a 2005 letter to the 
mayor of Boston. In response, the mayor convened a 
joint meeting with the activists and the Department of 
Public Health. As a result of the meeting, the Boston 
Public Health Commission (BPHC) authorised the 
development of an overdose-prevention programme 
with naloxone distribution through its mobile needle-
exchange programme. This programme was the first 
take-home naloxone programme that involved the 
distribution of intranasal naloxone (see Chapter 6), as 
opposed to the standard naloxone injection. Moreover, 
a standing order was passed by the Medical Director 
to allow trained, non-medical public health workers to 
issue the naloxone to injecting drug users and 
potential overdose bystanders. By 2009, the 
Massachusetts Department of Public Health had 
expanded the programme to seven more 
communities. At present, the Massachusetts take-
home naloxone programme provides overdose 
education and naloxone supplies at needle-exchange 
sites, methadone clinics, homeless shelters, inpatient 
detoxification programmes, community meetings, 
outpatient and residential addiction-treatment 
programmes and emergency departments. Taken 
together, as of 2014, the Massachusetts take-home 
naloxone programme had trained 4 926 drug users, of 
whom 373 (7.6 %) reported administering naloxone 
(Doe-Simkins et al., 2014). A 2013 interrupted-time 
series analysis compared overdose rates in 
Massachusetts-based communities with take-home 
naloxone programmes and those without and found 
that those communities where take-home naloxone 
was available had significantly lower overdose 
mortality rates (adjusted rate ratio 0.71; 95 % 
confidence interval 0.57–0.90) (Walley et al., 2013).
Spotlight: Massachusetts
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administration, while others deliver naloxone free of 
charge to existing clinics or trained peer groups.
Initial results are promising: in Kyrgyzstan and Tajikistan, 
where overdose deaths are common because of the 
geographical proximity to Afghanistan and easy access 
to high-purity heroin, naloxone usage rates (i.e. naloxone 
kits used as a proportion of all kits distributed) were 
calculated for two take-home naloxone programmes. The 
analysis was based on questionnaire data obtained from 
programme participants who returned for naloxone 
refills. In both countries, a high proportion of naloxone 
kits (Kyrgyzstan 47 %; Tajikistan 78 %) were used in 
overdose incidents (Kan et al., 2014).
I Lessons learnt
Largely run on a pilot basis, a wide range of naloxone 
distribution programmes currently exist. This variety of 
programme features is reflective of the need to tailor 
each individual programme to the available resources, 
local context and regulations. Despite these structural 
differences, the following joint lessons learnt may apply 
to the implementation of future take-home naloxone 
programmes:
n  Governmental support facilitates roll-out legally and 
financially (see Denmark, Estonia, Massachusetts, 
Norway, Scotland and Wales).
n  Gaining the support of local police is crucial for 
programme success (see Estonia and Norway), as it 
decreases users’ fear of contacting ambulance services.
n  Integrating naloxone provision into standard care at 
existing healthcare facilities promotes project 
sustainability (Norway).
n  Involvement of user groups facilitates outreach and 
promotes project acceptability (Massachusetts and 
Norway).
n  Family members and other carers can be vocal 
advocates to receive training themselves and to 
support wider provision to the user community 
(England and Scotland).
n  First-responder services such as ambulance services, 
firefighters and police are an important workforce to 
be trained and can be influential advocates (England 
and United States).
Toronto-based take-home naloxone programme that 
trained 209 injecting drug users in overdose prevention 
and naloxone administration, and registered 17 overdose 
reversals. In Vancouver and surrounding British 
Columbia, a multi-site take-home naloxone programme 
has dispensed over 1 200 naloxone kits since 2012, and 
125 overdose reversals have been reported (Canadian 
Drug Policy Coalition, 2014).
I Australia
The first Australian take-home naloxone programme 
was started in Canberra in December 2011. In a 
preliminary evaluation, 140 injecting drug users had 
been trained in overdose prevention and reported 23 
successful overdose reversals (ACT Health, 2014). 
Naloxone access in Australia has been facilitated by the 
addition of the antidote to the Pharmaceutical Benefit 
Scheme (Australian government programme that 
provides subsidised prescription drugs) in December 
2012, whereby Australian residents can now obtain 
naloxone made by an Australian manufacturer at a 
concession rate of AUD 5.90 (approximately EUR 4.20), 
rather than the previous AUD 60 (EUR 43) (Fowlie, 
2013). Provision of take-home naloxone is coordinated 
by different agencies, including charities such as the 
Salvation Army.
I Low- and middle-income countries
Over the course of the past 5 years, take-home naloxone 
programmes have been established as pilot projects in a 
number of low- and middle-income countries (LMICs), 
including Afghanistan, China, Georgia, India, Kazakhstan, 
Kyrgyzstan, Tajikistan, Thailand, Ukraine and Vietnam 
(UNODC and WHO, 2013). Funding of these 
programmes is heavily dependent on foreign aid. The 
need for such programmes in LMICs, where opioid 
substitution treatment availability is often limited, was a 
particular focus of the new guidelines on community-
based management of opioid overdose from the 
WHO (2014).
Take-home naloxone programmes are considered a 
central element of overdose prevention efforts across 
LMICs, where opioid users face significant barriers to 
medical care, such as the fear of arrest or forced detox 
following disclosure of opioid use, and prohibitive cost of 
treatment. Particularly in rural areas, emergency medical 
services are limited in availability, and lack of transport 
makes it difficult for individuals to access existing clinics. 
Some take-home naloxone pilot programmes provide 
naloxone directly to users and family members for lay 
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Based on these new research results, WHO published 
new guidelines on community management of opioid 
overdose (WHO, 2014), which are further described in 
Chapter 6 and recommend that ‘People likely to witness 
an opioid overdose should have access to naloxone and 
be instructed in its administration’.
Nonetheless, dissemination of take-home naloxone has 
been remarkably slow: almost 20 years after take-home 
naloxone was first proposed (1996), only Scotland and 
Wales have systems aiming at full national coverage of 
take-home naloxone. However, a growing number of EU 
Member States have introduced local take-home 
naloxone provision and a European exchange of 
experience and expertise on take-home naloxone was 
organised in October 2014 at the EMCDDA. Important 
remaining issues around implementation and scaling-up 
of take-home naloxone provision in Europe are 
addressed in the next chapter.
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I  Take-home naloxone training programmes overview
Training and advice on overdose management are 
recognised as key components of overdose prevention. 
The proposal to prescribe naloxone to opioid users, in a 
similar way to how adrenaline (epinephrine) is prescribed 
to someone with a severe allergy, has been welcomed by 
clinicians, patients and their family members. However, 
the enthusiasm for this new harm-reduction strategy has 
been accompanied by concerns related to the ability of 
patients to deal safely with an overdose emergency. 
These concerns included dealing with the potential 
recurrence of opioid toxicity, withdrawal symptoms of 
the overdose victim, summoning ambulance services 
and risk of blood-borne virus transmission.
Some of these concerns can be minimised by delivering 
good-quality training. However, implementing a take-
home naloxone programme can be challenging, 
particularly if services lack support and funding. Lack of 
training, time and prioritisation are some of the barriers 
cited by new programmes in England (Mayet et al., 2011), 
but information and training materials are now available to 
assist services willing to provide naloxone distribution.
I Is training necessary?
Training is an essential part of take-home naloxone 
distribution programmes. Most witnesses of overdoses 
try to assist the victims in many ways, but some actions 
that are often not taken are among the most important 
ones, such as calling for an ambulance (Darke et al., 
1996). Mistaken beliefs that overdoses can be reversed 
by putting the person in a cold bath, injecting salt 
solution or giving stimulants have also been reported by 
drug users (Beswick et al., 2002; Davidson et al., 2002). 
These beliefs are incorrect and can be potentially 
dangerous, as well as delaying appropriate medical 
assistance.
Community distribution of naloxone is a fairly recent 
intervention and individuals without a medical 
background are unlikely to be familiar with emergency 
overdose cases and the intramuscular administration of 
naloxone. Training helps bystanders to become familiar 
with this medication and to feel competent to use it in 
the event of witnessing an overdose.
I Is training effective?
Training in take-home naloxone can be beneficial to 
those at risk of witnessing an overdose. The short-term 
benefits can be seen immediately after training, in the 
increase of knowledge, confidence and skills of trainees. 
Several studies have assessed the short-term impact of 
take-home naloxone through knowledge acquisition and 
confidence enhancement (McAuley et al., 2009; Seal et 
al., 2005; Strang et al., 2008). A randomised controlled 
trial in England found that knowledge and positive 
attitudes relating to overdose and naloxone 
administration improved to a greater extent in the group 
receiving take-home naloxone training than in the control 
group, which received basic information only through 
leaflets. Positive outcomes were detected 3 months 
after the intervention (Williams et al., 2014). Another 
study found that drug users can be trained to be as 
competent as medical experts at distinguishing opioid 
overdose symptoms and administering naloxone 
appropriately (Green et al., 2008).
Long-term benefits of naloxone training have also been 
reported. A number of studies documented significant 
increases in the identification of overdoses and correct 
administration of naloxone by most trained individuals 
(Lopez Gaston et al., 2009; McAuley et al., 2009; Strang 
et al., 2008).
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training and feel confident and competent to train other 
individuals. Trainers should take time to understand 
opioid-overdose risk factors, the effects of opioids in the 
body and how an overdose can be reversed through the 
use of naloxone. Trainers should be able to explain step 
by step which actions need to be taken if someone 
witnesses an overdose. Trainers also need to feel 
competent to respond to trainees’ questions and to deal 
with sensitive information. A practical way of 
implementing take-home naloxone is by using the 
‘Cascadian Approach’ detailed by Mayet et al. (2011). In 
the Cascadian Approach, training is delivered to 
substance-misuse workers, who then take the lead in 
training their caseloads. To maximise impact, clients can 
also be asked to bring a friend to the training session 
(McAuley et al., 2009; Seal et al., 2005).
Trainers can be counsellors, ambulance service 
personal, harm-reduction workers, nurses, doctors, 
service users and carers. Adequate preparation is vital, 
as drug users have expressed concerns over 
professionals’ lack of credibility and understanding 
about the effects of heroin (Wright et al., 2006). It is 
extremely beneficial for the programmes to involve 
service users fully. Service users should be involved 
from the planning stages, so that their views and ideas 
are taken into account. It is also helpful to involve service 
users in the implementation and delivery of take-home 
naloxone training. Their support is likely to increase the 
credibility of the programme and facilitate recruitment of 
individuals at risk of overdosing.
To become a trainer, individuals should access good-
quality reading materials and have meetings with 
emergency medical personnel to discuss areas of 
conflicting information and clarify any doubts. It can be 
helpful to put together a simple protocol or manual for 
guiding the trainers in covering all the training content. 
Alternatively, available manuals (Perry and Mackintosh, 
2007; Williams et al., 2014) can be adopted or adapted. 
Before launching the programme, trainers could run a 
couple of ‘mock’ training sessions among their 
colleagues. This might be a good opportunity to receive 
feedback on the planned programme. Finally, a system 
of supervision for the trainers should also be put in 
place, so that trainers can receive adequate support 
throughout the programme.
I  Setting
Take-home naloxone training can take place in a variety 
of settings, such as treatment settings (hospital-based, 
residential treatment centres or outpatient clinics), 
prisons or hostels, or through needle-exchange 
Take-home naloxone training may also help to increase 
clients’ self-worth and give them a sense of 
empowerment by offering clients the knowledge, skills 
and competence necessary for them to increase control 
over their own opioid use. Take-home naloxone has the 
ability to transfer some of this control from the hands of 
health professionals into the hands of the clients and 
their social networks. This has the major additional 
advantage of greatly increasing the number of people 
who are competent at overdose management. For 
information on the effectiveness of training, see 
Chapter 6.
I Who needs training?
Most overdoses are reported to occur in private homes, 
and between 70 % and 90 % of them occur in the 
presence of someone else (Best et al., 2002; Lagu et al., 
2006; Tobin et al., 2005; Tracy et al., 2005). The groups 
known to be at risk of witnessing an opioid overdose are 
(see Chapter 4 for more information):
n  current and former drug users, especially those who 
use opioids, people who inject drugs, (former) users 
upon release from prison, (former) users upon 
release from inpatient drug treatment, ever-injectors 
upon release from any hospitalisation and all drug 
users with a personal history of opioid overdose;
n  family members, close friends, partners and other 
family members;
n  health professionals, drug workers, staff at 
supervised drug-consumption facilities, outreach 
workers, hostel staff and ambulance staff;
n  police officers, prison guards and firefighters.
I  Development and implementing training
Careful consideration needs to be given to how take-
home naloxone training is going to be delivered. These 
are some of the aspects that should be considered.
I  Trainers
Anyone can become a take-home naloxone trainer, as 
long as they themselves have received appropriate 
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opioid overdose, actions to take and how to 
administer naloxone safely, as well as on safe 
disposal of used naloxone kits. This information could 
be transmitted to patients individually or in pairs.
n  Standard training: The standard training could be 
delivered when more time and resources are 
available. This training session can include additional 
information on how opioid overdoses can be 
prevented and more detailed information on actions 
to take, with a focus on checking the airways and 
recovery measures. Practising how to check airways 
and breathing and how to place someone in the 
recovery position could be encouraged. This training 
session could be delivered individually, in pairs or in 
small groups. This type of training could also be 
delivered during a counselling session with a drug 
worker or key worker.
n  Advanced training: Services might wish to invest 
time, resources and personnel in a more extensive 
training programme, which could include practising 
how to inject naloxone intramuscularly (possibly 
using an injection trainer; see Figure 5.2) and also 
including some CPR training. For this extensive 
training session, ambulance personnel can be 
included in the delivery. The delivery can occur in 
larger groups. This training would be more directed to 
health professionals, as well as to drug users and 
their family members.
It is important that the training session be practical and 
dynamic, as well as educational. Practising life-saving 
skills at the training session will help reinforce 
knowledge and contribute to building clients’ confidence. 
The practical stage of training can be implemented in a 
systematic fashion, for instance using the four-stage 
method described in the Glasgow Manual (Perry and 
Mackintosh, 2007). This method makes use of adult 
learning principles by transferring the skills gradually 
further away from the instructor to the trainee (Peyton, 
1998). The four-stage teaching method consists of:
n  Conceptualisation: The trainer performs the skill, so 
the participants know what is expected of them.
n  Visualisation: The trainer performs the skill again but 
this time the trainer explains all the actions while 
performing them.
n  Verbalisation: The trainer performs the skill and the 
participants verbalise each action while the trainer is 
performing it.
n  Practice: Participants practise the skills themselves.
programmes and outreach/mobile services. Training can 
take the format of a structured teaching session (in small 
or large groups) or a friendly individual dialogue. These 
types of training might take longer and require more 
resources, but brief training sessions can also be 
beneficial and increase the accuracy in overdose 
identification. A brief training session might take place in 
a waiting room or while other interventions or checks are 
under way.
I  Training content
The training has focused on educating individuals about 
what naloxone is, how to use it and the possible risks 
and benefits involved. In some services, the naloxone 
component has simply been added to their already 
established overdose-management training. Over the 
years, different services have produced a range of 
training protocols, varying in their format, content and 
prescribing procedures.
Training content needs to be consistent and based on 
good-quality information. Some common themes 
covered are risk factors for an overdose, how to 
recognise an opioid overdose, actions to take and 
aftercare procedures (McAuley et al., 2009; Seal et al., 
2005; Strang et al., 2008; Wagner et al., 2010). The 
possibility of adverse reactions needs to be presented, 
alongside a balanced assessment of the dangers of an 
untreated overdose. The importance of calling for an 
ambulance needs to be emphasised, as some studies 
have reported a decrease in ambulance calls after 
implementation of take-home naloxone programmes 
(Bennett and Higgins, 1999; Dettmer et al., 2001; 
Doe-Simkins et al., 2009).
One point of divergence in terms of content has been the 
inclusion of cardiopulmonary resuscitation (CPR) 
training. Some programmes have liaised with local 
ambulance services to deliver naloxone training and CPR 
training together (McAuley et al., 2009; Seal et al., 2005; 
Tobin et al., 2005). However, CPR cannot be taught in a 
brief intervention, so other training programmes have 
excluded full CPR training, giving emphasis to the 
importance of airway and breathing and to consideration 
of naloxone administration (Strang et al., 2008).
I  Different training levels
n  Brief training: A brief training session can be delivered 
when time is short, for instance to patients waiting 
for an appointment. During this brief training, 
individuals should be advised on how to recognise an 
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abdomen. Breathing should be checked for 10 
seconds by:
–  looking to see if the chest is moving;
–  listening near the face for breathing sounds;
–  feeling for a breath on the cheek.
n  Practise how to put someone in the recovery position: 
The recovery position is basically putting someone on 
their side. In this position the airway is open, the 
person is balanced on their side and if the person 
vomits they are unlikely to choke. If the bystander 
needs to leave the scene, they should put the 
overdosed person in the recovery position before 
leaving. To place someone on the recovery position:
–  Put the right hand of the victim by the head as if 
they were waving.
–  Put the left arm across the chest, so that the back 
of the hand rests against the cheek.
–  Hold the hand in place and lift up the left knee.
–  Turn the person on their side by pushing down on 
the knee (see Figure 5.1).
n  Practise how to inject naloxone: Sometimes the 
overdose victim may make grunting, gasping or 
snoring-type breathing sounds for a couple of minutes. 
This is a sign that the person desperately needs 
oxygen. If a bystander observes this type of breathing, 
they should not delay naloxone administration. If a 
heroin user is unresponsive and not breathing (or is 
breathing abnormally), then they should call emergency 
services, put the person in the recovery position and 
give them naloxone. How to inject naloxone:
–  Take the syringe from box/pack.
–  Choose an injection site: the outer thigh, upper 
arm or buttock.
–  Hold needle at 90 degrees to skin.
–  Insert needle into the muscle.
–  Slowly and steadily push the plunger down.
–  Put the used syringe in a sharps box or in a safe place.
–  Do not cover needle, as this is how needle-stick 
injuries can happen.
I  Dealing with an overdose: step-by-step for advanced training
The specific step-by-step approach to managing an opioid 
overdose should be decided by each individual programme. 
Existing national or local guidelines for dealing with opioid 
overdose should be taken into account. Suggested steps 
are detailed below. This step-by-step approach will be most 
suitable when time and resources are available to 
implement advanced training.
n  Approach with care: In a suspected drug overdose 
the witness should be aware of any hazards to him-/
herself and to the suspected overdose victim. They 
should check for danger, such as being careful with 
needles that might be around.
n  Check for response: One of the first steps is to check 
if the overdose victim is conscious by calling their 
name, gently shaking their shoulders, talking loudly 
into their ears, rubbing their sternum or pinching their 
ears or the bed of the finger nail.
n  Call for assistance: The importance of calling for 
assistance should be emphasised. If there are other 
people nearby, the witness could ask them to call 
emergency services, so that the witness can continue 
to look after the overdose victim. If the witness is 
alone, they should call for an ambulance immediately. 
It is important to tell emergency services the exact 
address and directions, what substances they think 
the overdose victim may have taken and whether or 
not the overdose victim is conscious and breathing. 
Witnesses might be afraid of calling an ambulance 
for fear of the police attending. In many European 
countries the police might indeed come, either 
because it is routine practice or to make sure the 
ambulance crew is safe or in case a death has 
occurred. This will vary across countries and 
jurisdictions, so it is important to check local police 
practice and consider involving them in the 
programme, following the example of some US 
programmes (Davis et al., 2015; Rando et al., 2015).
n  Check airways and breathing: The mouth should be 
checked for any obvious obstructions. Any blockage 
should be cleared by kneeling by the side of the 
overdose victim and rolling the victim towards the 
person kneeling. If the blockage does not come away, 
the person should turn the overdose victim’s head to 
the side, hook two fingers together and sweep them 
through the mouth. Breathing should also be checked 
by opening the airways — lifting the chin and tilting 
the head — and then placing their ear above the 
victim’s mouth and looking along the chest and 
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trainer can be used to practise how to give an 
intramuscular injection of naloxone. Expired naloxone 
syringes can be pre-filled with water solution by a team 
member and used to practise naloxone injection at the 
training session. Alternatively, an orange can be used to 
practise giving an injection.
n  After administering naloxone: It is important 
to stay with the overdose victim, assist their 
breathing if necessary and evaluate if a second 
dose is necessary. The dose can be repeated 
if there is no response after 2 minutes. It is essential 
to let the paramedics know that naloxone has been 
given. If naloxone was used, the used naloxone kit, 
including any needles, should be disposed 
of safely in a sharp bin container 
(e.g. the paramedics’).
I  Training material
Training packs
A training pack can also be provided to the participants 
at the training session (Ashton and Hassan, 2006). The 
training pack can contain a number of useful items, such 
as a sharps box, gloves, face shield, swabs, leaflets and 
an emergency card.
Incentives/contingency management
If resources are available, a small incentive can be used 
to increase attendance. Common incentives are gift 
vouchers, food vouchers and public transport vouchers 
(Piper et al., 2008; Seal et al., 2005; Wagner et al., 2010). 
A certificate of training completion can also be issued in 
the trainee’s name.
An injection trainer (Figure 5.2) is a device that looks like 
an arm muscle and is made of multi-layered soft tissue 
pad for the practice of injection techniques. An injection 
FIGURE 5.1
Take-home naloxone training: step-by-step for 
advanced training (adapted from Williams, 
2010, p. 415)
GIVE NALOXONE
APPROACH GENTLY
CHECK FOR RESPONSE AND SIGNS OF OVERDOSE
PUT IN THE RECOVERY POSITION
NOT BREATHING NORMALLY
CHECK AIRWAY AND BREATHING
If not responsive: CALL FOR AN AMBULANCE 
Give the exact address and your phone number to the operator
Inject into the muscle: buttock, outer thigh
or upper arm.
1. Insert the needle at a 90-degree angle to
    the muscle.
2. Push down the plunger.
3. Put syringe in a safe place. 
    Don’t cover needle. 
Tell the paramedics what you have found, 
seen and done. 
FIGURE 5.2
Injection trainer
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a named patient for their personal use. Naloxone 
provision to family members can sometimes seem 
complicated. However, family members are normally 
allowed to collect the medication for a named patient. 
One approach is for the family member to be sent a 
consent form by post, which they need to have signed by 
the user/patient and bring along to the training session, 
and then collect the prescription at the service requiring 
the consent.
Another example for dealing with this issue has been 
seen in Scotland, where a ‘letter of comfort’ by the Lord 
Advocate was provided in 2011, authorising prescribers 
to supply naloxone to individuals likely to come into 
contact with those at risk of opioid overdose (Angiolini, 
2011). This legal document safeguards the prescriber 
from prosecution when prescribing naloxone to 
individuals other than the opioid-user patient.
I  Assessing knowledge and competence: before and after
Overdose and naloxone training is fundamentally an 
educational programme that aims to increase trainees’ 
knowledge and confidence in managing an emergency 
overdose. Questionnaires can be used to assess 
pre-training gaps and then be repeated to measure 
post-training gains in knowledge and confidence. 
However, their use should not become a barrier to 
receiving training and naloxone.
Knowledge and confidence have been assessed in 
several take-home naloxone programmes by asking 
participants before and after training to respond to 
questions related to heroin overdose, risk factors, 
overdose prevention and management strategies. 
Wagner and colleagues (2010), for example, assessed 
the likelihood that trainees would administer naloxone, 
call emergency services and teach someone else how to 
use naloxone. Other programmes looked at trainees’ 
level of comfort with naloxone administration (Piper et 
al., 2008; Tobin et al., 2009). Checklists, open-ended 
questions and recognition tests have also been used to 
evaluate overdose knowledge (Maxwell et al., 2006; Seal 
et al., 2005; Strang et al., 2008). However, few of these 
programme evaluations employed established 
instruments with known validity and reliability. When a 
scale of unknown validity is used, it is not possible to 
determine if it actually measures what it claims to 
measure and if the questions are relevant and clear to 
the trainees. To date, research measures in this field 
have been mostly ad hoc.
I  Naloxone prescription
Naloxone can be prescribed just after the training in a 
one-to-one session with a physician. In the United 
Kingdom, for example, naloxone can be prescribed by a 
nurse or non-medical health worker if a ‘patient group 
direction’ is in place. A patient group direction is a special 
document developed by services and approved by senior 
doctors and pharmacists, which allows professionals other 
than doctors to dispense certain medicines, enabling 
nurses or pharmacists to dispense naloxone legally to a 
named patient (Department of Health, 2000). Some 
aspects to be considered in regard to naloxone prescription 
are the following (see Chapter 3 for more information).
I Formulation
In Europe, preference has been given to dispensing 
pre-filled formulations of naloxone for intramuscular 
administration. Currently, intranasal naloxone is not 
licensed in most countries and has not undergone 
sufficient pharmacological testing to confidently support 
its use by community distribution programmes. 
Nevertheless, it has already been used by some take-
home naloxone programmes (Doe-Simkins et al., 2009) 
and developments are under way to produce and test an 
adequate formulation for intranasal administration.
The dose prescribed has varied, with doses ranging from 
0.4 mg (Galea et al., 2006; Seal et al., 2005) to a 10-ml 
multi-dose vial (Maxwell et al., 2006). A 2-mg/2 ml 
pre-filled formulation with nasal atomiser has been 
provided in the training programme described by Doe-
Simkins et al. (2009). Some training programmes have also 
opted to prescribe two supplies to each trainee (Piper et al., 
2008; Seal et al., 2005; Wagner et al., 2010), but a first dose 
ranging from 0.4 mg to 2 mg has been most recommended 
by programmes (see Chapter 3 for more information).
I Legitimacy of prescription
Some programmes have also provided a ‘proof of 
medication legitimacy’ (Maxwell et al., 2006; Piper et al., 
2008) to avoid problems with naloxone confiscation by 
police. Contacting local ambulance and police services 
might be an important first step when setting up a 
take-home naloxone programme (Seal et al., 2005).
I Consent for medication collection
Naloxone is a prescription-only medication in almost all 
countries and consequently it needs to be prescribed to 
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training should not be a barrier to prescribing another 
supply.
I Follow-up and evaluation
When training users or family members on how to deal 
with an overdose and supplying them with a naloxone 
kit, it is important to determine the long-term impact of 
the programme by evaluating whether or not trainees will 
attempt to use the medication in the future. Studies 
have reported the number of overdoses reversed with 
naloxone administered by the trained individual (Doe-
Simkins et al., 2009; McAuley et al., 2009). Systematic 
follow-up should be conducted to evaluate the quality 
and impact of take-home naloxone programmes. If 
resources do not allow systematic follow-up with all 
take-home naloxone recipients, then contacting a 
random subsample represents a viable follow-up 
strategy.
Many take-home naloxone programmes rely on the 
spontaneous self-report of programme participants who 
return for naloxone refills. When returning for refills, 
programme participants are typically interviewed or 
given a brief questionnaire to assess how they used their 
naloxone supply. Although this follow-up strategy is less 
labour-intensive than systematic follow-up, it is also 
more prone to selection bias, as those who may have 
had a negative naloxone experience will be less likely to 
return for a naloxone refill. Systematic follow-up (of all 
trainees or of a random subsample) is thus a superior 
evaluation method to relying on self-report data from 
those returning for naloxone refills.
Systematic follow-up assessments usually take place at 
3 months (Strang et al., 2008) and 6 months (Seal et al., 
2005). Arguably, a longer follow-up assessment, of at 
least 1 year, would be important, as an overdose is a 
relatively uncommon event. Take-home naloxone 
programmes might also choose to validate overdose 
reports by confirming information with emergency 
service records or by interviewing other witnesses 
(McAuley et al., 2009; Seal et al., 2005).
I Conclusion
Take-home naloxone training may vary in intensity and 
how much it covers. The choice of training level will be 
determined by the setting, the needs of the target group 
and the available resources. Regardless of the training 
level, good preparation and planning is the basis for an 
effective programme. The quality and benefits of 
The Brief Overdose Recognition and Response 
Assessment (BORRA) is one of the few standardised 
scales available to take-home naloxone training 
evaluators (Green et al., 2008). BORRA evaluates the 
ability to recognise overdose symptoms and naloxone 
indication through 16 overdose scenarios. The Opioid 
Overdose Knowledge Scale (OOKS) is a more 
comprehensive knowledge questionnaire that has been 
validated and tested (Williams et al., 2013). The OOKS 
assesses the level of knowledge of opioid overdose 
management, including risk factors of overdose, signs of 
an opioid overdose, actions to be taken in an overdose 
situation, naloxone effects and administration, adverse 
effects and aftercare procedures. The scale also 
identifies misinformation and myths about opioid 
overdose. The Opioid Overdose Attitudes Scale (OOAS) 
is also a validated questionnaire, which assesses 
positive attitudes towards managing an opioid overdose 
(Williams et al., 2013). It assesses self-perceived ability 
to manage an overdose, concerns on dealing with an 
overdose and willingness to intervene in an overdose 
situation. The OOKS and OOAS are brief self-
administered instruments that can be used before and 
after training. Both scales have been validated in 
samples of patients and family members and can also 
be administered to professionals (Ray et al., 2015). Full 
versions of the OOKS and the OOAS are available in the 
appendix to this publication.
I Post-training monitoring
It is important to consider that not all supplies of 
naloxone distributed by a programme will be used to 
reverse an opioid overdose (Bird et al., 2015). Some 
supplies will be lost, some will be confiscated by police 
and some will simply not be used. Therefore, many more 
naloxone supplies need to be distributed than the actual 
number of overdoses. Bird et al. (2015) analysed the 
data from the SNNP and estimated that ‘a country’s 
annual provision of THN-kits should be at least nine 
times its recent-past mean annual number of opiate-
related deaths’ (p. 71), but ideally it should aim at 
distributing around 20 times as many.
I Expired supplies and refresher sessions
Developing a strategy for the replacement of used 
naloxone supplies has been shown to be an easy 
method of keeping a record of the usage rate of naloxone 
kits (Dettmer et al., 2001; Maxwell et al., 2006). 
Refresher sessions could also be offered after a certain 
period of time (McAuley et al., 2009). However, re-
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The idea of providing naloxone to prevent opioid 
overdose deaths has come a long way and over the years 
we have gathered knowledge and experience of how to 
implement naloxone distribution effectively. The range of 
training formats, contents and procedures developed so 
far offers a number of options for services planning to 
set up a new take-home naloxone service. Training has 
been an important part of take-home naloxone 
programmes not just for the clients but also for 
professionals, who can see the benefits of their work by 
witnessing clients’ increase in knowledge, competence 
and self-worth, as well as positive reports of lives saved.
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I Introduction
As reviewed earlier in this volume, naloxone can reverse 
opioid overdose and save lives. We have a good 
understanding of how the drug works as an opioid 
antagonist, competing with opioids to bind to receptors 
and preventing opioids from influencing the body. The 
use of naloxone in emergency medicine is well 
established, but emergency services do not always 
reach overdose victims in time to act, and it is now 
twenty years since providing naloxone to laypersons 
likely to witness or experience an overdose was first 
suggested. We have reviewed the problems that have 
prevented the routine provision of naloxone — in 
combination with training in recognising and managing 
overdoses — to drug users, their peers and family for 
use in the event of an overdose. In addition, we have 
described how take-home naloxone programmes can be 
implemented. In this final chapter, the focus will be on 
the future. The World Health Organization’s (WHO) 
recently issued guidelines, which recommend naloxone 
provision for the community management of opioid 
overdose, provides a good starting point, and the 
EMCDDA’s systematic review highlights the evidence in 
support of the WHO recommendations. 
I  The WHO guidelines and evidence of effectiveness of take-home naloxone
I  The 2014 WHO guidelines: release and potential impact
On 5 November 2014, WHO launched guidelines on the 
community management of opioid overdose (WHO, 
2014) (see box ‘WHO guideline development: 
community management of opioid overdose’). The 
guidelines recommend that people who are likely to 
witness an opioid overdose, including people who use 
opioids and their families and friends, should be given 
access to naloxone and training in its use so that they 
can provide an emergency response to opioid overdose, 
while awaiting the arrival of an ambulance. A global 
panel of experts, the Guideline Development Group, 
‘judged the risk–benefit profile to be strongly in favour of 
naloxone distribution, due to its clear potential for saving 
lives and apparent low risk of significant adverse effects’ 
(WHO, 2014, p. 8). The Guideline Development Group 
recommended that, in addition to the use of naloxone, 
emergency care of suspected opioid overdose should 
include ventilation support, airway management and 
management of withdrawal effects. While basic training 
on the effective use of emergency naloxone was 
considered important, the Guideline Development Group 
considered that the lack of extensive emergency 
intervention training should not impede the use of 
naloxone in the community. The panel noted that, while 
minor adverse events from naloxone administration 
(such as vomiting and opioid withdrawal) were not 
uncommon, serious adverse events were extremely rare 
(WHO, 2014, p. 8). The guidelines further clarify that 
naloxone can be injected or administered intranasally 
and stipulate that ‘while naloxone administered by 
bystanders is a potentially life-saving emergency interim 
response to opioid overdose, it should not be seen as a 
replacement for comprehensive medical care’.
Historically, the use of naloxone had been limited to 
ambulance workers and medical staff at hospitals. The 
new guidelines constitute a paradigm shift in the 
pre-hospital management of opioid overdose, by 
identifying the responsibility of non-medical (and 
medical) bystanders to intervene in an overdose 
emergency and administer naloxone.
I EMCDDA systematic review of evidence
In January 2015, the EMCDDA published a systematic 
review of the effectiveness of take-home naloxone 
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population-based results of programme 
implementations.
A total of 21 studies (one randomised controlled trial, 
three case series and 17 pre–post studies) were 
identified, included in the analysis and evaluated, using a 
qualitative synthesis method.
Results of the analysis showed (1) evidence from all 
studies that take-home naloxone programmes increased 
overdose-related knowledge and (2) evidence from four 
studies (including the randomised controlled trial) that 
the programmes improved naloxone-related attitudes, 
whereas in three studies no improvement was observed.
With regard to naloxone usage, results showed that (3) 
naloxone was used in a median of 67 % of overdoses 
witnessed (range 0–100 %; in the seven studies based 
on active follow-up by researchers) and (4) adverse 
programmes that combine overdose education and 
training interventions with the distribution of naloxone 
kits (EMCDDA, 2015b). Relevant outcomes were (1) 
overdose-related knowledge; (2) naloxone-related 
attitudes; (3) naloxone use during witnessed overdose; 
(4) naloxone-induced adverse events; and (5) overdose 
deaths.
The Cochrane databases, PubMed, EMBASE, Cumulative 
Index to Nursing and Allied Health Literature and the 
Web of Science databases were searched for relevant 
entries. A total of 1 045 unique records were retrieved 
and assessed for eligibility. Studies reporting on take-
home naloxone programmes involving opioid users, their 
family members or peers were deemed eligible for 
inclusion in the analysis if their designs featured 
randomised controlled trials, controlled clinical trials, 
controlled cohort studies, interrupted time-series 
analyses, cross-sectional surveys, case series or 
After the feasibility of naloxone distribution 
programmes had been demonstrated in several 
countries and a 2012 UN resolution had called for the 
widespread adoption of this approach (UNODC, 
2012), WHO, in collaboration with the United Nations 
Office on Drugs and Crime (UNODC), was tasked by 
the United Nations Economic and Social Council to 
provide evidence-based guidance on preventing 
mortality from drug overdose, in particular opioid 
overdose (WHO, 2014). The guideline-development 
process included a systematic literature review, a 
stakeholder consultation in the form of an online 
survey among those affected by such guidelines, a key 
informant survey and assessments by a global expert 
group, nominated by WHO. The quality of available 
evidence regarding several key questions was 
assessed and evidence graded using standardised 
methodology (Guyatt et al., 2008, 2011). This process 
included ‘a narrative assessment of benefits versus 
risks and harms, the estimated values and 
preferences of those who might be affected by the 
guidelines, and the costs, resource utilisation and 
feasibility of the proposed interventions. Where 
necessary, these narrative descriptions also referred 
to other relevant evidence, not included in the 
systematic reviews’ (WHO, 2014, p. 6). All studies and 
relevant outcomes were thoroughly documented.
WHO made the following recommendations:
1.  People likely to witness an opioid overdose should 
have access to naloxone and be instructed in its 
administration to enable them to use it for the 
emergency management of suspected opioid 
overdose.
2.  Naloxone is effective when delivered by 
intravenous, intramuscular, subcutaneous and 
intranasal routes of administration. Persons using 
naloxone should select a route of administration 
based on the formulation available, their skills in 
administration, the setting and the local context.
3.  In suspected opioid overdose, first responders 
should focus on airway management, assisting 
ventilation and administering naloxone.
4.  After successful resuscitation following the 
administration of naloxone, the level of 
consciousness and breathing of the affected 
person should be closely observed until full 
recovery has been achieved.
WHO guideline development: community management of opioid overdose
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I Provider-level barriers
Lack of awareness and legal concerns
Many clinicians and local, national and international 
organisations have endorsed take-home naloxone (e.g. 
ACMD, 2012; AMA, 2012; ASAM, 2013; WHO, 2014). 
Nonetheless, awareness among practitioners is often 
low (Beletsky et al., 2007; Binswanger et al., 2015; Green 
et al., 2013) and can be shrouded in misperceptions 
around legal risks associated with naloxone prescribing 
(Tobin et al., 2005). The systematic review by Clark et al. 
(2014) found that most take-home naloxone programme 
participants did not call an ambulance when witnessing 
an overdose emergency, and it identified bystanders’ 
fear of possible legal repercussions as a central barrier. 
Some of the expressed concerns are genuine 
challenges, such as the legal limitation of parenteral 
drug administration to medically trained staff or only to 
medical doctors, while others are merely perpetuation of 
misperceptions about obstacles that are in large part 
imaginary, for example the real-world likelihood of police 
action or prosecution of bystanders who administer 
naloxone to an overdose victim.
Lack of accountability (opt-in versus opt-out)
The dissemination of take-home naloxone is more 
difficult to achieve when providers and patients need to 
‘opt in’, that is, when patients need to ask their doctors 
for a naloxone prescription or when providers consider 
prescribing take-home naloxone only on a case-by-case 
basis when specifically indicated (as opposed to ‘opt 
out’, where take-home naloxone provision would be 
standard; see also section ‘Increasing healthcare 
provider awareness’). Providers often struggle with 
competing clinical demands, and opt-in medical services 
that are not part of standard care are low priority. In a 
recent US qualitative survey (Binswanger et al., 2015), 
primary care providers mentioned insufficient time 
during patient appointments and the inability to follow 
up with patients as main organisational barriers to 
prescribing take-home naloxone. Similarly, a UK study 
found the integration of overdose prevention services to 
be challenging even among specialist addiction-
treatment staff (Mayet et al., 2011).
I Lack of research and development
Continued research is needed to establish beyond 
reasonable doubt to what extent take-home naloxone 
can reduce mortality among specific populations, along 
events beyond naloxone-induced withdrawal symptoms 
were rarely reported. In terms of (5) overdose deaths, 
results showed that opioid-overdose mortality was 
significantly lower in communities with active take-home 
naloxone programmes, and all take-home naloxone 
programmes had a high survival rate. The authors 
concluded: ‘there is evidence that educational and 
training interventions with provision of take-home 
naloxone decrease overdose-related mortality.’
The conclusion of the EMCDDA systematic review is in 
line with a previously published review by Clark et al. 
(2014) covering 19 of the 21 studies included in the 
EMCDDA review. Clark et al. did not analyse the impact of 
take-home naloxone programmes on opioid-overdose 
mortality but found that take-home naloxone programs 
were effective at training opioid users and potential 
bystanders in overdose-emergency management and that 
take-home naloxone recipients were likely to intervene 
and administer naloxone to reverse opioid overdoses.
I  Barriers to naloxone access in the European Union
Despite evidence of the effectiveness of take-home 
naloxone, a number of barriers to wider naloxone access 
in the European Union persist at the levels of providers 
and policy, as well as research and development.
I Policy-level barriers
In 2014, an EMCDDA network consultation (see 
Chapter 4, section ‘Take-home naloxone in Europe’) 
gathered evidence that some medico-legal concerns 
could continue to represent a central barrier to wider 
take-home naloxone provision in Europe. National policy 
experts were asked if, in their respective countries, 
possession or use of naloxone without authorisation 
could be considered an offence; if first responders could 
be held liable for injury or death of an overdose victim; 
and if doctors could be held liable for prescribing 
naloxone.
Policy experts from 13 EU Member States responded, 
and the results showed that in seven out of the 13 
countries the possession or use of naloxone without 
authorisation could theoretically constitute an offence. 
Bystanders could be held liable in five countries if the 
overdose victim died and in eight countries if the overdose 
victim incurred serious harm. Doctors could be held liable 
for prescribing naloxone in only one of the 13 countries.
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Many reported negative views, which were probably 
caused by excessive naloxone dosing; negative effects 
ranged from acute withdrawal and associated aggression 
towards staff to premature self-discharge from hospital 
and the need to use more illicit drugs to counter the 
effects of the antagonist (Neale and Strang, 2015).
In practice, potential overdose witnesses should be 
instructed to administer as little naloxone as possible 
(even if this means requiring a second dose) and as much 
naloxone as necessary (Strang et al., 2014), but research 
has yet to identify the upper and lower limits of this dose 
range. No studies comparing response to different 
naloxone doses or to different dosing regiments (e.g. 
single bolus versus titration) exist to date (WHO, 2014).
Existing naloxone formulations are not well suited
Currently available formulations of naloxone are licensed 
for administration only by intramuscular, subcutaneous 
or intravenous injection. In terms of suitability for use by 
non-medical personnel, injectable naloxone is not ideal 
and this may be limiting its use by laypersons (Beletsky 
et al., 2012); among the reasons cited are logistical 
challenges, including fear of needle/syringe preparation 
and injecting procedures, potential lack of sterile 
needles, and delays in administration due to insufficient 
training. Moreover, applying the injection can put first 
responders at risk of needle-stick injury and of 
contracting blood-borne diseases (e.g. hepatitis C) 
(Wermeling, 2013), which are highly prevalent among 
the target population.
The absence of naloxone formulations for non-injectable 
administration can present a twofold barrier: on a clinical 
level, a layperson who witnesses an overdose may be 
less likely to intervene and administer an injection for 
fear of needle-stick injury or for lack of familiarity with 
needle-and-syringe assembly; on a policy level, the 
exclusive availability of naloxone as formulated for 
injection may represent the main legal barrier, limiting its 
wider use, as certain jurisdictions restrict the 
administration of injections to medical professionals 
(Hughes, 2014).
How suitable is take-home naloxone for reversal of 
overdose from synthetic opioids?
The majority of take-home naloxone implementation 
studies have been conducted in the United States and 
have focused on heroin users, largely because 
participants are recruited via needle and syringe 
programmes. Less is known about the impact of take-
with investigations into the optimal dose range of 
naloxone for take-home kits, the identification of reliable 
injection-free routes of administration, and the suitability 
of take-home naloxone to reverse overdoses induced by 
long-acting prescription opioids.
Unsystematic take-home naloxone programme 
evaluations
The very nature of overdoses poses significant 
challenges for programme-evaluation designs. Firstly, 
while most opioid users have suffered overdoses (and 
survived), overdose death is a statistically rare event that 
is difficult to capture as a key outcome in a study. 
Randomisation of opioid users into intervention and 
control groups is ethically tricky, as it would imply 
denying members of the control group access to a 
potentially life-saving medication. Methodological 
limitations of many of the pilot studies on take-home 
naloxone include lack of systematic follow-up, lack of 
randomisation or control groups, reliance on self-report, 
selection bias largely determined by participants’ 
motivation, drop-out and the inability to quantify the 
number of lives saved.
What is the optimal dose range for take-home 
naloxone?
Disappointingly, it is currently unclear what the correct 
naloxone dose for community-based lay administration 
is, and clinical guidelines differ across EU Member 
States. In international take-home naloxone 
implementation trials, the amount of naloxone given out 
in the ‘kits’ has varied from two 1-ml vials of 0.4 mg/1 ml 
(Galea et al., 2006; Seal et al., 2005) to a 10-ml multi-
dose vial of the same concentration (Maxwell et al., 
2006).
A recent NHS England Patient Safety Alert (NHS 
England, 2014) warned prescribers that ‘larger than 
recommended doses [of naloxone] can cause a rapid 
reversal of the physiological effects [of opioids], leading 
to intense pain and distress, and an increase in 
sympathetic nervous stimulation and cytokine release 
precipitating an acute withdrawal syndrome.’
In qualitative interviews, opioid users have voiced 
concerns about administering take-home naloxone for 
fear of disturbing someone else’s high and inducing 
abrupt withdrawal (Richert, 2015). Moreover, a study by 
Neale and Strang (2015) assessed the views on naloxone 
of users who had themselves overdosed and received 
naloxone treatment in an ambulance or hospital setting. 
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administration (such as nasal) need development and 
validation.
In the following sections, we describe the nasal spray 
and give examples of other potential non-injectable 
routes that may warrant consideration.
Intranasal naloxone
Naloxone can be used ‘off label’ as a nasal spray by 
attaching a mucosal atomiser device to a pre-filled 
naloxone syringe. In the early 2000s, a number of 
ambulance services in the United States, Australia and 
the United Kingdom began using nasal naloxone to treat 
cases of suspected opioid overdose (Barton et al., 2005). 
The advantages are twofold: firstly, the nasal spray is 
quick to administer and, secondly, it protects ambulance 
workers from risk of needle-stick injury. These trained 
ambulance workers used nasal naloxone as the first line 
of treatment, and in cases of non-response administered 
a naloxone injection as a last resort.
Currently, no licensed nasal naloxone product is 
commercially available (6), as basic pharmacokinetics and 
safety data are still lacking. The only published 
pharmacokinetics study reported very low bioavailability 
(4 %) (Dowling et al, 2008), relative to 100 % intravenous 
bioavailability.
The non-response rate to intranasal naloxone has 
been assessed in studies in Australia and the United 
States. In an ambulance-based randomised controlled 
trial in Australia, intranasal naloxone recipients were 
found to be less likely to restore normal breathing than 
intramuscular naloxone recipients (63 % versus 82 %) and 
more likely to require a ‘rescue’ naloxone injection (26 % 
versus 13 %) (Kelly et al., 2005; Kerr et al., 2009). Similarly, 
an observational trial based in Denver (Colorado) found a 
non-response rate of 16 % among intranasal naloxone 
recipients (Barton et al., 2005).
In recent years, intranasal naloxone has also been 
introduced off label (7) in take-home naloxone schemes in 
(6)  While this book was in press, the FDA approved a naloxone nasal 
spray product on 18 November 2015 (FDA, 2015). The FDA approval 
only applies to US territory, and the nasal spray product has been 
licensed as a prescription-only medicine. A competitor nasal naloxone 
spray product was denied FDA approval on 24 November 2015, due to 
insufficiently rapid absorption of the nasal spray relative to the 
injectable naloxone reference (Reuters, 2015). As of late September 
2015, some pharmacies in 15 US states, including California and 
Pennsylvania, have special practice agreements which allow 
pharmacists to sell naloxone without a prescription. These practice 
agreements will also cover the newly approved nasal spray product.
(7)  Off label: when a medicine is prescribed for an indication that is not 
described in its licence (e.g. a different dose, indication, age group or 
route of administration).
home naloxone on the prevention of overdose deaths 
from synthetic (e.g. fentanyl, methadone or tramadol) 
and semi-synthetic opioids (e.g. hydromorphone, 
oxycodone, oxymorphone or buprenorphine). Overdose 
from synthetic and semisynthetic opioids is 
characterised by slow onset, as their half-life (2 hours 
and upwards) is more than 20 times the half-life of 
heroin (6 minutes; see Table 1.2 in Chapter 1). The 
interaction between naloxone and some of the synthetic 
opioids is more complex; especially long-acting opioids 
may require specific attention during the intervention 
with naloxone (see Chapter 3).
In addition to diverted prescription opioids, the supply of 
synthetic and semisynthetic opioids onto the European 
drug market includes illicit production and online sales 
(Mounteney et al., 2015).
The use of synthetic and semisynthetic opioids is 
growing in the European Union, and in some countries 
fatal overdoses from such substances even exceed 
deaths attributable to heroin. In Estonia, where the 
synthetic opioid fentanyl has replaced heroin in the illicit 
drug market, the highest per capita rate of opioid-related 
deaths in the European Union has been registered 
(EMCDDA, 2014). Even small amounts of fentanyl can be 
lethal: fentanyl is considered to be the most potent 
opioid analgesic, with a potency 30–50 times higher 
than that of heroin (Cassels, 2015).
In two EU Member States, overdoses from methadone 
(mostly diverted) exceed those from heroin (EMCDDA, 
2014). The implementation of take-home naloxone 
provision for the emerging target groups of individuals 
using synthetic or semisynthetic opioids needs to be 
further studied. The supply of take-home naloxone will 
be used only when overdose witnesses realise the 
danger. If someone slips slowly into overdose from 
synthetic or semisynthetic opioids, for example, the 
person may go to sleep and mistakenly be presumed to 
be safe. This means that risk awareness needs to be 
emphasised in training.
I  Paving the way to wider naloxone availability
I  Non-injectable naloxone products
As discussed above, the licensed naloxone injections are 
not well suited for out-of-hospital use by lay bystanders 
who lack medical training. The available naloxone 
products need improvement, and alternative routes of 
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naloxone blood levels, as a study assessing 
pharmacodynamic response to sublingual naloxone in 
an opioid-using sample (Preston et al., 1990) found high 
inter-subject variability. In contrast, buccal naloxone 
administration was found to produce good bioavailability 
in rodents (Hussain et al., 1987), and a first clinical trial 
investigating the pharmacokinetics of buccal naloxone is 
currently being carried out in the United Kingdom 
(EudraCT: 2014-001802-16). The buccal route is already 
used for other emergency medications; for instance, 
buccal midazolam has largely replaced rectal 
suppositories in the emergency management of seizures 
or status epilepticus (MHRA, 2011).
What criteria should a novel naloxone product fulfil?
The benchmark for any non-injectable naloxone product, 
if considered for wider community use, should be that it 
is as effective and reliable as the licensed injection.
According to guidelines presented at a 2012 meeting 
convened by the US FDA, a novel naloxone formulation 
would need to demonstrate bioequivalence to the 
licensed injection in order to obtain regulatory approval 
(FDA, 2012). Bioequivalence between a novel naloxone 
product and the licensed injection can be assumed if the 
administration of one or more standardised doses of the 
new product results in at least as much drug exposure 
as a parenteral dose of at least 0.4 mg. If the relative 
bioavailability of the new product compared with the 
approved injection is low, then it is unclear if adequate 
efficacy can be reached. Vice versa, if the relative 
bioavailability is unexpectedly high, then this may have 
implications for the safety profile of the novel 
formulation. Furthermore, the relative bioavailability 
compared with injection would need to be reasonably 
constant between different individuals. Absorption will 
need to be at least as rapid as intramuscular injection, 
whereby onset of effect starts within 3 to 7 minutes of 
administration (see Chapter 1).
To be considered for registration by the European 
national medicines regulatory bodies, any novel 
naloxone product will need to fulfil similar quality 
standards to those defined in the United States 
(Table 6.1). A novel naloxone formulation will also need 
to be reviewed for safety (8) and usability (9). The FDA 
advises that the amount of safety data required will 
(8)  Drug safety evaluation (also known as pharmacovigilance) is the 
assessment of side effects (harm information) based on the results of 
animal testing and clinical trials. How a drug is manufactured is also 
considered as part of the safety evaluation.
(9)  ‘Usability’ refers to the interaction between human factors and the 
device of drug delivery, with focus on user safety and potential risks 
and errors.
Massachusetts and other parts of the United States, in 
Denmark and Norway, and in the Highland region of 
Scotland, where naloxone nasal spray kits were 
distributed to at-risk patients who had received overdose 
response training. While the ease of administration may 
make the nasal spray particularly suitable for 
administration by layperson responders without medical 
training, the non-response rate to the nasal spray is a 
major concern in a community-based environment, where 
no backup naloxone injection is available to lay 
responders (i.e. until an ambulance arrives) (Strang, 
McDonald et al., in press). The Danish take-home 
naloxone programme gives out naloxone kits with both 
the mucosal atomiser device for nasal administration and 
a needle for intramuscular injection. According to a 2013 
survey of 136 US-based take-home naloxone 
programmes, 51 % of programmes provided only 
injectable naloxone, 37 % provided only nasal kits and 
12 % provided both injectable and intranasal naloxone 
(CDC, 2015).
The nasal spray is typically distributed as a 2-mg/2 ml 
formulation. It remains unclear whether using a more 
concentrated naloxone formulation could reduce the 
nasal naloxone non-response rate or the non-response 
rate reflects a subgroup of opioid users with severe 
damage to their nasal mucosa from snorting drugs. 
Dose-ranging studies with dependent volunteers could 
provide an answer to this question.
Clinical trials investigating the pharmacokinetics of 
intranasal formulations are under way in Norway and the 
United States, but no results have been published to 
date. Two companies have separately filed FDA 
applications for new intranasal naloxone products, on 
which they gave presentations at an FDA-convened 
naloxone meeting in the United States in July 2015 
(Hebert, 2015; Mulligan, 2015). At the earliest, these 
products would enter the market in late 2015.
A further complication with naloxone nasal spray kits is 
that they are currently more expensive than standard 
naloxone injections, and there are reports of 
pharmaceutical companies increasing the price of the 
naloxone nasal kits as demand increases (Clausen, 
2014; Fiore, 2014; see also Chapter 4).
Other non-injectable routes
Among possible alternative routes, rectal suppositories 
can be excluded because of poor acceptability to family 
and peers. Oral ingestion is not possible, as much of the 
active naloxone dose is lost when metabolised by the 
liver. Sublingual delivery appears to lead to unreliable 
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mainly uses an injectable naloxone formulation (with the 
exception of NHS Highland, which uses intranasal 
naloxone; see ‘Conclusion’ below), possible and allowed 
the widespread implementation of take-home naloxone 
in community centres. Firstly, in June 2005, national 
legislation was changed to add naloxone to the list of 
injectable medicines that can be given ‘by anyone for the 
purpose of saving life in an emergency’ (Medicines for 
Human Use Order, 2005). An emergency dose of 
naloxone could now be given to reverse heroin overdose 
without specific medical instruction. This legal change 
opened the doors to take-home naloxone provision and 
to training family members and peers in naloxone 
administration. The first Scottish pilots were launched in 
2007 (McAuley et al., 2012).
Secondly, in 2011, the Scottish Lord Advocate passed 
guidelines that allowed naloxone to be provided to opioid 
users without prescription for use in an emergency 
(ACMD, 2012) and to be stored in non-medical facilities. 
The new guidelines allowed the placement of naloxone in 
locations with high overdose risk (e.g. shelters and 
hostels) and allowed the distribution of take-home 
naloxone from community centres without a physician 
on site, which significantly reduced the staffing burden 
of take-home naloxone prescribing. New legislation 
along similar lines is expected for England in late 2015.
In the United States, Good Samaritan laws granting legal 
immunity to bystanders summoning aid in the event of 
an overdose are increasingly common. By 2014, at least 
14 states had passed such laws to allow take-home 
naloxone administration (NPHL, 2014), and 18 states 
and the District of Columbia had amended their laws to 
promote wider access to naloxone by relieving 
prescribers of the risk of prosecution when prescribing 
take-home naloxone (Alcorn, 2014). In Europe, such 
legislation exists in Luxembourg (see also Chapter 4).
Sharing models of legal approaches across the 
European Union
Most EU Member States currently do not have legal 
provisions for take-home naloxone in place, but a 
number of individual communities and countries in 
Europe have clarified the legal status of take-home 
naloxone prescribing and administration.
At least two levels of facilitating naloxone laws exist in 
the European Union: in Member States where naloxone 
is a prescription-only medication, the legal status of 
naloxone can be matched to the status of other 
injectable antidotes with life-saving potential that can be 
administered by bystanders, such as adrenaline for the 
depend on how much the pharmacokinetic profile of the 
novel formulation differs from the licensed injection 
(Hertz, 2012). A crucial step is to test whether or not the 
novel naloxone product is suitable for layperson 
administration (Compton et al., 2013; FDA, 2012; Volkow 
et al., 2014): can laypersons without medical training 
correctly diagnose an overdose and administer the 
formulation? Vice versa, is the novel naloxone 
formulation safe if it ends up in the hands of a non-
intended population, for example children?
In addition, standard requirements for product 
manufacturing and quality apply, and stability controls, 
excipient controls and batch controls will need to be 
conducted to ensure that different samples of the novel 
naloxone product are sufficiently similar in drug content 
and that the active ingredient, naloxone, does not 
diminish significantly over time.
Provided these criteria are fulfilled, the development of an 
injection-free formulation may enable re-classification of 
naloxone from prescription-only medicine to over-the-
counter medication by the national medicine regulatory 
bodies or at a European level under the European 
Medicines Agency, which would promote wider access to 
the antidote. Critics warn that this regulatory process may 
be lengthy and cost-intensive (Burris et al., 2001).
I  Creating a legal framework for take-home naloxone
Positive examples
Two distinct legal changes in the United Kingdom made 
the Scottish National Naloxone Programme, which 
TABLE 6.1
Product criteria for novel naloxone formulation 
Key criterion Question
Bioavailability How much naloxone is absorbed in the 
bloodstream, compared with naloxone 
injection?
If low bioavailability, is product effective?
If high bioavailability, is product safe?
Speed of 
onset
How quickly is naloxone absorbed?
Duration of 
action
How long is naloxone available in the 
bloodstream?
Reliability Is variability between subjects sufficiently low?
Usability Ease of administration: suitable for layperson?
Storage Is storage in home environment possible? 
Does active ingredient remain sufficiently 
stable? 
NB: Adapted from FDA, 2012. These criteria refer to the US FDA approval 
process for novel naloxone products. EU criteria may differ. Reference 
product: Licensed naloxone injection.
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hostels and shelters for the homeless, to outreach 
workers and to those working in prisons.
In addition, non-medical first responders such as police 
officers and firefighters can be instructed in overdose 
management and naloxone administration, as has 
already been successfully implemented in several states 
in the United States.
I Scaling up: examples of good practice
treatment of severe allergic reactions (anaphylactic 
shock). In Italy, naloxone has over-the-counter status; 
that is, pharmacists can dispense the antidote without a 
prescription.
The roll-out of take-home naloxone implementation in 
Europe can be accelerated by the sharing of model 
legislation, lessons learnt and best practices, which can 
then be adapted to the situation in different countries.
I Increasing healthcare provider awareness
Provider awareness of take-home naloxone can be 
augmented by offering accreditable continuing medical 
education courses on overdose prevention. Provider 
education initiatives should include clarification of the 
legal status of take-home naloxone and particularly 
focus on medical services that constitute points of first 
access for opioid users: general practitioners, 
emergency care and drug-treatment services.
Take-home naloxone coverage among at-risk patients 
can be increased through the introduction of clinical 
guidelines that require providers to implement take-
home naloxone on an opt-out basis, whereby all at-risk 
patients are prescribed naloxone unless patients 
specifically decline. This proactive approach to naloxone 
prescribing is considered to generate higher naloxone 
coverage among patients than a more passive approach, 
whereby patients are asked if they would like to receive a 
take-home naloxone prescription (and are then offered a 
prescription only if they opt in).
Policymakers can also support the implementation of 
take-home naloxone programmes by requiring insurers 
to cover individual naloxone kits (Beletsky et al., 2012).
I  Wider target groups to become involved in take-home naloxone programmes
How can the 2014 WHO guidelines be more fully 
implemented throughout the European Union? To 
answer this question, we need to define the groups of 
people in the community who are likely to witness an 
opioid overdose. Obvious target groups include opioid 
users themselves and their partners, families and peers, 
as well as ambulance staff.
However, it is also important to consider professionals 
whose workplaces bear a high risk of witnessing opioid 
overdose: naloxone should be available to trained health 
professionals, to people working with people who use 
drugs, including staff at drug-treatment centres and 
Scotland and Wales currently operate the only 
national take-home naloxone programmes in the 
world (see Chapter 4). Both started off as local 
pilots in 2007 and expanded to national scope in 
2011. Both programmes are fully government 
funded and use central databases to track the 
number of naloxone kits issued and project impact.
Between 1 July 2009 and 31 March 2014, 4 579 
take-home naloxone kits were issued in Wales, and 
use of the kits was reported in 375 opioid overdose 
events. In an effort to increase the volume of 
take-home naloxone kits in circulation, 1 802 kits 
were issued in Wales in 2013/14 alone; 150 
recorded overdose reversals were recorded in the 
same period. Two deaths were reported (not further 
specified). The Welsh take-home naloxone 
programme tracks overdose prevention training 
and the provision of take-home naloxone kits in a 
national Harm Reduction Database, which 
subsumes local data from 37 registries across 
Wales (Public Health Wales, 2014).
Scotland has its own registry for drug-related 
deaths, which enables the Scottish National 
Naloxone Programme to track the number of opioid 
overdose deaths in relation to the number of 
take-home naloxone kits in circulation. In 2013/14, 
the programme issued 6 472 naloxone kits, of 
which 5 395 were in the community and 1 077 to 
prisoners on release. Analysis of the drug-related 
deaths data from the Scottish registry was able to 
show that, since the programme’s start in 2011, the 
number of heroin-related deaths within 4 weeks of 
release from prison decreased gradually every year, 
Best practice: national programmes 
(Scotland, Wales)
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New pilots
Recent community-based take-home naloxone 
programmes have been launched in Denmark, Estonia 
(both 2013) and Norway (2014; see Chapter 4). While 
Estonia relies on the licensed pre-filled naloxone syringe 
for intramuscular injection, the Norwegian take-home 
naloxone kit contains a spray device (mucosal atomiser) 
for nasal administration and the Danish kit contains 
both. Preliminary data from all three programmes are 
reported in Chapter 4. As part of the Norwegian 
programme it is also planned to expand take-home 
naloxone provision to released former prisoners who 
have a history of opioid use.
New pilots are planned in France (likely to use intranasal 
naloxone) and in Ireland. The Irish government has 
released plans to provide 600 take-home naloxone kits 
for intramuscular injection to active opioid users and 
(former) users upon release from prison. The Irish 
naloxone website can be accessed at www.drugs.ie/
resources/naloxone/. Poland is currently considering the 
introduction of a take-home naloxone scheme.
I Stronger research designs
For better methodological quality, future studies could 
use time-series analyses, stepped-wedge randomised 
trial designs or prospective controlled cohort designs, 
comparing communities where take-home naloxone is 
implemented with communities where it is not 
implemented or only partial roll-out has taken place. 
Self-report data should be complemented with verifiable 
coinciding with a steady increase in the number of 
take-home naloxone kits provided.
The Scottish National Take-home Naloxone 
Programme has managed to raise public 
awareness around overdose risk factors, symptoms 
and emergency response through a resourceful 
project website (www.naloxone.org.uk), which 
includes instructional videos, a ‘naloxone finder’ 
tool and a free overdose app for download.
With regard to best practice, the Welsh naloxone 
programme makes several recommendations: 
firstly, to ensure optimal data quality, take-home 
naloxone programme evaluations should also 
enquire about non-fatal overdose history, housing 
status, ethnicity and risk behaviour; secondly, 
treatment agencies should offer take-home 
naloxone to all patients enrolled in opioid 
substitution treatment; and, thirdly, all take-home 
naloxone recipients (regardless of treatment status) 
should be contacted before the expiry of their 
naloxone kit for re-supply. The Scottish protocol for 
data analysis has recently been published (Bird et 
al., 2014).
New take-home naloxone programmes should pay 
special attention to providing naloxone when 
prisoners with a history of opioid use are released. 
The period following release from prison is 
characterised by a high concentration of heroin 
overdose deaths: among prisoners with a history of 
injection drug use, one in 200 will die of an opioid 
overdose within the first 4 weeks after release from 
prison (Strang et al., 2013). Providing training in 
overdose risk and crisis management plus take-
home naloxone at the time of prison release could 
significantly improve the survival rate of imprisoned 
(former) opioid users.
The UK-based N-ALIVE randomised controlled trial 
(duration: May 2012 to December 2014) was the 
first trial to provide naloxone to former heroin-
injecting prisoners on their release, and the results 
are due to be published in late 2015 (see also 
Best practice: prison-release schemes
Chapter 4). Prison-based or post-prison release 
take-home naloxone distribution has since been 
introduced in the United States, in San Francisco, 
Rhode Island and New York (Clear, 2015), as well as 
in Tomsk, Russia (OSF, 2013).
A recent example of a healthcare intervention that 
has been successfully integrated into prison-based 
routine care is hepatitis-B vaccinations in the 
United Kingdom. Prisoners in the United Kingdom 
are now all offered hepatitis-B vaccination on an 
opt-out basis (NICE, 2012). This could serve as an 
implementation model for future prison-based 
take-home naloxone schemes targeting (former) 
opioid users at release.
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From a harm-reduction perspective, the guidelines 
represent a significant and necessary step towards the 
prevention of overdose deaths. Take-home naloxone has 
been well received by drug users and carers — groups 
that demonstrate enthusiasm, commitment, trainability 
qualities and insight into potential risks — and the 
intervention has been piloted with great commitment by 
early adopters.
Take-home naloxone is currently available in fewer than 
10 of the 28 EU Member States. Overdose deaths across 
the European Union remain at a remarkably high level, 
and action is urgently needed to improve take-home 
naloxone availability.
Member States without existing take-home naloxone 
programmes should move quickly to clarify the legal 
status of the harm-reduction intervention in their 
countries. Moreover, clinical guidelines across the 
European Union should be adapted to establish take-
home naloxone provision as a care standard (e.g. on an 
opt-out basis), where (former) opioid users are routinely 
offered a take-home naloxone kit and can choose to 
refuse the naloxone supply based on their personal 
preference (opt out).
Finally, take-home naloxone programmes should carefully 
document and monitor national data on take-home 
naloxone provision and associated overdose mortality as 
a basis for programme evaluation and sustainability.
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I  Opioid Overdose Attitudes Scale (OOAS): Instructions
I The Opioid Overdose Attitudes Scale (OOAS)
The OOAS is a self-administered questionnaire which 
aims to evaluate attitudes towards managing an opioid 
overdose among addiction professionals, patients and 
their family members. It takes approximately 15 minutes 
to complete.
The OOAS has 28 items grouped into three sub-scales 
relating to overdose management: Competence 
(self-perceived ability to manage an overdose), 
Concerns (concerns on dealing with an overdose) and 
Readiness (willingness to intervene in an overdose 
situation).
n  Competence 10 items: 1, 2, 3, 11, 12, 14, 20, 21, 
24, 26
n  Concerns 8 items: 4, 6, 7, 15, 16, 18, 23, 25
n  Readiness 10 items: 5, 8, 9,10, 13, 17, 19, 22, 27, 28
I Psychometric properties
The OOAS was adapted from the structure of the Drug 
and Drug Problem Perception Questionnaire (Watson et 
al., 2007). Its psychometric properties are described in 
Williams et al. 2013. The scale has proved to be internally 
reliable (alpha coefficient 0.90) and robust over time 
(Intra-Class Correlations = 0.82). Competence, concerns 
and readiness items’ scores fall in the fair-to-excellent 
range for test–retest reliability (ICC = 0.92, 0.55 and 
0.65, respectively).
The scale has also proven to have face, content and 
construct validity. Content validity was tested by 
comparing the scores of addiction professionals and 
family members of opioid users. Professionals reported 
significantly higher scores than family members. 
Concurrent validity was tested by correlating the OOAS 
score and the General Self-efficacy Scale, but no 
association was found.
I Scoring
The OOAS is scored continuously using a 5-point Likert 
scale: completely disagree (1 point), disagree (2 points), 
unsure (3 points), agree (4 points) and completely agree 
(5 points).
Reverse negative items:
The following negative items need to be reversed before 
computing the total of scale points: 4, 6, 7, 9, 11, 15, 16, 
17, 18, 23, 24, 25. You can use the ‘record into same 
variables’ function of SPSS. Recode these items as: 
completely disagree (5 point), disagree (4 points), unsure 
(3 points), agree (2 points) and completely agree 
(1 point).
Totals scores:
Once negative items have been reversed, add all items’ 
points. The total scale points can range from 28 to 140 
points.
Sub-scores
n  Competence: add the points of the following items: 1, 
2, 3, 11, 12, 14, 20, 21, 24, 26
n  Concerns items: add the points of the following items: 
4, 6, 7, 15, 16, 18, 23, 25
n  Readiness items: add the points of the following 
items: 5, 8, 9,10, 13, 17, 19, 22, 27, 28
SPSS data-base and syntaxes can be obtained from the 
author (please see contact details below).
I Data
The table below presents OOAS values that have been 
recorded for drug users and family members:
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The data are available in Anna Williams’ PhD thesis 
(2011) and were published in Williams et al. (2013, 2014):
Williams AV (2011). Training on overdose management 
and naloxone administration for family members and 
carers of opioid users: an evaluation of the short-term 
benefits using validated measures. PhD Thesis. King’s 
College London: UK.
Williams AV, Marsden J & Strang J (2014), Training 
family members to manage heroin overdose and 
administer naloxone: randomized trial of effects on 
knowledge and attitudes. Addiction, 109: 250–259.
Williams AV, Strang J & Marsden J (2013). Development 
of Opioid Overdose Knowledge (OOKS) and Attitudes 
(OOAS) Scales for take-home naloxone training 
evaluation. Drug Alcohol Dependence, 132(1–2):383–6.
Further information can be found at: http://www.kcl.
ac.uk/ioppn/depts/addictions/research/drugs/
Naloxone/Resources.aspx
Family members (n = 73) Drug Users (n = 89)
Mean (SD) Mean (SD)
Pre-training
Immediately 
post-training
3-months
post-training
Pre-training
Immediately 
post-training
3-months
post-training
Total OOAS 97.99 (± 12.7) 118.06 (± 12.8) 116.25 (± 9.7) 102.63 (± 10.4) 118.80 (± 13.9) 113.44 (± 9.9)
Competence 28.28 (± 7.1) 41.61 (± 4.4) 40.83 (± 3.4) 31.46 (± 5.8) 42.48 (± 5.4) 40.60 (± 3.6)
Concerns 28.51 (± 6.2) 32.71 (± 6.5) 32.08 (± 3.7) 28.87 (± 4.7) 31.98 (± 5.5) 30.44 (± 3.9)
Readiness 41.21 (± 4.9) 43.73 (± 4.7) 43.34 (± 4.1) 42.29 (± 4.4) 44.34 (± 5.1) 42.39 (± 3.8)
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Opioid overdose: difficulty breathing, turning blue, lost 
consciousness unable to be roused, collapsing occurring 
in conjunction with opioid use (opioids such as: heroin, 
methadone, morphine, oxycodone, tramadol, fentanyl or 
codeine).
Naloxone: is a medicine (a kind of ‘opioid antidote’) 
commonly used by ambulance services to reverse the 
effects of an opioid overdose and bring the person back 
into consciousness.
I Opioid Overdose Attitudes Scale 
Please, answer the following questions thinking about 
how you would deal with an opioid overdose (opioids 
such as: heroin, methadone, morphine, oxycodone, 
tramadol, fentanyl or codeine).
Before you start answering the questions please read 
the following definitions:
Please, mark how much you agree with each statement:
Completely 
Disagree
Disagree Unsure Agree
Completely 
Agree
 1.  I already have enough information about how to manage 
an overdose
О О О О О
  2.  I am already able to inject naloxone into someone who 
had overdosed
О О О О О
  3.  I would be able to check that someone who had an 
overdose was breathing properly
О О О О О
  4.  I would be afraid of giving naloxone in case the person 
becomes aggressive afterwards
О О О О О
  5.  If someone overdoses, I want to be able to help them О О О О О
  6.  I would be afraid of doing something wrong in an 
overdose situation
О О О О О
  7.  I would be reluctant to use naloxone for fear of 
precipitating withdrawal symptoms
О О О О О
  8.  Everyone at risk of witnessing an overdose should be 
given a naloxone supply
О О О О О
  9.  I couldn’t just watch someone overdose, I would have to 
do something to help
О О О О О
10.  If someone overdoses, I would call an ambulance but I 
wouldn’t be willing to do anything else
О О О О О
11.  I am going to need more training before I would feel 
confident to help someone who had overdosed
О О О О О
12.  I would be able to perform mouth to mouth 
resuscitation to someone who had overdosed
О О О О О
13.  Family and friends of drug users should be prepared to 
deal with an overdose
О О О О О
14.  I would be able to perform chest compressions to 
someone who had overdosed
О О О О О
15.  I would be concerned about calling emergency services 
in case the police come around
О О О О О
16.  If I tried to help someone who had overdosed, I might 
accidently hurt them
О О О О О
17.  If I witnessed an overdose, I would call an ambulance 
straight away
О О О О О
18.  I would be afraid of suffering a needle stick injury if I 
had to give someone a naloxone injection
О О О О О
19.  If I saw an overdose, I would panic and not be able to 
help
О О О О О
20.  If someone overdoses, I would know what to do to help 
them
О О О О О
21.  I would be able to place someone who had overdosed in 
the recovery position
О О О О О
22.  I would stay with the overdose victim until help arrives О О О О О
23.  I would prefer not to help someone who has overdosed, 
because I’d feel responsible if they died
О О О О О
24.  I know very little about how to help someone who has 
overdosed
О О О О О
25.  Needles frighten me and I wouldn’t be able to give 
someone an injection of naloxone
О О О О О
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Reverse negative items:
The following negative items need to be reversed before 
computing the total of scale points: 4, 6, 7, 9, 11, 15, 16, 
17, 18, 23, 24, 25. You can use the ‘record into same 
variables’ function of SPSS. Recode these items as: 
completely disagree (5 point), disagree (4 points), unsure 
(3 points), agree (2 points) and completely agree (1 
point).
Totals scores:
Once negative items have been reversed, add all items’ 
points. The total scale points can range from 28 to 140 
points.
Sub-scores
n  Competence: add the points of the following items: 1, 
2, 3, 11, 12, 14, 20, 21, 24, 26
n  Concerns items: add the points of the following items: 
4, 6, 7, 15, 16, 18, 23, 25
n  Readiness items: add the points of the following 
items: 5, 8, 9,10, 13, 17, 19, 22, 27, 28
I  The Opioid Overdose Attitudes Scale (OOAS): Scoring instructions
The OOAS is a self-administered questionnaire which 
aims to evaluate attitudes towards managing an opioid 
overdose among addiction professionals, patients and 
their family members. It takes approximately 15 minutes 
to complete.
The OOAS has 28 items grouped into three sub-scales 
relating to overdose management: Competence (self-
perceived ability to manage an overdose), Concerns 
(concerns on dealing with an overdose) and Readiness 
(willingness to intervene in an overdose situation).
n  Competence 10 items: 1, 2, 3, 11, 12, 14, 20, 21, 24, 26
n  Concerns 8 items: 4, 6, 7, 15, 16, 18, 23, 25
n  Readiness 10 items: 5, 8, 9,10, 13, 17, 19, 22, 27, 28
I Scoring
The OOAS is scored continuously using a 5-point Likert 
scale: completely disagree (1 point), disagree (2 points), 
unsure (3 points), agree (4 points) and completely agree 
(5 points).
Please, mark how much you agree with each statement:
Completely 
Disagree
Disagree Unsure Agree
Completely 
Agree
26.  I would be able to deal effectively with an overdose О О О О О
27.  If I saw an overdose, I would feel nervous, but I would 
still take the necessary actions
О О О О О
28.  I will do whatever is necessary to save someone’s life in 
an overdose situation
О О О О О
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answer scores one point. ‘Don’t know’ and incorrectly 
marked responses (mistakes) are scored zero. Total 
score range: 0–45 points.
Total Score (45 items):
n  One point if marked (33 Correct/True items): 1a, 1b, 
1c, 1d, 1e, 1f, 1g, 1h, 1i, 2b, 2c, 2d, 2e, 2g, 2h, 3a, 3b, 
3d, 3f, 3g, 3i, 3j, 4a, 5a, 5b, 5c, 6a, 7a, 8b, 9T, 11T, 
12T, 14T
n  One point if NOT marked (12 Incorrect/False items): 
2a, 2f, 2i, 2j, 3c, 3e, 3h, 3k, 5d, 5e, 10F, 13F. You might 
choose to use the ‘record into same variables’ 
function of SPSS and inverse the values of these 
items.
Risk (9 items):
n  One point if marked: 1a, 1b, 1c, 1d, 1e, 1f, 1g, 1h, 1i
Signs (10 items):
n  One point if marked: 2b, 2c, 2d, 2e, 2g, 2h
n  One point if NOT marked: 2a, 2f, 2i, 2j
Action (11 items):
n  One point if marked: 3a, 3b, 3d, 3f, 3g, 3i, 3j
n  One point if NOT marked: 3c, 3e, 3h, 3k
Naloxone Use (15 items):
n  One point if marked: 4a, 5a, 5b, 5c, 6a, 7a, 8b, 9T, 11T, 
12T, 14T
n  One point if NOT marked: 5d, 5e, 10F, 13F
SPSS data-base and syntaxes can be obtained from the 
author (please see contact details below).
I Data
The table below presents OOAS values that have been 
recorded for drug users and family members:
I Opioid Overdose Knowledge Scale
The OOKS aims to assess the level of knowledge of opioid 
overdose management among addiction professionals, 
patients and family members. It records knowledge about 
risk factors for having an opioid overdose, signs of an 
opioid overdose, actions to be taken in an overdose 
situation, naloxone effects and administration, adverse 
effects and aftercare procedures. The scale also identifies 
misinformation and myths about opioid overdose.
The OOKS has scores on four domains:
n  Risk: risk factors for an overdose
n  Signs: signs of an overdose
n  Action: actions to be taken in an overdose
n  Naloxone use: naloxone effects, administration and 
aftercare procedures
It is a self-administered structured questionnaire which 
takes approximately 10 minutes to complete. The scale 
is formed of 4 multiple-choice questions, 4 forced-
choice questions and 6 true/false statements.
I Psychometric Properties
The psychometric properties of the OOKS are described 
in Williams et al (2013). The scale has proved to be 
internally reliable (alpha coefficient 0.83) and robust over 
time (Intra-Class Correlations = 0.90). The domains’ 
reliability (ICC) are as follow: risks 0.87, signs 0.69, 
actions 0.53 and naloxone use 0.83.
The scale has also proven to have face, content and 
construct validity. Content validity was tested by 
comparing the scores of addiction professionals and 
family members of opioid users. Professionals reported 
significantly higher scores than family members. 
Concurrent validity was tested by correlating OOKS 
score and the Brief Overdose Recognition and Response 
Assessment (BORRA). The OOKS total score was 
positively correlated with the BORRA’s Overdose 
Recognition (r = 0.5, P < 0.01) and BORRA’s Naloxone 
Indication sub-scales (r = 0.44, P < 0.05).
I Scoring
The OOKS items use a ‘yes/no or don’t know’; or ‘true/
false or don’t know’ response format. Each correct 
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to other languages. Please contact the author for other 
versions of the instrument.
Dr Anna V. Williams
King’s College London,
Addictions Department, Institute of Psychiatry, 
Psychology and Neuroscience
Addiction Sciences Building,
4 Windsor Walk,
London, SE5 8AF, United Kingdom
anna.v.williams@kcl.ac.uk or annaw06@gmail.com
Further information can be found on: http://www.kcl.
ac.uk/ioppn/depts/addictions/research/drugs/
Naloxone/Resources.aspx
The data are available in Anna Williams (2011) PhD 
thesis and it was published in Williams et al. (2013, 
2014):
Williams AV (2011). Training on overdose management 
and naloxone administration for family members and 
carers of opioid users: an evaluation of the short-term 
benefits using validated measures. PhD Thesis. King’s 
College London: UK.
Williams AV, Marsden J & Strang J (2014), Training 
family members to manage heroin overdose and 
administer naloxone: randomized trial of effects on 
knowledge and attitudes. Addiction, 109: 250–259.
Williams AV, Strang J & Marsden J (2013). Development 
of Opioid Overdose Knowledge (OOKS) and Attitudes 
(OOAS) Scales for take-home naloxone training 
evaluation. Drug Alcohol Dependence, 132(1–2):383–6
I Author contact details
Both the OOKS and OOAS scales are currently available 
in English, Portuguese and Italian and can be translated 
Family members (n = 73) Drug users (n = 89)
Mean (SD) Mean (SD)
Pre-training
Immediately 
post-training
3-months
post-training
Pre-training
Immediately 
post-training
3-months
post-training
Total OOKS 30.41 (± 7.1) 39.20 (± 3.1) 37.30 (± 4.5) 33.14 (± 4.6) 39.43 (± 3.5) 39.05 (± 3.5)
Risks 6.79 (± 2.27) 8.41 (± 1.4) 7.45 (± 1.7) 7.18 (± 1.8) 8.25 (± 1.1) 7.85 (± 1.4)
Signs 6.38 (± 1.9) 7.89 (± 1.5) 7.48 (± 1.4) 7.24 (± 1.5) 8.42 (± 1.4) 8.08 (± 1.2)
Action 9.46 (± 1.6) 10.10 (± 1.48) 10.25 (± 1.1) 9.86 (± 0.8) 10.42 (± 0.9) 10.64 (± 0.5)
Naloxone 7.77 (± 3.7) 12.79 (± 1.4) 12.21 (± 1.8) 8.83 (± 2.8) 12.33 (± 1.7) 12.48 (± 1.7)
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  To reverse the effects of an amphetamine overdose
  To reverse the effects of a cocaine overdose
  To reverse the effects of any overdose
  Don’t know
5.  How can naloxone be administered? (Tick all that apply)
  Into a muscle (intramuscular)
  Into a vein (intravenous)
  Under the skin (subcutaneous)
  Swallowing — liquid
  Swallowing — tablet
  Don’t know
6.  Where is the most recommended place for non-
expert to administer naloxone?
  Outside of thighs or upper arms
  Any vein
  Heart
  By mouth
  Don’t know
7. How long does naloxone take to start having effect?
  2–5 minutes
  5–10 minutes
  10–20 minutes
  20–40 minutes
  Don’t know
8. How long do the effects of naloxone last for?
  Less than 20 minutes
  About one hour
  1 to 6 hours
  6 to 12 hours
  Don’t know
Please mark “true”, “false” or 
“don’t know”
True False
Don’t 
know
 9.  If the first dose of naloxone has no 
effect a second dose can be given
  
10.  There is no need to call for an 
ambulance if I know how to 
manage an overdose
  
11.  Someone can overdose again even 
after having received naloxone
  
12.  The effect of naloxone is shorter 
than the effect of heroin and 
methadone
  
13.  After recovering from an opioid 
overdose, the person must not 
take any heroin, but it is ok for 
them to drink alcohol or take 
sleeping tablets
  
14.  Naloxone can provoke withdrawal 
symptoms
  
I Opioid Overdose Knowledge Scale
Please answer the following questions about heroin 
overdose (or an overdose from other opioids such as: 
methadone, morphine, oxycodone, tramadol, fentanyl or 
codeine):
1.  Which of the following factors increase the risk of a 
heroin (opioid) overdose? (Tick all that apply)
  Taking larger than usual doses of heroin
  Switching from smoking to injecting heroin
  Using heroin with other substances, such as alcohol 
or sleeping pills
  Increase in heroin purity
  Using heroin again after not having used for a while
  Using heroin when no one else is present around
  A long history of heroin use
  Using heroin again soon after release from prison
  Using heroin again after a detox treatment
2.  Which of the following are indicators of an opioid 
overdose? (Tick all that apply)
  Having blood-shot eyes
  Slow/shallow breathing
  Lips, hands or feet turning blue
  Loss of consciousness
  Unresponsive
  Fitting
  Deep snoring
  Very small pupils
  Agitated behaviour
  Rapid heartbeat
3.  Which of the following should be done when 
managing an opioid overdose? (Tick all that apply)
  Call an ambulance
  Stay with the person until an ambulance arrives
  Inject the person with salt solution or milk
  Mouth to mouth resuscitation
  Give stimulants (e.g. cocaine or black coffee)
  Place the person in the recovery position (on their 
side with mouth clear)
  Give Naloxone (opioid antidote)
  Put the person in a bath of cold water
  Check for breathing
  Check for blocked airways (nose and mouth)
  Put the person in bed to sleep it off
4.  What is naloxone used for?
  To reverse the effects of an opioid overdose (e.g. 
heroin, methadone)
Preventing opioid overdose deaths with take-home naloxone
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Total score (45 items):
n  One point if marked (33 Correct/True items): 1a, 1b, 
1c, 1d, 1e, 1f, 1g, 1h, 1i, 2b, 2c, 2d, 2e, 2g, 2h, 3a, 3b, 
3d, 3f, 3g, 3i, 3j, 4a, 5a, 5b, 5c, 6a, 7a, 8b, 9T, 11T, 
12T, 14T
n  One point if NOT marked (12 Incorrect/False items): 
2a, 2f, 2i, 2j, 3c, 3e, 3h, 3k, 5d, 5e, 10F, 13F. You might 
choose to use the ‘record into same variables’ 
function of SPSS and inverse the values of these 
items.
Risk (9 items):
n  One point if marked: 1a, 1b, 1c, 1d, 1e, 1f, 1g, 1h, 1i
Signs (10 items):
n  One point if marked: 2b, 2c, 2d, 2e, 2g, 2h
n  One point if NOT marked: 2a, 2f, 2i, 2j
Action (11 items):
n  One point if marked: 3a, 3b, 3d, 3f, 3g, 3i, 3j
n  One point if NOT marked: 3c, 3e, 3h, 3k
Naloxone use (15 items):
n  One point if marked: 4a, 5a, 5b, 5c, 6a, 7a, 8b, 9T, 11T, 
12T, 14T
n  One point if NOT marked: 5d, 5e, 10F, 13F
SPSS data-base and syntaxes can be obtained from the 
author.
I  Opioid Overdose Knowledge Scale (OOKS): Scoring instructions
The OOKS aims to assess the level of knowledge of 
opioid overdose management among addiction 
professionals, patients and family members. It records 
knowledge about risk factors for having an opioid 
overdose, signs of an opioid overdose, actions to be 
taken in an overdose situation, naloxone effects and 
administration, adverse effects and aftercare 
procedures. The scale also identifies misinformation and 
myths about opioid overdose.
The OOKS has scores on four domains:
n  Risk: risk factors for an overdose
n  Signs: signs of an overdose
n  Action: actions to be taken in an overdose
n  Naloxone Use: naloxone effects, administration and 
aftercare procedures
It is a self-administered structured questionnaire which 
takes approximately 10 minutes to complete. The scale 
is formed of 4 multiple-choice questions, 4 forced-
choice questions and 6 true/false statements.
The OOKS items use a ‘yes/no or don’t know’; or ‘true/
false or don’t know’ response format. Each correct 
answer scores one point. ‘Don’t know’ and incorrectly 
marked responses (mistakes) are scored zero. Total 
score range: 0–45 points.
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About the EMCDDA
The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is the 
central source and confirmed authority on drug-related issues in Europe. For 
over 20 years, it has been collecting, analysing and disseminating scientifically 
sound information on drugs and drug addiction and their consequences, 
providing its audiences with an evidence-based picture of the drug 
phenomenon at European level. 
The EMCDDA’s publications are a prime source of information for a wide range 
of audiences including: policymakers and their advisors; professionals and 
researchers working in the drugs field; and, more broadly, the media and general 
public. Based in Lisbon, the EMCDDA is one of the decentralised agencies of 
the European Union.
About this series
EMCDDA Insights are topic-based reports that bring together current research 
and study findings on a particular issue in the drugs field. 
Preventing opioid overdose deaths with take-home naloxone examines the case 
for distributing naloxone, an emergency medication, to people who inject 
opioids such as heroin and to others who might witness an opioid overdose. 
Through its capacity to reverse opioid overdose, naloxone can save lives if 
administered in time. This comprehensive review begins by looking at the 
pharmacology of naloxone and the opioids it counteracts, and the physiological 
mechanisms involved. The chapters that follow look at the circumstances of 
opioid overdose deaths and the use of naloxone in regular clinical practice. The 
historical development and spread of take-home naloxone programmes and the 
practical side of their implementation — focusing on training recipients in how 
to recognise and respond to an overdose — are each the subject of a chapter. 
The study closes by considering the prospects for the future, in the context of 
the development of new products, new legislation and new initiatives.
